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I 
 
Abstract 
Outcomes of Periodontal Treatment in Patients with Rheumatoid Arthritis (OPERA) 
was a pilot randomized controlled trial (RCT) that aimed to assess the feasibility for 
a larger, multi-center RCT which would investigate the efficiency of non-surgical 
periodontal treatment in reducing disease activity levels in patients with rheumatoid 
arthritis (RA). 
The OPERA trial used a mixed methods approach. The quantitative approach 
delivered pilot data regarding the clinical outcomes of the intervention, whilst the 
role of qualitative data was to provide a better insight into the experiences and 
values of the patients that would encourage their participation in the larger, 
definitive study.  
The findings of this trial highlighted the specific issues of the patient population, the 
logistic challenges and provided some possible solutions to facilitate patient 
participation. 
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1 Introduction 
1.1 Outcomes of Periodontal Treatment in Patients with Rheumatoid 
Arthritis – The OPERA Study: 
Rheumatoid arthritis (RA) is chronic progressive immune-mediated inflammatory 
condition, characterized by inflammation of the joints. Untreated, it can lead to joint 
destruction and consequently functional impairment and disability. Rheumatoid 
arthritis is associated with significant morbidity and patients with RA have a higher 
risk for cardiovascular conditions, which leads to increased mortality associated 
with RA. Over 500,000 people in England suffer from rheumatoid arthritis, with 
approximately 26,000 new cases being diagnosed every year [1, 2]. RA is 
considered to be one of the main reasons for loss of productivity and early 
retirement in the working population and it represents an economic burden of 
almost £8 billion per year [52].  
Chronic periodontitis is one of the most prevalent chronic inflammatory conditions 
in humans. It affects nearly half of the UK adult population and over 60% of the 
elderly [3, 4]. Several lines of evidence indicate that periodontitis may be a causal 
risk factor for rheumatoid arthritis [5-7]. 
Given the high prevalence of chronic periodontitis in the UK, this condition may 
represent an important modifiable risk factor leading to increased incidence and 
severity of rheumatoid arthritis. Data from a few interventional studies with small 
sample sizes suggests some beneficial effect of periodontal treatment on the 
disease parameters of rheumatoid arthritis [8, 9].  
5 
The main hypothesis that guided the design of the OPERA study was that the 
control of periodontal inflammation by means of intensive non-surgical therapy 
administered by a dental hygienist would provide epistemically possible benefit in 
terms of reduction of rheumatoid disease activity whilst improving articular function 
and quality of life. 
In order to be able to evaluate this hypothesis in a definitive trial, the present pilot 
trial randomly allocated patients with RA who also suffered from moderate to 
severe chronic periodontitis to two treatment arms: Immediate treatment and 
Delayed Treatment. The Immediate treatment group received intensive non-
surgical periodontal treatment. The Delayed treatment group received oral hygiene 
instructions for the duration of the trial, and full treatment at the end of the study.  
The patients were followed up for six months.  
The primary objective of this pilot trial was to assess the feasibility of the research 
design and the clinical intervention, to establish recruitment and retention rates and 
to gauge the acceptability of the intervention and study procedures to patients 
through the use of mixed methods (quantitative and qualitative).    
The secondary objective of this study was to collect pilot data about the efficacy of 
periodontal treatment in patients with rheumatoid arthritis and subsequently it’s 
influence on health related quality of life.  
 
6 
1.2 Historical background 
The evidence of mankind’s preoccupations for oral health is lost in the mists of time. 
Early prehistoric populations developed basic tools and instruments to make their 
life easier. One of the first tools ever made was designed to remove food particles 
from the interdental space and alleviate pain caused by the inflammation of the 
gums and teeth [10]. Archeologists studied the bone loss levels on the jaws of 
ancient human populations all around the world, from Egypt to China from over 
5.000 years ago and identified evidence of horizontal alveolar bone recession due 
to periodontitis [11].   
It is believed that Hippocrates was one of the first ones to describe the 
associations between periodontitis and rheumatoid arthritis [12]. Although this 
might seem anecdotal since the two conditions were defined only much later, it 
appears that The Father of Medicine presented the case of a patient with chronic 
inflammation of the joints that started to feel better after having a tooth extracted.  
Rheumatoid arthritis was described much later, in the XIX-th century. The first to 
describe this condition in a scientifically systematic way was Dr Augustin Jacob 
Landré-Beauvais, presenting it as a chronic inflammatory condition of the joints 
that is different from gout and affects mainly female patients [13] 
 
1.3 Focal infection theory 
Focal infection theory was first developed at the end of the XIX-th century together 
with the developments in the field of bacteriology. A large amount of studies were 
7 
showing an association between systemic conditions and oral bacteria [14]. The 
scientific community however, dismissed these theories later, in the middle of the 
XX-th century [15]. There is an increasing amount of evidence to support of a 
refreshed version of the “Focal infection theory” and of the role that chronic oral 
infections could play over the increase of systemic inflammatory burden. This role 
has been demonstrated especially with the recent developments in the field of 
periodontal medicine [14]  
 
1.4 Oral vs systemic conditions 
Periodontal disease (PD) and rheumatoid arthritis (RA) share a number of 
similarities at different levels. According to some authors, periodontitis and 
rheumatoid arthritis are so similar disorders that they are in fact the same disease 
with localized inflammation in different parts of the body [16]. The arguments for 
this are that both conditions are autoimmune, genetically modulated, causing a 
progressive degeneration of the cartilage tissues and bone [17, 18]. 
The periodontal tissue and the synovial joints share histological and morpho-
anatomical similarities. The gomphosis, as component of the periodontal tissue, is 
a specialized fibrous joint, considered a synarthrosis and connects the tooth to the 
maxillary or mandibular alveolar bone. The periodontal tissue contains collagen, 
proteoglycans and hyaluronic acid, components that can be identified in some of 
the joints as well [19].  
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Figure 1 presents an overview of the number of scientific articles exploring the 
associations between periodontal and systemic conditions published every year 
between 2000 and 2015. This was based on a simple search performed on the 
Web of Science Database on the 15th of August 2016. Figure 2 presents the 
number of citations for all these publications.  
It can be easily observed the increasing interest of the scientific community 
regarding the associations between periodontal and oral health. 
With a constantly increasing number of scientific publications exploring the 
associations between oral health conditions and systemic health, we can only 
wonder the same question that was asked by Vieira et al in 2009 - Could the mouth 
finally return to the body? [20]  
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Figure 1 - Publications between 2000-2015 
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1.5 Chronic periodontitis 
Periodontitis is a chronic, inflammatory condition manifested through gingival 
inflammation with loss of periodontal ligament from the cementum and the 
junctional epithelium [21]. The inflammatory process is determined by the presence 
of bacteria and the host modulated immune response. The progression of the 
disease leads to loss of connective tissue in the periodontal pockets and alveolar 
bone loss. Periodontitis is considered to be the main cause for tooth loss in the 
adult population [4, 22].  
 
1.6 Case definitions and heterogeneity of the literature 
One of the main challenges highlighted in the scientific literature is represented by 
the lack of consensus over a universally accepted definition for periodontitis in 
epidemiological studies [23, 24] resulting in a large level of heterogeneity between 
different studies about how periodontitis is defined. The reasons for this can be 
traced back to the different types of probes that are used, the number of sites of 
teeth that are being assessed for diagnosis and the different criteria for threshold 
for clinical attachment loss (CAL) and pocket probing depth (PPD) [23] 
The main endpoints that are generally used to define periodontitis in 
epidemiological studies refer to periodontal probing depth (PPD), clinical 
attachment loss (CAL) and bleeding on probing – with different threshold 
classifications to categorize the severity of the condition.  
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1.6.1 The WHO definition 
The Community Periodontal Index (CPI) score was developed by the World Health 
Organization (WHO) in order to facilitate comparisons between countries regarding 
the periodontal health of their populations [25]. The CPI Scores are representing 
percentage of persons by their maximal CPI score (prevalence rate) and the mean 
number of sextants with certain CPI scores: Score 0 = healthy periodontal 
conditions; Score 1 = gingival bleeding; Score 2 = gingival bleeding and calculus; 
Score 3 = shallow periodontal pockets (4–5 mm); Score 4 = deep periodontal 
pockets (≥ 6 mm); Score 9 = excluded; and Score X = not recorded or not visible. 
The extent of loss of attachment (CAL) is recorded for sextants using the following 
codes: Score 0 = LA 0–3 mm; Score 1 = LA 4–5 mm; Score 2 = LA 6–8 mm; Score 
3 = LA 9–11 mm; Score 4 = LA ≥ 12 mm; Score X = excluded; and Score 9 = not 
recorded [26]. 
 
1.6.2 The EFP definition 
The European Academy of Periodontology (EAP) developed the currently accepted 
definition for periodontal disease. In 1999 EAP merged with the European 
Federation of Periodontology (EFP) becoming a subcommittee within the EFP with 
the objective of organizing periodically scientific workshops for specialists in the 
field. 
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The 5th European Workshop of The EAP proposed a new case definition for 
periodontal disease in epidemiological studies. While it acknowledged the large 
heterogeneity of outcome measures that are used in clinical studies it emphasized 
on the idea of using the clinical attachment loss (CAL) as primary outcome variable 
[27]. Furthermore the participants at the workshop proposed that the severity of 
periodontitis could not be expressed only by a single outcome variable and 
recommended the use of other variables as well such as periodontal probing depth 
(PPD) and bleeding on probing (BOP) for a more accurate description of the 
severity of the condition.  
The participants at the workshop proposed a case definition for periodontitis based 
on two levels: 
1. CAL ≥ 3mm on ≥ 2 non-adjacent teeth 
2. CAL ≥ 5mmin on ≥ 30% of teeth present 
Furthermore, for the case definition for the progression of periodontal disease, the 
participants proposed the presence of ≥ 2 teeth with CAL ≥ 3 mm. The group also 
suggested that the clinical examination could be substituted in certain cases where 
it is not possible to record the data by the use of dental radiographies. In this case 
longitudinal bone loss should be ≥ 2 m on ≥ 2 teeth [27]. 
 
1.6.3 The CDC/AAP definition 
The Centre for Disease Control and Prevention (CDC) from the United States in 
partnership with the American Academy of Periodontology (AAP) proposed a 
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clinical case definition for population-based surveillance of periodontitis [28]. This 
classification is presented in Table 1. The classification was based on National 
Health Surveys conducted in the US between 1960 and 2000 and the definitions 
provided by the AAP in 1999 with additional modifications in 2012. 
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Table 1 - The CDC Case Definitions for Periodontitis 
Disease 
classification 
Clinical definition of periodontitis 
 
PPD 
 
 CAL 
Severe [28] 
≥ 1 interproximal site 
with PPD ≥5 mm 
and ≥2 interproximal sites 
with CAL ≥ 4 mm (not 
on same tooth) 
Moderate [29] 
≥ 2 interproximal sites 
with PPD ≥ 4 mm (not 
on the same tooth) 
and ≥2 interproximal sites 
with CAL ≥3 mm (not on 
the same tooth) 
 1 site with PPD ≥5 mm or 
Mild or no 
periodontitis [28] Neither ‘‘moderate’’ nor ‘‘severe’’ periodontitis 
 
 
1.6.4 The Joint EU/USA recommendation 
The joint EU/USA Periodontal Epidemiology Working Group proposed a series of 
recommendations to serve as potential standards for reporting chronic periodontitis 
prevalence and severity in epidemiologic studies [30]. 
The working group presented a systematic overview of the scientific literature 
regarding population based, epidemiological studies for periodontitis. This included 
an assessment of potential study designs, sample sizes with accounting for drop-
outs (with reasons), assessment of periodontal measurements and recording 
protocols and case definitions for periodontitis.  
The working group recommended the use of the case definitions developed by the 
Centers for Disease Control and Prevention and the American Academy of 
Periodontology (CDC/AAP) as standard for reporting on periodontitis for 
epidemiological studies. Furthermore, considering the large amount of different 
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clinical endpoints, in order to be able to facilitate comparisons between different 
studies, the working group created a list of key items together with a ranking of 
their importance that are recommended to be reported on in epidemiological 
studies. 
 
1.6.5 Aggregate measures of periodontal inflammatory burden  
The case definitions used for epidemiological studies were developed to present 
an accurate description of the prevalence and incidence of periodontitis at 
population level. These measures, however did not present an accurate evaluation 
of the chronic inflammatory burden, as they did not take into account variables 
such as the number of teeth present or the cumulative value of deep periodontal 
pockets. In order to provide a more precise evaluation of the periodontal 
inflammatory burden that could contribute to the overall systemic inflammatory 
burden associated with systemic conditions, a number of different aggregate 
measures were developed.  
The periodontal inflamed surface area (PISA) was proposed in 2008 by Nesse et al 
[31]. This aggregate measure was developed to quantify “the surface area of 
bleeding pocket epithelium in square millimeters” which represents the sum of 
periodontal probing depths weighted by the size of the affected tooth. PISA is 
calculated using clinical attachment loss (CAL), periodontal pocket depth (PPD) 
and bleeding on probing (BOP) [31].  
16 
A different aggregate measure used in clinical studies is cumulative pocket depth 
(CPD). This is calculated as the sum of the deepest probing depths for each tooth 
that is ≥ 4 mm [32] to ensures a minimum number of teeth with deep periodontal 
pockets present. Both CPD and PISA attempt to estimate the surface area of the 
inflamed periodontium. CPD however is characterized by a more simplistic 
approach compared to PISA. CPD is not using tooth specific weights nor BOP, the 
only measure being the deepest pocket per tooth.  
 
1.7 Epidemiology and burden of periodontal disease in Europe 
It is difficult to assess the state of periodontal health at European level. There is a 
lack of epidemiological data that is comparable and consistent across the different 
EU Member States [33]. By using data from epidemiological studies employing the 
Community Periodontal Index (CPI) developed by the WHO, Konig et al presented 
an overview of the current status of periodontal health between the EU Member 
States. It is believed that over 50% of Europeans are suffering of some form of 
periodontitis, the severe form affecting over 10% of the population with the highest 
prevalence (70-85%) among the 60-65 years old age group [33].  
The authors of this study suggest that the actual prevalence could be even higher 
and there is a tendency for an increased rate of incidence among all the EU 
Member States [33]. This can be related on the increased prevalence of diabetes 
as comorbidity for periodontitis, higher life expectancy and on the large number of 
elderly that are able to retain their teeth at advanced age as well.  
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1.8 Periodontal care in the NHS 
Periodontal care in the NHS is currently provided under the framework of the 
Dental Contract from 2006 and with the modifications of 2010 issued by the 
Department of Health [34]. Periodontal care in this context is represented by oral 
hygiene instruction, scaling and root surface debridement and supportive care. 
According to the Clinical Audit Committee of the Royal College of Surgeons of 
England periodontal diseases can be classified into 3 codes of complexity [35]. 
These codes are based upon the Basic Periodontal Examination (BPE) Criteria 
and are as follows:  
Complexity 1: 
• BPE Score 1 – 3 in any sextant  
Complexity 2: 
• BPE Score of 4 in any sextant 
• Surgery involving the periodontal tissues 
Complexity 3:  
• Surgical procedures associated with osseointegrated implants  
• Surgical procedures associated with osseointegrated implants 
• Surgical procedures involving periodontal tissue augmentation and/or bone 
removal 
• BPE Score of 4 in any sextant including one or more of the following factors: 
o Patients < 35 years old and smoking > 10 cigarettes/day 
18 
o Concurrent medical factor affecting periodontal tissues 
o Root morphology adversely affecting prognosis 
o Rapid periodontal breakdown > 2 mm clinical attachment loss (CAL) 
in any one year 
 
Under these guidelines, general dental practitioners are advised to only refer 
patients with relatively rare aggressive forms of periodontitis to specialist care. 
However, chronic periodontitis is under-diagnosed and under-treated in the general 
dental services (GDS), for a variety of reasons including the limited availability of 
dental hygienists in NHS general dental practices [36]. Furthermore, specialist care 
is more intensive than that performed within the GDS [36] and the greater time 
spent and expertise employed within specialist environments results in greater 
periodontal stability [37].  
 
1.9 Dysbiosis and host-mediated tissue damage 
Oral bacteria was first described by Antonie van Leeuwenhoek in 1683 [38, 39].  
Since then, our understanding of the role played by bacteria in the mechanisms 
that leads to disease shifted from the idea that bacteria are the sole etiological 
agents responsible for diseases to the idea of bacterial homeostasis where 
bacteria are necessary companions for a healthy human life and humans are 
rather superorganisms composed of human and bacterial cells [39]. When the 
balance of symbiotic bacteria shifts towards parasitic bacteria or the numbers of 
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symbiotic bacterial organisms exceeds the number that is beneficial for the body or 
with other words the homeostasis is disrupted – is the moment when disease 
occurs [40].  
In 1972, the microbiologist Thomas Luckey estimated the bacterial cells ratio to 
human cells is 10 to 1 in a healthy organism [41]. Until very recently, this was 
accepted both in science and popular culture. Later on, the National Institutes of 
Health from the United States published the Human Microbiome Project (HMP) 
which presented a comprehensive mapping of the different types of bacterial 
colonies in the human body [42].  Sender revised Luckey’s estimate in 2016 [43] 
and proposed a ratio of 1.3 to 1 of microbial to human cells. [38] 
 
1.10 Human impact (DALY, QUALY, Economic burden, QoL, mortality) 
Non-communicable diseases are becoming a high priority for stakeholders and 
decision makers.  This is a result of an increasing ageing population in most of the 
industrialized countries due to higher life expectancy and lower birth rates. 
According to a study published by Harvard School of Public Health and the World 
Economic Forum [44, 45] non-communicable diseases (NCDs) will cost global 
economies $47 trillion by 2030. Such NCDs are the leading cause of death in the 
UK – from the total deaths in 2008 in the UK (518 400), 23.75% were among the 
under the age of 70.  
Economically oral diseases represent a major impact in most countries, being the 
fourth most expensive diseases; they represent 6-12% of the health budgets for 
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OECD countries and affect more than 90% of the world’s population [46].  
According to the British Dental Health Foundation more than 415,000 employees 
took days off work in 2011 due to dental problems while more than 1.1 million 
people took days off to look after a child suffering from oral health problems 
leading to yearly loss of  £36.6 million for the British economy.  
 
1.11 Epidemiology and burden of rheumatoid arthritis  
The European League Against Rheumatism (EULAR) defines rheumatoid arthritis 
(RA) as a “chronic inflammatory disease characterized by joint swelling, joint 
tenderness, and destruction of synovial joints, leading to severe disability and 
premature mortality”[47]. The first symptoms of RA are noticed usually between the 
age of 35 and 50. Within 5 years of diagnosis, 40% of patients from developed 
countries will reduce their working week from full time to part time, with a decrease 
of 50% at 10 years from the first diagnosis [48].  In the UK, according to the 
National Rheumatoid Arthritis Society, 29.3% of the RA patients left their job with 
28.4% doing so on the first year of diagnosis, and 59% within six years. With 
690,000 RA patients in the UK, the economic burden represented by this condition 
is almost £8 billion per year and it is considered to be one of the main reasons for 
loss of productivity and early retirement in the working population[49] . 
A recent study from Australia showed that 65% patients with RA declared that their 
condition affected their personal and professional relationships, the negative 
consequences of the disease affects especially younger people (p=0.021). Patients 
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reported reduced opportunity for social interaction, reduced opportunity for sports 
and outdoor activities as well as maintaining their roles in family life. Rheumatoid 
arthritis is transforming the daily routine of the patients and influences their quality 
of life. They have to abandon their work in certain cases, move house, accept help 
from external sources (family, friends or social workers) and increase their feeling 
of vulnerability which is added as a psychological burden for their condition [51]. 
 
1.12 Etiology and pathogenesis 
The current evidence for the etiology of rheumatoid arthritis points towards both 
genetic and environmental risk factors. In terms of environmental risk factors, 
smoking is considered to be the most important one meanwhile genetic 
predisposition is accounting for over 50% of the new cases [52].  
 
1.13 Progression 
The pre-clinical phase of rheumatoid arthritis is manifested by the appearance of 
autoantibodies including rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA). 
The sensitivity of RF was estimated to 60-70% with a specificity of 78% whilst the 
ACPA sensitivity was estimated to higher values - between 69.6% and 77.5% and 
specificity between 87.8% and 96.4%[53] 
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The initiation of the preclinical phase and T cell activation is followed by chronic 
inflammatory phase with progressive tissue damage caused by cytokines IL–1, 
TNF-alpha and IL–6 [54].  
 
1.14 Biological models to explain the associations between periodontitis and 
RA 
There are several theories regarding the associations between rheumatoid arthritis 
and periodontal disease. Some studies suggested the hypothesis that bacteremia 
caused by periodontal pathogens could be an etiological agent for RA progression 
and pointed towards oral bacterial DNA in patients synovial fluid and serum that 
could be transported via free form of DNA [55] 
Another model, with a wide support of the research community is pointing towards 
a host-mediated mechanism. This model supports the hypothesis of a potential 
causal relationship between periodontitis and RA severity and progression. This is 
based on the assumption that bacterial byproducts from the periodontal tissue 
could enter the systemic circulation and stimulate an increased immune response 
in certain susceptible individuals.  
One of the main aetiopathological agents responsible for periodontal disease is 
Porphyromonas gingivalis. With the recent recognition of the importance of anti-
citrullinated protein antibodies (ACPA) in RA and the discovery that P. gingivalis 
expresses peptidyl arginine deiminase (PAD), there is potential evidence to 
support a plausible pathobiologic mechanism by which periodontitis may cause or 
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sustain the inflammatory response in RA. At this moment P. gingivalis is 
considered to be the only bacterium from the oral cavity known to be capable of 
producing the PAD enzyme [17]. PAD is responsible for the post-translational 
citrullination of peptide antigens on arginine residues [56], and microbial PAD 
deiminates arginine in fibrin found in periodontal tissue [57]. For patients with 
periodontitis who are exposed to PAD therefore, to citrullinated antigens these 
might become systemic immunogens [9]. 
Before the first clinical manifestations of rheumatoid arthritis, the anticitrulinated 
protein antibodies (ACPA) are already present with elevated cytokines in the 
gingival crevicular fluid (GCF) [17, 56-58]. The levels of antibodies against P. 
gingivalis have been correlated with levels of ACPA in patients with RA [7]. 
Antibodies to citrullinated α-enolase are specific for RA [59, 60]; an 
immunodominant epitope in this protein that shows sequence similarity and cross-
reactivity with P. gingivalis enolase could indicate a role for P. gingivalis infection in 
priming the autoimmune response in RA [60].  
Recent studies have also demonstrated that the uncitrullinated peptides play a 
major role in the antibody response for periodontitis resulting in a systemic spread 
of citrullinated epitopes in the presymptomatic phase of RA. Autoantigens modified 
by citrullination through exposure to periodontal pathogens might sustain synovial 
inflammation in the context of untreated periodontitis [56]. Antibodies for 
uncitrullinated RA autoantigens precede the ACPA formation and facilitate the loss 
of tolerance to uncitrullinated peptides [61].  
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1.15 Epidemiological associations between periodontitis and RA 
The biological plausibility of the associations between periodontitis and rheumatoid 
arthritis have been successfully demonstrated in animal models [62, 63] and 
observational data suggests a higher incidence of periodontitis in patients with 
rheumatoid arthritis [64-67] there is little known in terms of causality of this 
relationship.  
The scientific literature presents an increasing amount of evidence from 
observational studies regarding the associations between periodontitis and 
rheumatoid arthritis (RA) [68]. The patients who are diagnosed with RA are more 
likely to have chronic periodontitis and have lost more teeth compared to those 
without RA [64, 69].  
Table 2 presents an overview of observational studies that investigated the 
associations between clinical attachment loss and rheumatoid arthritis. This table 
was adapted from a systematic review performed in 2013 by Kaur et al [70].  
Table 2 – Associations between periodontitis and RA in case-control studies 
Studies		 Sample	size	and	CAL	
Statistical	
significance	RA	patients	 Non	RA	patients	
N	 CAL	 N	 CAL	
Joseph	et	al,	2013	[71]	 100	 2.88	±	1.10	 112	 0.98	±	1.04	 p	>	0.05	
Garib	et	al,	2011	[72]	 50	 3.24	±	0.65	 50	 2.09	±	1.09	 p	<	0.001	
Okada	et	al,	2011	[73]	 80	 3.0	±	0.1	 38	 3.1	±	.01	 p	=	0.1	
Vakar	et	al,	2010,	[74]	 101	 3.05	±	1.02	 101	 2.84	±	0.89	 No	
Ishi	et	al,	2008	[75]	 39	 4.4%	>	5.0	mm	 22	 2.8%	>	5	mm	 p	<	0.05	
Pischon	et	al,	2008	[76]	 57	 4.37	±	1.3	 52	 3.40	±	0.89	 p	<	0.001	
Biyikoglu	et	al,	2006	[77]	 17	 2.6	±	0.05	 17	 3.3	±	1.2	 p	>	0.05	
Bozkurt	et	al,	2006	[78]	 17	 4.92	±	0.73	 17	 1.43	±	0.7	 p	<	0.05	
Gleissner	et	al,	1998	[79]	 100	 2.5	±	1.8	 112	 1.0	±	0.7	 p	<	0.0001	
Kaber	et	al,	1997	[80]	 50	 2.6	±	1.7	 50	 0.95	±	0.7	 p	<	0.0001	
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Data from the third National Health and Nutrition Examination Survey (NHANES III) 
from the United States presented evidence to support a four times higher 
probability of having periodontitis for patients with RA, even after adjusting for 
potential confounders [64].  
 
By using a mixed methods approach, the study combines the strengths of 
quantitative research with qualitative research and brings together the findings with   
 
1.16 Brief introduction to qualitative research methodology 
In this chapter the reader will be presented with a brief description of a number of 
different qualitative research designs that are most widely used and the justification 
for the use of each of these methodologies.  
 
1.17 The nature of qualitative research  
According to Creswell [81] there are four main perspectives that can shape a 
research design: 
• Post-positivism 
• Constructivism 
• Advocacy 
• Pragmatism 
Post-positivism  
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This approach is also called the “scientific approach” or quantitative research. It is 
characterized by a deterministic approach for a temporal succession of the events 
of interest, whereby causes determine effects or outcomes.  
Constructivism 
This approach is also called interpretivism and is based on the direct 
interpretations of the study participants for different events or experiences. The 
views of the participants are combined with those of the researcher to provide a 
“subjective” interpretation of a broader construct. 
Advocacy 
This approach is somewhat connected to the constructivist approach and takes 
things a little further by actively engaging the researcher in advocating/representing 
the rights of the research subjects in order to change policy and/or legislation for 
their benefit. Specific issues are addressed through a concrete agenda o 
Pragmatism 
The pragmatic approach states that the research problem is more important the 
research method. The researcher is  
Based on these perspectives [82] the five most important qualitative research 
designs can be described as:  
• Narrative research  
• Phenomenological Research 
• Grounded theory 
• Case Study Research 
• Ethnographic Research 
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`Table 3 -The main methodologies 
used in qualitative research  
Dimension 
Narrative Phenomenology Grounded  
Theory 
Ethnography Case Study 
Focus 
Exploring the 
life of an 
individual 
The essence of 
experiences about 
a phenomenon 
Developing a 
theory from 
the data in the 
field 
Describing and 
interpreting 
cultural or social 
group 
In depth 
analysis of a 
single/multiple 
case(s) 
Data 
Collection 
Interviews and 
documentaries 
Long interviews 
(=<10 people) 
Interviews till 
saturation (20-
30) 
Observations 
and interviews 
over extended 
time  
Documents, 
interviews, 
observations, 
artefacts  
Data 
analysis 
Stories 
Historical 
content 
Statements 
Meanings 
General description 
of the experience 
Open coding 
Axial coding 
Selective 
coding 
Description 
Analysis 
Interpretation 
 
Description 
Themes 
Assertions 
Product of 
the study 
Detailed 
description of 
an individuals 
life 
Description of the 
“essence” of the 
experie ce 
Theory or 
theoretical 
model 
Description of the 
cultural 
behaviour or a 
group or 
individual 
In depth study 
of case(s) 
 
• Ethnographic Research 
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`Table 3 presents some of the main methodological approaches used in qualitative 
research. 
 
1.17.1 Grounded theory research 
Grounded theory research aims to explore the common experiences of individuals 
in order to develop a new theory and was chosen as the most appropriate for this 
research project. Grounded theory can be used in health promotion research and 
can be helpful in exploring socio-psychological problems as well as to identify 
determinants of various health behavior patterns. 
Grounded theory is a research method that is characterized by a systematical 
collection and analysis of data [83]. This systematical approach made grounded 
theory very popular amongst researchers and it became widely used in research 
projects that included mixed methods as it can be paired in a more consistent way 
with quantitative methods [84]. It explains and shows depth of the researched 
phenomenon. Grounded theory is a creative process, which is used when there is 
no sufficient theory or knowledge related to the researched problem [85], and 
existent theories do not offer the solutions. Grounded theory allows for the 
identification of various phenomena and their changes over time. Grounded theory 
research is a good approach to study patients with chronic diseases [86].  
The goal of grounded theory research is to  
• Generate new hypothesis based on ideas and concepts 
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• Prioritize the importance of understanding the researched phenomenon 
from the perspectives of the subjects of the study, rather than presenting an 
objective and impartial “truth”.  
Grounded theory research presents a set of advantages: 
• Ecological validity represents the context specificity of the grounded theory 
data, which reflects the situation from a real world setting. Although the data 
is context specific it can also be successfully used to extrapolate the results 
to different settings. 
• Novelty of grounded theory – the potential for innovation and exploration of 
new areas by creating knowledge in previously unexplored areas or in areas 
that were approached differently before. 
• Parsimony: a simple and straight forward way of reducing complex 
phenomena to easy to understand concepts by assessing the relationships 
between the different factors and the roles that are played over the 
outcome.[87]  
Grounded theory is ideal to be used in mixed methods research in combination 
with quantitative research methods in order to gain an in depth understanding of 
the researched phenomenon. This is especially applicable for explorative research 
or new, previously less researched fields.  
 
1.17.2 Qualitative vs. quantitative research 
One of the main differences between qualitative and quantitative research 
methodology resides in the fact that qualitative research is significantly more 
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flexible than quantitative research. In general, quantitative methods are not very 
flexible. Using quantitative methods such as surveys and questionnaires, for 
example, researchers ask all the participants to provide answers to identical 
questions in the same order. The response categories from which participants may 
choose are typically “closed-ended” or fixed. The advantage of this inflexibility is 
that it allows for meaningful comparisons of the responses across participants and 
study sites. However, it requires a thorough understanding of the important 
questions to ask, the best way to ask them, and the range of possible responses.  
 
 Rigorousness of the qualitative versus the quantitative research 1.17.2.1
methodologies 
While qualitative research has a subjective perception of the reality from the 
perspective of the participants, quantitative methods are using an objective 
perception. The relation of the researcher to the research project is interactive in 
the qualitative paradigm and independent in the case of quantitative paradigm. 
Qualitative research methods are characterized by an informal and personal 
language meanwhile quantitative research methods are typically using a formal 
language with a clear set of definitions. Qualitative research methods are flexible 
by definition and allow the necessary freedom to be perfectly tailored and adapted 
to the specific context of a research project.  
Table 4 presents a comparison on measures of rigorousness between qualitative 
and quantitative research approaches. According to Guba et al [88] the four 
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measures of rigorousness in qualitative research are credibility, dependability, 
transferability and confirmability. Each of these are corresponding to a measure of 
rigour in quantitative research.  
Table 4 - Comparison between quantitative and qualitative research 
Quantitative research Equivalent in qualitative research 
Validity Credibility 
Reliability Dependability 
Generalizability  Transferability  
Objectivity Confirmability 
 
 Credibility  1.17.2.2
Credibility is a measure of rigour to assess the trustworthiness and quality of the 
data that is presented. This is done from a perspective of depth or richness of data 
rather than from the perspective of large quantity of data.  
 Dependability 1.17.2.3
Dependability is similar to reliability as it refers to the repeatability and consistency 
of the methods that were used for the study in order to assure that the data is 
comparable with other, similar studies. It also involves a scientifically sound and 
consistent method to report on the collected data.  
 Transferability 1.17.2.4
Transferability in qualitative research is equivalent to some extent to 
generalizability in quantitative research. The quality of the research is assessed by 
the reader in order to establish if the findings of the study can be transferred to 
different contexts or not. A better level of comparability or transferability increases 
the level of credibility of the study.  
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 Confirmability 1.17.2.5
As qualitative research could potentially be more vulnerable to bias if the 
researchers findings are not supported by the collected data, a second, 
independent researcher could check the quality of the data and if the data is 
supporting the findings of the study. If the independent researcher confirms the 
findings of the study, then the study is considered objective or confirmable from a 
qualitative perspective.  
 
1.18 NICE Guidelines 
There is a continuously increasing amount of interest of the scientific community 
towards the type of evidence provided by qualitative research methods. This 
interest has been obvious especially in terms of the guidelines developed by the 
National Institute for Health and Clinical Excellence (NICE). Between the years 
2002 and 2007, 45 % of the guidelines developed by the NICE were based on 
qualitative studies as source of the evidence for these guidelines [89].  
 
 
1.19 Sampling in qualitative research  
Table 5 - Sampling methods in qualitative research 
Type of sampling Purpose 
Maximum variation Documents diverse variation and identifies 
 important common patterns 
Homogenous Focuses, reduces, simplifies, facilitates group 
 interviewing 
Critical case Permits logical generalization and maximum  
application of information to other cases 
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Theory based Finding examples of a theoretical construct and 
thereby elaborate and examine it 
Confirming and 
disconfirming cases 
Elaborating initial analysis, seeking exceptions, 
looking for variations 
Snowball or chain Identifies cases of interest from people who 
know people who know what cases are 
information rich 
Extreme or deviant cases Learning from highly unusual manifestations of 
the phenomenon of interest  
Typical case Highlights what is normal or average 
Intensity  Information rich cases that manifest 
information but not extremely 
Politically important cases Attracts desired attention or avoids attracting 
undesired attention 
Random purposeful  Illustrates subgroups; facilitates comparison 
Stratified purposeful Adds credibility to sample when potential 
purposeful sample is too large 
Criterion All cases that meet some criterion: useful for 
quality assurance 
Opportunistic Following new leads; taking advantage of the 
unexpected 
Combination or mixed Triangulation, flexibility, meets multiple 
interests and needs 
Convenience Saves time, money and effort, but at the 
expense of information and credibility 
 
Table 5 presents a list of different sampling types in qualitative research and a 
short description of the purpose of each one of these methods [90, 91]. In the 
OPERA trial a random purposeful sampling procedure was adopted until saturation 
was reached.  
Sample size determination and sample selection in qualitative research are 
different than in quantitative research. Whilst in quantitative research, larger 
sample size increases the validity of the study in qualitative research, larger 
numbers are not increasing the quality of the study. The purpose of sampling in 
qualitative research is to make sure that the participants directly experienced the 
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problem of interest and they are covering all the possible dimensions and areas of 
interests.  
 
As there can be a number of different characteristics of potential types of 
participants, events or processes to be sampled, the study design and research 
paradigm will lead the type of sampling that will be made. 
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1.19.1 Sample size  
Estimates are provided based on previous studies, experience, pilot work, etc. It is 
important to take into account also the logistic aspects to carry out the study 
methodology and assure the sampling is feasible in the chosen context. These can 
be related to access to participants, communication and logistics, safety and data 
processing.  
 
1.19.2 Saturation  
Saturation is the one of the possible ways to determine sample size in qualitative 
research. Saturation in interviewing is defined as the stage in which the 
participants are not providing any more additional information to the researcher 
and the qualitative data starts to become repetitive. The common practice at this 
stage is for researchers to continue to conduct a small number of additional 
interviews to make sure that the saturation is real. If saturation is real and no more 
new information is provided by the participants the researchers can decide to stop 
the data collection and resume the sample size to the number of participants that 
provided data until that particular moment.  
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1.20 Strengths and weaknesses of using mixed research methodology 
The outcomes that are important for clinicians are not always the most relevant for 
patients [92-94]. While clinicians can focus on clinical and biological parameters, 
quantitative or “hard endpoints” it has been demonstrated that patients sometimes 
are more concerned about issues regarding their quality of life. This often is 
translated by their ability to live with dignity and independently. Exploring the 
differences between patient and clinician centered outcomes is especially 
important for pilot studies where one of the main objectives is to try to understand 
the values, priorities and experiences of the patients all of which determine their 
choices for treatments and outcomes.  
 
The qualitative research approach brings a substantial advantage to this study by 
providing an interdisciplinary and comprehensive approach to answer not only the 
research question but also to generate a deeper understanding of the phenomenon 
that is being studied. Through an integrated qualitative research designs we can 
provide a fusion of disciplinary knowledge with the know-how and personal 
experience of patients.   
 
This approach was considered especially important because of the lack of 
information regarding the feasibility of the protocol of the interventional study.  
Considering that there is a lack of interventional studies regarding the associations 
between periodontitis and rheumatoid arthritis, the use of a mixed approach of 
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quantitative and qualitative research methods was considered appropriate in order 
to develop a better understanding of the specific context of the patient population 
that was being investigated.  
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2 Aims and Objectives 
The primary aim of this study was to pilot the feasibility of an interventional trial that 
aims to evaluate the efficiency of intensive periodontal treatment administered by 
Dental Hygienists in a secondary care setting to reduce disease activity and 
improve function for patients with Rheumatoid Arthritis (RA).  
 
To achieve this aim, the following set of objectives was carried out: 
• Assess patient recruitment and retention rates 
• Refine study protocol and logistics 
• Evaluate the efficacy of periodontal treatment using a randomized controlled 
trial approach in a secondary care setting.  
• Evaluate the effects of periodontal treatment on the rheumatoid arthritis disease 
activity parameters.  
This objective was carried out by monitoring the following clinical outcomes:  
o Disease activity scores (DAS28); 
o Musculoskeletal ultrasound of the joints (Power-Doppler and Gray 
Scale); 
o Patient reported outcomes: a set of standardized and validated quality of 
life questionnaires 
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• Use of qualitative research methods to evaluate the patient’s perspectives 
regarding the relevance and acceptability of the trial 
This objective was carried out by  
o Identifying hindering and encouraging factors for study participation; 
o Tackling the impact of rheumatoid arthritis on the patient’s quality of lives 
the place of oral health on their scale of health priorities.  
 
By using qualitative research methods the project intended to develop a deeper 
understanding of the values, beliefs and principles of the patients with rheumatoid 
arthritis. These factors could potentially contribute and shape their decisions 
regarding their choices to access certain types of health care services. 
 
As for any feasibility study, one of the main endpoints of the OPERA study 
represented the evaluation of the pre-screening and screening logs together with 
The CONSORT Diagram (Figure 4 – The CONSORT Flow Diagram) [95, 96]. This 
was particularly important in order to assess the feasibility of the protocol and 
together with the qualitative data to tackle the potential problems regarding the 
implementation of the methodology. Furthermore this could also highlight some 
important technical and logistic issues and identify possible solutions to overcome 
these problems. As part of the feasibility findings, it was necessary to get a deeper 
understanding of the reasons why some of the patients might dropout and to 
identify the barriers to access and care in order to use this pilot data to develop a 
larger, statistically powered interventional trial.  
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3 Rationale for carrying out the study  
The Introduction Chapter outlined the current knowledge about the associations 
between oral health status and systemic conditions as well as the specific 
associations between periodontitis and rheumatoid arthritis.  
 
The increasing number of publications regarding the associations between oral and 
systemic conditions reflects the increasing attention of the scientific community 
towards this topic. However, most of the research performed in this field has used 
observational designs. The few interventional studies used small sample sizes and 
were not sufficiently powered to draw any definitive conclusion regarding a causal 
relationship between exposure and outcome and the effectiveness of periodontal 
treatment to improve RA outcomes. For all these reasons, it emerged a real 
necessity to further explore this field by developing a pilot randomized controlled 
trial (RCT) to assess the feasibility for a larger interventional trial.  
 
The rationale to carry out this study emerged from the need of assessing not only 
the correlation but also a potentially causal relationship between the two conditions 
of interest. In order to assess causal relationships between an intervention and 
outcome, randomized controlled trials are considered the gold standard in clinical 
research. As it is with any new area of scientific inquiry in clinical research, the 
theoretical approaches developed by the research community need to reflect the 
real world setting. The effects of periodontal treatment on patients diagnosed with 
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rheumatoid arthritis can be assessed from a clinical and biological perspective but 
some of the specific problems of this patient group cannot be evaluated using 
purely quantitative methods. The purpose of incorporating qualitative methods was 
to develop our knowledge and understanding of the specific reasons for patients to 
participate in the study, to identify potential hindering factors and possible solutions 
for those and to tackle the acceptability of the intervention for the patients. As part 
of the feasibility findings, it was necessary to get a deeper understanding of the 
reasons why some patients might drop-out and to identify the barriers to access 
and care in order to use this pilot data to develop a larger, statistically powered 
interventional trial. 
Furthermore the outcomes that are relevant for clinicians and researchers might be 
different for the patients. This could be especially the case for patients that are 
diagnosed with a chronic condition and might suffer also of a set of specific 
comorbidities [94, 97, 98]. Understanding the health care priorities of this specific 
patient population and the importance of oral health on this set of priorities was one 
of the most important factors in designing the protocol of research project 
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4 Methodology 
4.1 Overview 
The OPERA study was a feasibility parallel group randomized controlled clinical 
trial of the short-term effects of non-surgical periodontal treatment on rheumatoid 
arthritis disease parameters.  
A total of 60 RA patients with chronic periodontitis were randomly allocated to 
either immediate intervention or control (delayed intervention) group. The 
intervention consisted of non-surgical periodontal therapy with intensive 
maintenance therapy delivered by a dental hygienist. Periodontal parameters and 
RA disease activity parameters were assessed at baseline and at three and six 
months. At the end of the 6-months study, patients in the control arm were offered 
the same non-surgical periodontal therapy. Considering that this was a feasibility 
study, the primary outcome measures were represented by the recruitment and 
retention rates. The secondary outcome measures provided clinical and non-
clinical data about the efficacy of periodontal treatment in patients with rheumatoid 
arthritis in terms of disease activity and disability, periodontal measures, as well as 
general and oral-health related quality of life. Moreover, the study included a 
qualitative assessment, which provided an insight about the acceptability of the 
intervention and the study procedures from the patients’ perspective. 
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4.2 Study oversight  
The Outcomes of Periodontal Therapy in Rheumatoid Arthritis (OPERA) trial took 
place based on the approval of the National Research Ethics Service (NRES) 
Committee West Midlands - South Birmingham Research Ethics Committees 
(REC) Number 11/WM/0235 (Appendix 2), protocol number RG_10-138 (Appendix 
1: Study Protocol) and registered via the Integrated Research Application System 
(IRAS) with project ID 53163.  
The recruitment for the trial started in January 2014 and the last patient was 
randomized in October 2015. 
Research and development (R&D) approval was obtained for all the participating 
sites: Queen Elizabeth Hospital Birmingham (University Hospitals Birmingham 
NHS Foundation Trust), City Hospital Birmingham (Sandwell and West 
Birmingham Hospitals NHS Trust), Heartlands Hospital (Heart of England NHS 
Foundation Trust) and Birmingham Dental Hospital - (Birmingham Community 
Healthcare NHS Trust.  
Heartlands Hospital was the last initiated site. This site had it’s own local research 
team with one rheumatology consultant, one research nurse and one research 
administrator. 
 
4.3 Study population  
The study population was represented by the patients diagnosed with rheumatoid 
arthritis from The Outpatient Rheumatology Departments from Queen Elizabeth 
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Hospital Birmingham (University Hospitals Birmingham NHS Foundation Trust), 
City Hospital Birmingham (Sandwell and West Birmingham Hospitals NHS Trust) 
and Heartlands Hospital (Heart of England NHS Foundation Trust). 
 
4.4 Recruitment procedures 
The rheumatology clinic lists for the follow-up appointments from the participating 
NHS Trusts were pre-screened by the research team one week in advance. A list 
of the potentially eligible patients was created by filtering the clinic list, based on 
the clinical information available in the patient’s electronic records. There were 
minor differences regarding the recruitment procedures in the three different NHS 
Trusts. While the potentially eligible patients in the Outpatient Rheumatology 
Department of Queen Elizabeth Hospital Birmingham (University Hospitals 
Birmingham NHS Foundation Trust), were contacted by post one week before their 
appointment for follow-up at the rheumatology department, inquiring about their 
potential willingness to be approached by the research team, the patients from the 
other 2 NHS Trusts were contacted directly during their follow-up appointments at 
the rheumatology departments. This decision was taken by the research team at 
the suggestion of the rheumatology consultants in order to facilitate the recruitment 
process.  
Written information was sent to these patients together with pre-stamped and 
addressed envelopes, informing them about the research project and the possibility 
to find out more details, during their visit at the rheumatology clinic. The patients 
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that returned the letters with a positive answer were approached by the research 
team and provided with detailed information about the research project.  
Patients from City Hospital Birmingham (Sandwell and West Birmingham Hospitals 
NHS Trust) and Heartlands Hospital (Heart of England NHS Foundation Trust) 
were approached directly by the research team during their follow-up appointments. 
The researchers explained the aims of the study, the methodology and the option 
of free withdrawal at any given time after consenting, without providing any specific 
reasons. The patients were offered the patients information sheet (see appendixes) 
and written consent forms. 
The recruitment times were Monday mornings for Queen Elizabeth Hospital 
Birmingham and Tuesday afternoons for City Hospital Birmingham. For the clinics 
on all the other days of the week, written information was available for the patients 
at the reception desks and in the consultation rooms together with contact 
information of the research team).  
Those patients that met the inclusion criteria in terms of their rheumatoid arthritis 
diagnosis, stability of treatment and excluded comorbidities and endentulism and 
expressed their interest to take part in the study were approached during their 
follow-up appointments and informed about the possibility of participation in the 
trial. The patients read the Patient Information Sheet and had the possibility to ask 
questions and find out detailed information about the trial. Participation in the trial 
was offered to patients that filled out and signed the Informed Consent Form (see  
Appendix 6: Informed Consent Form (ICF) Screening. The time and date for the 
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periodontal screening at Birmingham Dental Hospital, was mutually agreed with the 
patients for a Wednesday, Thursday or Friday.  
The patient’s personal details were electronically transferred through the secured 
NHS email system from the recruitment sites to Birmingham Dental Hospital where 
new patient notes were created. 
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4.5 Inclusion criteria 
• Ability and willingness to give written informed consent and comply with the 
requirements of the study protocol. 
• Age above 18 years 
• Patients with rheumatoid arthritis, diagnosed according to the revised 1987 
ACR criteria for the classification of the condition [99] 
• DAS28 score ≥3.2 (see paragraph 4.7.3 Disease Activity Score (DAS28) 
• DAS28 score >5.1 only if patient on biologics or patient unwilling to take 
biologics 
• Treatment with DMARD for ≥ 3 months and stable dose for ≥ 2 months 
• Generalized moderate to severe chronic periodontitis as evidenced by 
pocketing with clinical attachment loss (CAL>=4 mm on at least 2 non-
adjacent teeth AND cumulative probing depth>=40mm) (see paragraph 
4.7.4 Periodontal examination) [28, 100] 
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4.6 Exclusion criteria 
• Rheumatic autoimmune disease other than rheumatoid arthritis, or significant 
systemic involvement secondary to RA (including but not limited to vasculitis, 
pulmonary fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome or 
secondary limited cutaneous vasculitis with RA was permitted. 
• History of, or current, inflammatory joint disease other than RA (including, but 
not limited to, gout, reactive arthritis, psoriatic arthritis, seronegative 
spondyloarthropathy) or other systemic autoimmune disorder (including, but not 
limited to, systemic lupus erythematosus, inflammatory bowel disease, 
scleroderma, inflammatory myopathy, mixed connective tissue disease or any 
overlap syndrome). 
• Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis 
(JRA) and/or RA before age 16. 
• Any surgical procedure, including bone/joint surgery/synovectomy (including 
joint fusion or replacement) within 12 weeks prior to baseline or planned during 
study 
• Significant concomitant disease, which would preclude patient participation in 
the investigators’ opinion. 
• Intra-articular or parenteral glucocorticoids within 4 weeks prior to baseline 
• Any dental condition that would preclude, in the investigator’s opinion, 
participation in the trial (including but not limited to restorations impairing oral 
hygiene or instrumentation, need for extractions or extensive restorative work) 
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• Periodontal treatment (surgical or non-surgical, excluding supragingival 
cleanings) within 12 months prior to baseline 
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4.7 Clinical assessments 
4.7.1 General examination  
The general examination consisted on data collection about the patient’s height 
and weight, blood pressure, current medications, medical history and comorbidities, 
smoking status, alcohol consumption and socio-economic data. 
4.7.2 Rheumatologic examination  
A trained and calibrated examiner assessed the patient’s rheumatoid disease 
activity using DAS28 (Disease Activity Score).  
The training and calibration took part before the start of the recruitment process. 
The examiner attended several rheumatology consultation clinics at Queen 
Elizabeth Hospital Birmingham. A specialist in rheumatology assessed the DAS28 
score of the patients that accepted to help with the calibration process. The 
examiner for the research project was instructed about the DAS28 examination 
process and after several observations, performed blinded examinations on 
patients. The scores of the examiner were compared with the scores given by the 
rheumatology specialist. This process was repeated over several weeks, until a 
good reliability was obtained. 
The patients that attended the screening visit at Birmingham Dental Hospital were 
examined for their DAS28 score. If this score was greater or equal to 3.2 one of the 
inclusion criteria was fulfilled. In order to qualify for the intervention, the patient 
needed to be on treatment with disease-modifying anti-rheumatic drugs (DMARD) 
for at least 3 months and stable dose for at least 2 months before screening.  
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4.7.3 Disease Activity Score (DAS28) 
The 28 joints that were assessed for DAS28 were: 
• Shoulder, 
• Elbow, 
• Wrists, 
• 1-5 Metacarpophalangeal (MCP) joints,  
• 1-5 Proximal interphalangeal [101] joints, 
• Knee 
All of which for were assessed for both right and left side of the patient. A 
calibrated examiner was assessing swelling and tenderness of the examined joints. 
For each sign of tender joint one point was and for each swollen joint a second 
point was recorded. Total tenderness and swelling was be calculated and added to 
the ESR level and the patient’s global health self-assessment using a visual 
analogic scale (VAS) with 0 = best, 100 = worst health status. 
DAS28 was calculated using: 
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Where: 
t28 = number of painful joints from 28 joints 
sw28 = number of swollen joints from 28 joints 
ESR = erythrocyte sedimentation rate in mm/first hour 
VAS = general health or patient's global assessment of disease activity on a 100 
mm visual analogic scale [102]. 
The DAS28 was developed in the early 1980 is The Netherlands and it is widely 
used ever since as a valid measure of disease activity in both clinical trials and 
clinical practice in rheumatology [103].  
 
4.7.4 Periodontal examination  
A calibrated dentist performed detailed periodontal pocket charting assessing 
probing pocket depth (PPD) recession level and bleeding on probing. Missing teeth 
were recorded for each patient and the PPD and recession were recorded on the 4 
interproximal sites for each tooth. Periodontal status was assessed using a UNC 
15 periodontal probe, after the sampling of gingival crevicular fluid and saliva. In 
order to be randomized the patients had to present generalized moderate to severe 
chronic periodontitis as evidenced by pocketing with clinical attachment loss (CAL) 
greater or equal to 4 mm on at least 2 non-adjacent teeth and cumulative probing 
depth greater or equal to 40mm. The threshold based on CAL was consistent with 
the case definition proposed by the CDC/APP working group [104]. Cumulative 
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pocket depth is the sum of the deepest probing depths of at least 4mm on each 
tooth [32]. The proposed threshold ensures a minimum number of teeth with deep 
periodontal pockets, e.g., a patient who had 8 teeth with 5mm pockets met this 
criterion. 
In order to increase the reliability of the findings and considering the large 
heterogeneity of definitions and thresholds used in studies investigating periodontal 
disease, additionally percentage of sites with probing pocket depths ≥ 3mm and 
probing pocket depths ≥ 5mm was reported. Furthermore percentage of teeth with 
probing pocket depths ≥ 3mm and probing pocket depths ≥ 5mm were also 
analyzed as suggested in the most recent literature [30]. 
The Periodontal Inflamed Surface Area (PISA) is a measure of the disease burden 
that is aims to quantify the total surface of the inflamed periodontal tissue relative 
to the number of sites examined and number of teeth that are present [105]. 
 
4.8 Patient reported outcomes 
In order to evaluate the impact of rheumatoid arthritis and oral health on the 
different dimensions of the quality of life of the patients, validated questionnaires 
for the United Kingdom were self-administered by the patients at screening and 
follow-up visits. The data was collected on scannable, case-report forms developed 
in Keypoint (2014 Speedwell Software Limited). 
The following questionnaires were used:  
• Euro-Quol; (Appendix 9) 
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• Patient Health Questionnaire (PHQ-9); (Appendix 10) 
• Oral Health Impact Profile (OHIP) (Appendix 11) 
4.8.1 Euro-Quol;  
This questionnaire is a widely used, standardized instrument to assess quality of 
life as a measure of health outcome. It was developed and validated in certain 
European Union Member States (United Kingdom, The Netherlands and 
Sweden)[106] 
 
4.8.2 Patient Health Questionnaire (PHQ-9);  
PHQ-9 is a reliable and validated questionnaire to assess depression severity. It 
can be used as an additional measure of psychosocial impact of rheumatoid 
arthritis over the quality of life of patients living with this condition[107] .  
 
4.8.3 Oral Health Impact Profile (OHIP) 
OHIP is a self-administered questionnaire with 14 items, designed to evaluate the 
impact of oral health over the quality of life of patients. The instrument contains 
questions, with a high level of reliability and it was used across a large number of 
studies (Cronbach's α (alpha) = 0.70-0.83) and validity (ANOVA, p < 0.05)[108] 
 
4.9 Data management 
All the collected data was collected on standardized case report forms (CRF)s as 
presented in  Appendix 9: Case report form. The quality of life questionnaires were 
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developed using Keypoint (2014 Speedwell Software Limited) and scanned 
automatically. After scanning the data was manually checked for validity by two 
independent researchers. The clinical data was collected using CRF’s and patient 
notes. As Birmingham Dental Hospital has moved to a new building during the 
implementation of this research project, the Governing Body of the Birmingham 
Community Healthcare NHS Foundation Trust decided that from 01.03.2016 would 
be no more physical patient notes in the new hospital. All the clinical notes were 
transferred into the R4 system developed by Carestream Dental. The clinical data 
collected on the CRF forms was manually imputed in a database developed in 
Microsoft Access (Microsoft® software) at University of Birmingham, School of 
Dentistry in 2014. The patient sensitive and confidential data was transferred 
between the participating NHS Trusts using the secured NHS email system.  
 
4.10 Data monitoring 
As this was a feasibility trial with a relatively small sample size, there was no 
formally constituted Data Monitoring Committee by the Sponsor Organization 
(University of Birmingham). Data monitoring was done periodically by members of 
the research team and a midterm audit was performed by an independent clinical 
researcher. 
 
56 
4.11 Biological samples collection 
Biological samples were collected from all screened patients and they were 
repeated at the 3 months and 6 months follow-up visits for the randomized patients. 
 
4.11.1 Venous blood sampling and processing 
From each consented patient were collected 48 ml of blood using red/white 
(E1480-0304) tubes for serum and green/white (E1480-0302) for plasma. Each 
tube was labeled with stickers with sample screening number, visit number, time 
and date. The red/white (E1480-0304) tubes for serum were let to clot for 30 
minutes, and then all the tubes were kept on ice for another 30 minutes. Each tube 
was centrifuged (2680rpm at 4 degrees) for 30mins. The allocated aliquots were 
1.5 mls (2 x750ul per tube). 
 
4.11.2 GCF sampling 
Gingival crevicular fluid was collected from four sites from the upper right and 
upper left quadrant (two premolars and two molars) using periopaper strips. 
(BRAND). Each site was isolated with sulcus cotton rolls and dried with air from 
triple syringe with 5 blasts buccal and palatal. The direction of the blast was from 
gingival to occlusal surface. The paper portion of the strip was inserted in the 
gingival crevice until gentle resistance was felt. The paper strip had to be stable, 
without falling for 30-seconds and then removed. If the strip has came out during 
sampling, the site was considered lost. The paper strip was inserted in a pre-
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calibrated Periotron 8000 (Oraflow, Plainview, NY) and the readings were recorded 
on the CRF form. The 4 paper strips were placed 2 by 2 in cryotubes (Appleton 
Woods, Birmingham, U.K.) and dry frozen with liquid nitrogen. 
 
4.11.3 Saliva sampling 
The purpose of saliva sampling was to allow the assessment of the presence of 
potential biomarkers of periodontal disease and/or systemic diseases. From each 
patient 1 ml of saliva was collected using a graded Falcon tube (Corning®, Corning 
Incorporated NY) and a sterile marble. Time was recorded, and if the target volume 
was not collected during the first 5 minutes, it was allocated another slot of 5 more 
minutes. Time was recorded for each 5 minutes necessary to obtain the 1 ml of 
saliva. When the target was reached, time and total volume were recorded, and 
based on this the flow rate was calculated automatically, when the data was 
introduced in the database. The samples were stored on ice, and then centrifuged 
at 2500rpm for 10 min to remove debris. The supernatant was transferred into a 
cryogenic vial (Greiner Bio-One, UK), without disturbing the pellet. A maximum of 
1.8ml was snap frozen in liquid nitrogen and stored in freezer at -80 °C. 
 
4.11.4 Subgingival plaque sampling 
The objective was to sample subgingival plaque from up to 6 “representative sites’” 
for a patient with periodontitis and 6 sites for a patient with healthy gums or 
gingivitis. These sites were as distant as possible from each other, one per sextant, 
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when possible. The deepest pockets (greater or equal to 4mm) were identified 
using detailed periodontal charting. For healthy patients or patients with gingivitis 
with less than 6 eligible pockets, there were selected as many pockets as possible. 
Once representative teeth have been identified, they were isolated using cotton 
wools rolls. Supragingival plaque was removed using a cotton wool pledget and air 
dried. 
 
4.12 Ultrasound 
Muskuloscheletal ultrasonography is considered an objective and reliable 
measurement of RA disease activity [109, 110].   
Before the start of recruitment, as part of this study, the researcher was trained and 
calibrated for the ultrasonic examinations at the Rheumatology Department of the 
Queen Elizabeth Hospital Birmingham. The researcher observed over several 
weeks ultrasonic assessments for patients with rheumatoid arthritis performed by a 
consultant rheumatologist specialised in musculoskeletal ultrasounds. After this, 
the researcher performed musculoskeletal ultrasonic assessments on healthy 
volunteers in order to get familiarised with the techniques and recognise the 
relevant anatomical structures. Following this phase, the researcher performed 
musculoskeletal ultrasonic assessment of wrists, knuckles and toes of patients 
diagnosed with rheumatoid arthritis. For each joint, several images longitudinal 
images were recoreded both in power-doppler and gray-scale format. For each 
joint a score was given from 0 to 3 whilst 0 representing no active inflammation and 
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3 representing high level of active inflammation (Table 6 and Table 7). The 
examination was performed independently both by the researcher and the 
consultant rheumatologist involved in the training and calibration of the researcher. 
The scores were compared and the examinations were repeated over several 
weeks on a large number of patients, until the assessments were presenting a high 
level of reliability with each other. 
The examination technique was developed and validated by the European Society 
of Musculoskeletal Radiology (ESSR) and used widely in other research projects 
as well, like APIPPRA (Arthritis Prevention In The Pre-Clinical Phase of RA with 
Abatacept) [111]. 
The randomized patients from both groups of this study were assessed at baseline, 
3 months and 6 months for grey-scale and power-doppler longitudinal ultrasound of 
the wrist (Inter-carpal, radio-carpal and ulnar-carpal) and metatarsophalangeal  
(MCP 1,2,3,4,5) joints.  A trained ultrasonographer, blinded for the patients 
periodontal treatment status, recorded a gray-scale and a power-doppler image on 
longitudinal view for each joint. Erosions, tenosynovitis and enthesitis was not be 
recorded in this study. 
The power-doppler grading was be based on OMERACT (Outcome Measures in 
Rheumatology) definitions [112] and the scheme of Szkudlarek [113] 
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Table 6 -Power-Doppler grading system 
Grade Description 
0 Absence of inflammatory signals 
1 Isolated signals 
2 Confluent signals in less than half of the synovial area 
3 Confluent signals in more than half of the synovial area 
 
Table 7 - Gray Scale grading system 
Grade Description 
0 Normal view 
1 Low grade synovitis. It will be measured the distance from the surface of 
the bone to the highest vertical point of the synovium) 
2 Moderate visible synovitis, not distorting overlying structures 
3 marked or very extensive synovitis, or synovitis distorting the overlying 
extensor tendons and related structures 
 
In the event of isoechoic synovitis (frequently seen in the wrist), the grayscale 
grade was estimated with the aid of the power-doppler grade if this was available. 
For example: if the power-doppler was showing active signal of at least grade 1 
synovitis, the greyscale image could never be graded as grade 0.  
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Figure 3 – Gray Scale and Power Doppler images of the wrist  
Gray scale Power Doppler 
 
Right Inter-Carpal longitudinal view 
 
 
Right Inter-Carpal longitudinal view 
 
Right Ulnar-Carpal longitudinal view 
 
Right Ulnar-Carpal longitudinal view 
 
Figure 3 presents an example of Gray Scale and Power Doppler images of the 
Right Inter Carpal joint and Right Ulnar Carpal joint, both in longitudinal view. The 
thick, black areas surrounding the epiphysis of the bone in Gray Scale are signs of 
synovitis as chronic inflammation (not active). The images in Power Doppler are 
presenting the same bones but with added information regarding the active 
inflammation (in red).  
The grading sheet used for this trial can be found in Appendix 13. 
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4.13 Randomization 
The patients that fulfilled the inclusion criteria and consented for treatment were 
randomized to one of the intervention arms: immediate treatment or delayed 
treatment. Birmingham Clinical Trials Unit (BCTU) generated the randomization list. 
The Treatment allocation was based on stratified randomization by anti-citrulinated 
protein antibody (ACPA) status (positive or negative). 
4.14 Intervention 
The patients randomized to the immediate treatment group were invited for 
treatment appointment with the dental hygienist allocated for this study. When the 
patients attended this appointment, before seeing the hygienist, a detailed, bilateral 
musculoskeletal ultrasound was performed as described in section 4.12. The 
reason for this was to minimize the possibility of influence of treatment at baseline. 
After the ultrasonic assessment, the patients received their first course of treatment. 
The treatment consisted of non-surgical periodontal therapy, completed in two or 
more sessions within three weeks of the baseline. Following oral hygiene 
instruction, scaling and root surface debridement (RSD) was performed under local 
anaesthesia using ultrasonic scalers and hand instruments as appropriate. After 
the follow-up appointments, all sites with greater or equal of 4mm probing depth 
and bleeding on probing were reinstrumented. The delayed treatment group 
(control group) received oral hygiene instructions only during the study period. 
Ultrasonic assessment was performed for this patient group as well, as per the 
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immediate treatment group. In the event of an increase in probing depth or clinical 
attachment loss of more than 2 mm (active site) between baseline and follow-up, 
site-specific rescue treatment was performed. All patients in the control group were 
offered the same periodontal therapy as the intervention group after study 
completion (6 months after baseline). 
 
4.15 Follow-up assessments 
All patients were followed-up at three months and six months after intervention. At 
the follow-up visits, the same biological samples, clinical rheumatologic and 
periodontal examinations and data from the validated questionnaires were 
collected as at baseline. 
 
4.16 Patients study flow 
Table 8 presents the patient study flow. The clinical patient lists for patients who 
were waiting for their follow-up appointment on the rheumatology clinic from the 
participating hospitals was pre-screened to identify the potentially eligible patients 
based on the eligibility criteria presented in paragraph 4.5 Inclusion criteria and 
paragraph 4.6 Exclusion criteria.  
The list of patients created was shared with the nurses and reception personnel 
that were awaiting the arrival of patients. Occasionally this list was also shared with 
the rheumatologists in case time allowed it.  
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The nurses or receptionists asked the patients if they are willing to have a 
discussion about the research project with a member of the research team while 
are waiting to be called for consultation. The patients’ answers were recorded on 
the pre-screening sheet. If the patient did not wish to have the discussion but 
provided reasons for that, those were also recorded on the prescreening sheet. 
If the patient agreed to have the discussion, the nurse or receptionist guided the 
patient to a room where a member of the research team (in most of the cases the 
author of this thesis) had a discussion with the patient. The patient was presented 
with the aims and methods of the OPERA study and all the aspects regarding 
confidentiality were respected. The patient had the possibility to ask questions and 
which were answered by the researcher. A written informed consent was offered to 
the patient if he or she decided to participate in the study. The next step was 
represented by setting up a date and time that was convenient for the patient, to 
attend the Screening visit at Birmingham Dental Hospital. At this occasion, the 
patient was asked if any assistance was required for transportation to the Dental 
Hospital from home or to return. If the patient required assistance, the researcher 
presented the option of free taxi that was made available through the Trust that 
operates the Dental Hospital. The researcher checked if the patient had any 
available ACPA results or ESR. If these were not available, the patient was asked 
if it would be convenient to have the blood tests done at the rheumatology clinic. 
 
Each patient received a the following documents: 
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• The Patient Information Sheet for Screening ( Appendix 5: Patient 
Information Sheet (PIS) Scr),  
• The written Informed Consent Form ( Appendix 6: Informed Consent Form 
(ICF) Screening)  
• Set of quality of life questionnaires (Appendix: 9, 10 and 11) 
The patients were asked to complete the questionnaires at home, before the 
Screening visit and to bring the questionnaires with them to the Dental Hospital at 
the time of their appointment.  
After these steps were completed the patients’ details were transmitted through 
secured NHS email to the Booking Office of Birmingham Dental Hospital. A new 
patient clinical note was created for each one of the new patients. A reminder letter 
with the appointment date and time for the Screening visit was sent out by post to 
each newly booked patient together with the phone number of the researcher in 
case the patient needed to change the booking on short notice.  
One or two days before the appointment, a research nurse called the patients to 
remind them of their appointment. If they were not available to answer the phone, 
an answer phone message was left where this was possible.  
After the patient arrived to Birmingham Dental Hospital, the patients reported to the 
reception and were guided to the waiting area for their Screening visit. In case the 
patients forgot to bring the completed questionnaires with them, they received one 
to fill out while they were waiting to be seen. 
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A specially allocated clinic was available for the patients during the time of the 
OPERA project in the Dental Hospital. The patients were invited for screening and 
the clinical measurements described in the Methodology chapter were performed.  
If the patients fulfilled the eligibility criteria for randomization and treatment, they 
were explained about the possibility to participate in the interventional phase of the 
study. The patients were offered written information about the intervention 
(Appendix 7: Patient Information Sheet (PIS) Treatment and if they agreed to 
participate, they were offered a written consent form (Appendix 7) 
The results of the Screening were completed in the Case report form specially 
developed for the OPERA project ( Appendix 9: Case report form) and in the 
clinical notes of Birmingham Dental Hospital.  
Birmingham Clinical Trials Unit (BCTU) was contacted over telephone and 
provided a random allocation to one of the treatment arms for the patient, as 
described in paragraph 4.13 Randomization. If the patient was allocated to the 
Immediate treatment group, the research nurse from the Periodontology 
Department booked three appointment with the Hygienist allocated for the project 
with a maximum three weeks after the Screening visit. If the patient was allocated 
to the Delayed treatment group, the research nurse booked only one appointment 
with the Hygienist.  
When the patients returned to the Dental Hospital, before meeting the hygienist, 
the patients from both groups had an approximately half an hour appointment with 
the author of this thesis for ultrasonic assessment as described in subchapter 4.12 
Ultrasound. This was important to avoid the potential contamination of the 
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ultrasound assessment by the dental hygiene treatment. The author of this study 
was blind to the treatment allocation status of the patients to assure consistency of 
the assessment across treatment arms.  
After the ultrasonic assessments the patients were accompanied for the first 
appointment with the Dental Hygienist.  
The OPERA study protocol required that the first Follow-up appointment for the 
Immediate treatment group to be booked at three months after the completion of 
the non-surgical periodontal treatment. For the Delayed treatment group this was 
at three months after their one appointment with the Dental Hygienist.  
For the first follow-up visit the patients from both groups, completed the same 
questionnaire and had the same clinical assessments and ultrasound like at the 
Baseline visit. After the periodontal examination, if the patients from the Immediate 
treatment group presented the need for more periodontal treatment, a new 
appointment was booked with the same Dental Hygienist. If the patients from the 
Delayed treatment group presented a significant increase of their level periodontitis 
as described in the Protocol, they were offered localized rescue treatment.  
The last follow-up appointment was at three months after the second appointment 
for both groups, or at three months after the completion of periodontal treatment for 
the cases where this was necessary.  
The same quality of life questionnaires and clinical assessments were performed 
as at the three months appointment. The patients that were part of the Delayed 
treatment group were offered three appointments with the same Dental Hygienist 
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for periodontal treatment. All the patients, at the end of the study received £150 to 
cover the possible costs regarding their time for study participation.  
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Table 8 - OPERA patient’s study flow 
 
  
Study procedure Screening Visit 1 with 
hygienist 
Follow-up 1 Follow-up 2 
 Rheumatology 
Clinic 
Dental 
Hospital 
   
Informed consent 
for screening X X    
General 
examination  X  X X 
Inclusion 
exclusion  X    
Disease Activity 
Score (DAS28)  X  X X 
Periodontal 
examination  X  X X 
Quality of life 
questionnaires  X  X X 
Biological sample 
collection  X  X X 
Informed consent 
for treatment  X  X X 
Randomization  X     
Ultrasound    X X X 
Intervention    X   
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4.17 Objectives 
4.18 Primary objectives 
The primary objective of this pilot study was to assess the feasibility of the 
intervention, to establish recruitment and retention rates, to gauge the acceptability 
of the intervention and study procedures to patients. This was achieved through a 
mixed methods approach of qualitative and quantitative research methods as 
described in the Methodology section. 
4.19 Secondary objectives 
The secondary objective was to collect pilot data regarding the efficacy and safety 
of intensive periodontal therapy and maintenance administered by dental 
hygienists in a secondary care setting to reduce disease activity and improve 
function for patients diagnosed with rheumatoid arthritis. 
4.20 Statistical analysis 
This trial was a pilot study and no formal sample size calculation was required. 
However, being also a feasibility study, the periodontal treatment that was 
delivered needed to achieve a minimum level of clinically significant outcome in 
terms of periodontal healing (pocket probing depths reduction at 3 and 6 months). 
A reasonable minimum threshold criterion was to expect an effect size of 1 for 
reduction of mean probing depth. This feasibility study had >90% power to detect 
such an effect size, even allowing for 20% loss to follow-up. The plan of analysis 
took into consideration the following endpoints:  
• •Periodontal endpoints  
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• Ultrasound joint scores  
• DAS28 scores 
• Quality of life questionnaires (OHIP, EQ-5D, PHQ9)  
Summary statistics were calculated as appropriate. To test for between group 
differences at 3 and 6 months, parametric and non-parametric methods were used 
as appropriate. For continuous variables, differences between groups at 3 and 6 
months, adjusted for baseline. For normally distributed endpoints t-test was used 
and skewed data was analyzed using Mann–Whitney–Wilcoxon test. The 
categorical variables were analyzed using chi-squared test [114].  
All the statistical analysis was performed using StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP.   
  
72 
4.21 Qualitative research methodology 
Using qualitative research methods it was possible to get a more detailed insight 
about the way rheumatoid arthritis affects the life of the patients, as well as their 
values and perceptions about oral health that could influence their choices to 
participate in such a study. 
 
4.22 One to one interviews 
Semi-structured interviews were designed to include the views of all the patient 
categories in this study.  
These categories were:  
a. Patients randomized to the immediate treatment group  
b. Patients randomized to the delayed treatment group  
c. Patients that were screened but were not eligible for treatment  
d. Patients that refused to be screened  
 
Data from the first five patients in these groups was used to design the topic guide 
for the semi-structured interviews. The initial topic framework that was developed 
by the research team included: oral health maintenance, treatment preferences 
(dental and medical), access to dental care, priorities/values placed on oral health, 
quality of life issues, acceptability of the intervention and, if applicable, reasons for 
non-participation. The interviews were conducted at Birmingham Dental Hospital, 
Queen Elizabeth Hospital or over the phone. The interviews were audio recorded 
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and, subsequently, fully transcribed. Consecutive patients were sampled and the 
interviews were conducted until saturation was reached. We intended to include 
subsamples of the patient population as patients who refused to consent for trial 
participation, patients who were screened but not eligible for randomization, 
patients who were randomized in the immediate treatment group and patients who 
were randomized in the control (delayed treatment) group.  This ensured a broad 
range of views and provided a more comprehensive understanding of the subject. 
 
4.23 Qualitative data analysis 
A framework approach to data analysis was adopted in the manner suggested by 
Pope et al. [28] Based on the research questions, was developed a preliminary 
framework. The transcripts were read and, following familiarization with the data, 
the initial framework was expanded to reflect themes emerging from the interviews. 
The data was then indexed according to the framework and further refined. To 
guard against bias the transcripts were analyzed independently by a second 
researcher. The findings were presented and consensus was achieved on the 
emergent themes and issues. 
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4.24 Qualitative research methodology used in the OPERA study  
4.24.1 A brief overview of the methodology 
Patients diagnosed with Rheumatoid Arthritis that attended the Outpatient 
Rheumatology Clinics from Queen Elizabeth Hospital Birmingham, City Hospital 
Birmingham and Heartlands Hospital Solihull, were approached by members of the 
research team and offered participation in the OPERA trial. The patients that 
expressed their interest to find out more about the study were offered written 
information sheets with detailed description of the study and the members of the 
research team explained the procedures and the purposes of the research project. 
The patients had the possibility to ask questions from members of the research 
team. The patients that agreed to participate were offered written consent form for 
the screening visit at Birmingham Dental Hospital. A number of patients who did 
not wish to consent for the screening were offered the possibility to help the project 
by participating in a qualitative interview, either face to face either over the phone. 
This was necessary to gather qualitative data about reasons to participate or not in 
the study and identify potential barriers to access and care that could be addressed 
by the research team. The patient population that did not wish to participate in the 
screening for OPERA but agreed to participate in the qualitative interviews was 
especially important to fulfill the feasibility aim of this study by providing valuable 
insights in their perceptions about the study, about oral health and about their 
health care priorities.  
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All the participants that were interviewed were consented verbally on the recording 
device. The patients were provided with detailed explanations about confidentiality 
and their possibility to withdraw anytime from the study. The author conducted 
semi-structured interviews with the patients, based on the initial topic guide 
developed by the research team and implemented as pilot with the first three 
participants.  
As new themes emerged from the discussions, the topic guide was constantly 
adapted and new themes were added until saturation was reached. Saturation was 
defined as the stage in which no new themes emerged from the interviews and the 
data started to become mainly repetitive. After saturation, three more interviews 
were conducted for quality assurance purposes.  
The semi-structured interviews were conducted face to face in a room with closed 
doors to assure privacy. The location was either at the Queen Elizabeth Hospital 
Birmingham, Rheumatology Outpatients Department, either at Birmingham Dental 
Hospital. At the first five interviews, a more experienced qualitative researcher that 
observed the interview process and intervened and provided feedback when 
necessary accompanied the author of this study. This was important to assure the 
correct calibration of the interviewer and the accurate implementation of the 
methodology. For a few patients that preferred the interviews to be conducted over 
the telephone, the researcher accommodated this request. The reason for this was 
mainly through time constraints, logistics and convenience on the patient’s side.  
After the methodology and aims of the qualitative research approach were 
explained in details to the patients, and the issues related to confidentiality and 
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freedom for withdrawal from the study was underlined, informed consent was 
obtained from all the patients.  
The semi-structured interviews were recorded on a digital recorder (Olympus VN-
713PC Voice Recorder - 4GB Flash Memory, WMA/MP3, Manufacturer Part 
Number 4545350039745 Black). This was used both for the face to face interviews 
as well as for the interviews that were conducted over the telephone. 
 
4.25 Topic guide - development and pilot 
A multidisciplinary team of experts composed of specialists in rheumatology, 
qualitative researchers and dentists, developed the initial topic guide before the 
start of the patient’s recruitment in the study. This topic guide was based on the 
clinical experience of the experts involved in the study and then corroborated with 
additional topics identified from the literature. This initial topic guide was applied as 
a pilot with 3 patients that consented to participate. The piloting phase was 
developed and implemented by the author and an expert in qualitative research to 
assure the methodological accuracy of the interview process. The results of these 
3 interviews were included in the overall findings.  Based on the dynamics of the 
discussions and the flexible structure of the interviews, new themes emerged that 
were incorporated in the topic guide and added to the interviews with the following 
participants. Each time a new theme emerged from an interview, this new theme 
was added to the topic guide and discussed with the next participants. 
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4.26 Saturation  
The semi-structured interview framework allowed the necessary flexibility and 
freedom for discussion with the participants in order to identify all the possible new 
themes that could emerge. As new themes emerged, these were added to the 
topic guide and included in the discussions with new participants. When no more 
new themes emerged and the discussions started to reach a repetitive status it 
was considered that saturation was reached. A second researcher, expert in 
qualitative research methods was involved independently in the data analysis and 
confirmed the saturation status of the interview process. In order to assure a 
stronger internal validity, three more interviews were conducted following 
saturation. No new information emerged from these discussions, as a result 
saturation was considered to be reached. 
 
4.27 Population sample for the qualitative part of OPERA 
For the aims of this study, random purposive sampling was considered the 
appropriate method of sampling of the participants until saturation was reached. 
Patients diagnosed with rheumatoid arthritis visiting the Outpatient Rheumatology 
Clinics from Queen Elizabeth Hospital Birmingham, City Hospital Birmingham and 
Heartlands Hospital Solihull represented the patient population. The patients were 
approached by members of the research team and offered detailed information 
about the research project.  
For the qualitative interview process, the patient sample was composed of: 
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• patients who consented for screening for the clinical research project,  
• patients who were found eligible after the screening and were randomized 
to either the intervention or the control group 
• patients who did not consent to be screened for the clinical trial. 
 
4.28 Interviews   
The interview process was realized by using a one to one, face to face, semi-
structured interview process. The patients were explained initially about the ethical 
considerations, confidentiality and freedom to withdraw from the study. After the 
patients consented, the interviews commenced and were recorded on a recording 
device. The recordings were transcribed without incorporating any personal 
information from the patients. The transcription was performed by one medical 
secretary working for Birmingham Dental Hospital. The interviews were conducted 
in a suitable room, assuring the patients right for privacy and comfort at Queen 
Elizabeth Hospital and Birmingham Dental Hospital. In a few cases, the patients 
preferred to have the interview conducted over the phone.  
 
4.29 Analysis  
After the interviews were transcribed, data analysis was performed. The transcripts 
were read carefully and all the new themes that emerged from the discussions 
were added to the topic guide. The relevant quotes from patients were identified 
from the transcripts and added to each theme. The data was independently 
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analyzed by a second researcher, expert in qualitative research methods to assure 
validity and reliability of the findings.  
One of the reasons why this was important was to assure quality and consistency 
through the data analysis in order to be able to present the findings in a 
comparable way with the current literature. Another reason was to control for any 
potential bias in data analysis and interpretation from the author of this thesis thus 
assuring a higher level of objectivity of the results. 
After this topic guide was applied as a pilot for to the first three participants, further 
topics emerged from the discussions that were included on an on-going basis to 
the final framework. 
The first three topics: Introduction, Rheumatoid arthritis and systemic health and 
Periodontitis and oral health did not suffer significant changes. The final initial topic 
guide and the final topic guide can be found in Appendix 16.  
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5  Results 
 
5.1 Pre-screening  
The pre-screening phase of the trial took place in the Rheumatology Outpatient 
Departments from the Queen Elizabeth Hospital Birmingham (University Hospitals 
Birmingham NHS Foundation Trust) and City Hospital Birmingham (Sandwell and 
West Birmingham Hospitals NHS Trust). At a later stage, the Rheumatology 
Outpatient Department of Heartlands Hospital (Heart of England NHS Foundation 
Trust) was initiated as well as a recruitment site. The reason for this was to 
increase the number of patients participating in the study. The first two sites were 
operated directly by the author of this study, whilst the third site was operated by 
the members of the research team from the department: one rheumatology 
consultant, one research nurse and one research administrator.  
A pre-screening log was created, as part of the feasibility endpoints to identify the 
potential number of patients that could be approached for consent and study 
participation. Information was recorded also regarding the potential causes for 
refusal of study participation.  
Of a total number of 649 patients identified, 296 consented to take part in the 
screening phase of the trial. The main reason reported by patients for refusing 
study participation was lack of interest. This was reported by 85 patients.  
Other reasons that were reported were edentulism, severe comorbidities that 
would have impaired study participation, good self-perceived oral health, work and  
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language barriers. These categories of reasons are presented in Table 9- Pre-
screening log. The prescreening log was not available at HEFT 
Out of the 296 patients that consented to take part in the screening phase of the 
trial, 95 did not attend the screening visit as illustrated in Figure 4 – The 
CONSORT Flow Diagram 
Table 9- Pre-screening log 
 
QEHB= Queen Elizabeth Hospital Birmingham; SWBH = City Hospital, Birmingham;  
HEFT = Solihull Hospital 
*Pre-screening log data unavailable at HEFT due to shortage of personnel in the local research 
team. 
 
5.1.1 Informed refusal 
Informed refusal was defined as the patient’s choice to refuse consenting for study 
participation after being informed by one of the members of the research team 
about the study. Almost half of the patients (85 patients) who refused to participate 
in the study were part of the informed refusal group. Considering that this is a 
feasibility study, it was important to tackle the more specific reasons for the 
phenomena and to get a deeper understanding of the reasons for this choice of the 
patients. Some of the patients that refused to consent as being part of the informed 
		
Total		 Total	Consent	
Total	
refuse	
Refused	with	reasons	
Not	
eligible	
(Edent)	
Missed	
Comorb	
Good	 Dental	
Work	 Lang.	
		 		
OH	 phobia	
QEHB	 290	 103	 73	 52	 11	 2	 6	 2	 20	 80	
SWBH	 359	 182	 45	 33	 2	 1	 3	 6	 19	 109	
HEFT*	 		 11	 		 		 		 		 		 		 		 		
Total	 649	 296	 118	 85	 13	 3	 9	 8	 39	 189	
82 
refusal group, kindly agreed to be part of the qualitative interview process. The 
results of those interviews are presented in the Qualitative Results chapter. 
 
5.1.2 Edentulism 
The patient’s medical history was assessed on the day’s clinic list at the Outpatient 
Rheumatology Departments from the participating NHS Trusts. After identifying the 
patients who would potentially fulfill the inclusion/exclusion criteria, the patients 
were approached for informed consent. The medical history of the patients did not 
contain information regarding the state of their dentition. Edentulism was the 
second most prevalent cause for not being eligible for consent for study 
participation. This was reported by 39 patients.  
 
5.1.3 Comorbidities 
As described in the Methods Chapter, comorbidities were defined as any condition 
that would not represent any exclusion criteria but which could potentially preclude 
study participation from the patient’s perspective. These could be severe cardio-
vascular conditions, severe respiratory conditions or severe mobility problems. The 
patients described the fact that because of their comorbidities they already struggle 
attending several hospital appointments and they do not wish to commit to the 
research project, which could be a potentially increased burden for them in regards 
of new hospital appointments at Birmingham Dental Hospital. The comorbidities 
group was composed of 85 patients. 
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5.1.4 Good self-reported oral health 
A number of patients that were approached for study participation answered that 
they are happy with their current oral health status and do not wish to participate in 
the study. Some of these patients described that they do not believe to have 
periodontal disease or that they believe that in case they would have this condition, 
their general dental practitioner would have informed them about this and offered 
them treatment. There were 13 patients in this group. 
 
5.1.5 Work commitments 
A small number of patients, in general from a younger age group were unable to 
consent because of work commitments. These patients reported the fact that their 
work schedule is not flexible and it would not allow them to attend screening and 
treatment appointments to Birmingham Dental Hospital. 
 
5.1.6 Language barrier 
Language was considered a potential challenge for this study. Some patients that 
were not fluent in English did consent to participate as they had family members 
whom were happy to provide translation. As this study had also a component 
regarding quality of life questionnaires, it was considered unfeasible to offer study 
participation for patients who did not have any family support that could have 
offered them help to fill out the questionnaires. 
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5.1.7 Dental phobia 
Three patients reported that they experienced traumatizing events with regards to 
dental treatment in the past, which lead them to dental phobia. The patients 
reported that this would make it impossible for them to attend the screening visit at 
the Dental Hospital. 
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5.2 OPERA – Patient flow 
 
5.2.1 Recruitment  
The first consented patient attended the screening visit on the 01.02.2014. The 
recruitment stopped with the last patient who was randomized on the 08.10.2015  
A number of different recruitment approaches were developed for the OPERA trial, 
as presented in section 4.4 Recruitment procedures.  
 
 Letters to request permission for approach  5.2.1.1
In the beginning of the trial the clinical team from the rheumatology department of 
Queen Elizabeth Hospital Birmingham, recommended that the patients should be 
contacted by post, one week prior to their clinical appointment to request their 
permission to be approached during their clinical appointment regarding study 
participation. Standard letters were issued together with pre-stamped and pre-
addressed response envelopes and these letters were sent to the patient list for 
the following weeks rheumatology clinics. The standard letters are presented in 
section 10 
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 Appendix 4: Recruitment letter. The patients had the option of ticking one box if 
they were happy to be approached by members of the research team or another 
box if they were not. The letters were sent back to Birmingham Dental Hospital – 
Oral Surgery Department. The following week, the members of the research team, 
approached the patients that expressed their permission to be approached in 
person. A number of issues were identified with this procedure that is presented in 
section 6. 
 Recruitment posters 5.2.1.2
As the recruitment days were Mondays and Tuesdays and screening days were 
Wednesday to Friday, the research team considered developing a poster with 
basic information about the study and contact details from the investigator. An 
amendment was submitted for ethical approval (Appendix 2: Ethics Approvals) and 
after receiving permission recruitment posters were placed in the rheumatology 
departments of all three participating hospitals ( Appendix 13: Recruitment poster) 
As the outpatients rheumatology department of Queen Elizabeth Hospital 
Birmingham is situated in a new building, which is part of a Private Finance 
Initiative (PFI) with Consort Healthcare Ltd., the recruitment posters for the study 
were not placed on the corridors and waiting areas because of the technical and 
financial burden that this would have imposed but they were placed inside the 
consultation rooms. The poster was designed by the author of this thesis.  
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In all the other participating NHS Trusts, the recruitment posters were placed in the 
waiting areas and corridors where patients could easily see them while waiting for 
their consultations. 
In general, the posters were received with interest and enthusiasm from both 
patients and clinicians. On several occasions, on days when members of the 
research team were not present in the rheumatology departments, patients 
contacted a member of the research team via phone to express their interest for 
study participation. After providing their details, a member of the research team 
would check their potential eligibility for the study via the clinical portal and contact 
the patients regarding their potential eligibility for screening.  
 
 Technical aspects 5.2.1.3
Birmingham and Black Country Comprehensive Local Research Network (BBC 
CLRN) requested that all members of the research team that recruited patients 
across the NHS Trusts should have a research passport set in place. The 
procedure to obtain took nearly six months however, shortly after this, the BBC 
CLRN confirmed that this was an administrative failure on their side, as the 
requirements should have been only for an NHS to NHS letter of access which is a 
much easier and straight forward procedure. In the beginning of the recruitment 
phase, the members of the research team were present only in outpatient 
rheumatology department of Queen Elizabeth Hospital, Birmingham. 
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In City Hospital and Heartlands Hospital, local research administrators and 
research nurses did the recruitment initially. As the recruitment was stagnating in 
these two sites compared to Queen Elizabeth Hospital, after a number of meetings 
it was decided that members of the recruitment team should also visit City Hospital, 
Birmingham to assist the local team with the recruitment process. After the author 
of this thesis was allocated to recruit patients from all sites, the number of patients 
increased to 10-15 patients for each week from Queen Elizabeth Hospital and City 
Hospital. This however, only happened after members of the research team 
personally attended the outpatient rheumatology clinics from the participating NHS 
Trusts.  
Heartlands Hospital (Heart of England NHS Foundation Trust) was the last site that 
was initiated for recruitment. Here the recruitment was done exclusively by the 
local research team of the outpatient rheumatology department with aid of the 
approved recruitment posters.  
The patients consented during their routine follow-up visit at the Outpatient 
Rheumatology Departments of the NHS Trusts that were participating in the study. 
At this routine visit, the patients were give the written “Patient Information Sheet 
(PIS) Screening” that provided information regarding the aims and objectives of the 
study. The PIS described in lay terms the methodology of the study and 
confirmation of the patients freedom of withdrawal at any point during the study. 
The patients had the possibility to ask questions about the trial and if they agreed 
to participate, they were provided with written Informed Consent Forms (ICF). With 
this occasion they were also offered a time and date that was convenient for them 
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for the screening visit at Birmingham Dental Hospital (Birmingham Community 
Healthcare NHS Foundation Trust) 
 
5.2.2 Screening 
The screening visit took place at Birmingham Dental Hospital and it was attended 
by 201 (67.9%) patients of the 296 of the total number of consented patients. A 
total number of 95 patients failed to attend their screening visit. 
 
5.2.3 Inclusion/Exclusion 
From the total number of 201 patients who attended the screening visit 100 
(49.7%) did not fulfill the periodontal inclusion criteria. Furthermore, 46 (22.8%) 
patients did not fulfill the rheumatologic criteria having a rheumatologic disease 
activity score (DAS28) of less than 3.2.  
 
5.2.4 Randomization 
Of the 201 patients that attended the screening visit, 60 were randomized into one 
of the treatment arms: Immediate or Delayed Treatment. The number of 
randomized patients was agreed based on the estimates made by the consultant 
rheumatologists involved in the trial by and consulting the literature as described in 
the study protocol. The treatment allocation was random and it was operated via a 
telephone service by Birmingham Clinical Trials Unit (BCTU) - University of 
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Birmingham. The randomization was stratified based on age, gender, and anti-
citrullinated protein antibody (ACPA) values that could be positive or negative.  
The first follow-up visit, as described in the methodology chapter, was scheduled at 
3 months from baseline for the Delayed Treatment group and 3 months after 
completion of the periodontal treatment for the Immediate Treatment group. 
 
5.2.5 Loss to follow-up 
Visit number two was the first follow-up visit. At this time point 4 patients dropped-
out from the Immediate treatment group and 3 patients from the Delayed 
Treatment group. 
The third visit represented the last follow-up visit. This took place at three months 
from visit number two for the Delayed Treatment group. If patients from the 
Immediate treatment group required more periodontal treatment as evidenced at 
the first follow-up visit, the last follow-up visit took place at three months after the 
completion of this treatment. 
The third and last follow-up visit took place at six months from Baseline. One more 
patient was lost to follow-up in the Delayed Treatment group, which was attended 
by 26 patients. There were three more patients that were lost to follow-up in the 
Immediate Treatment group, which in the end had 23 patients (Figure 4 – The 
CONSORT Flow Diagram) 
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Figure 4 – The CONSORT Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Some of the Excluded patients did not meet both periodontal and rheumatologic 
chriteria. The total number of ineligible patients after screening was 141. 
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5.2.6 Follow-up appointments  
Several patients experienced significant delays in their appointments. The study 
protocol established that after consenting for treatment, the patients were 
randomized to one of the treatment arms and they received their first appointment 
with the Dental Hygienist two weeks after the screening visit. In practice this was 
not always feasible as often patients were not free in the exact given time frame. 
Furthermore other delays were caused by issues relating to staffing and waiting 
times at Birmingham Dental Hospital or patients cancelling appointments on short 
notice without being able to find a new appointment on a close enough time scale. 
This was especially the case for the first appointment with the Dental Hygienist.  
In case a patient failed to attend the appointment with the Dental Hygienist, 
Birmingham Dental Hospital’s policy is to discharge the patient and send a letter to 
the referring dentist. As the referring dentist for this study was also from the Dental 
Hospital, if a patient failed to attend the appointment with the Hygienist it often took 
a long time until the information was forwarded to the members of the research 
team and they managed to book a new appointment for the patient.  
This has led to significant delays for the first appointment with the Hygienist and as 
a consequence for the first follow-up appointment in the study.  As the first follow-
up appointment (Visit 2), according to the study protocol should have taken place 
at three months after the final treatment performed by the Dental Hygienist (for the 
Immediate Treatment Group) and three months after the one appointment with the 
Hygienist (for the Delayed Treatment Group) this often took place much later. As 
illustrated by Table 10 - Time spent between follow-up appointments, it took a 
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median of 1.5 months for the patients to see the Hygienist for the first time. The 
protocol required for this period to be no longer than 2 weeks. The treatment for 
the Immediate treatment group took approximately 2 weeks. These delays lead to 
an average waiting time of 5 months from Baseline to Visit 2. For the final visit 
(Visit 3) the delays were less severe with a median of value of 2.9 months for the 
Immediate treatment group and 3.2 months for the Delayed treatment group.  On 
average a patient spent over eight months as part of the study. 
These caused no statistically significant differences between the immediate and 
delayed group in terms of visit delays.  
Table 10 - Time spent between follow-up appointments 
Time 
Immediate 
Treatment 
(n=30) 
Delayed 
Treatment 
(n=30) 
p-value 
Baseline- Treatment start, 
median [IQR] (months) 
1.51 
 [0.93, 2.1] 
1.38  
[0.98, 2.5] p=0.794 
Treatment duration, median 
[IQR] (days) 
14  
[7, 31] N/A N/A 
Baseline - Visit 2, median 
[IQR]  (months) 
5.0  
[4.0, 6.6] 
4.8  
[4.3, 6.8] p=0.782 
Visit 2 - Visit 3, median 
[IQR] (months) 
2.9  
[2.7, 3.2] 
3.2  
[2.5, 3.9] p=0.286 
Overall time in study 
median [IQR] (months) 
8.1  
[7.1, 9.4] 
8.2  
[7.3, 10.5] p=0.325  
Mann-Whitney two-sample test presenting the differences between the two 
treatment arms in terms of time spent between appointments.  
(Median represents the 50% percentile and the interquartile range (IQR) is the 75th 
percentile minus the 25th percentile.) 
 
5.3 Sample characteristics – Screening 
The screening process started on the 01.02.2014 with the first patient screened, 
and ended with the last patient randomized on the 08.10.2015  
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Table 11 – Patient characteristics by eligibility  
		 Eligible 
(n=60) 
Not 
Eligible 
(n=141) 
p-value 
Demographic 
characteristics    
Age, years 58 [51, 64] 60 [49, 67] p=0.382 
Female, N (%) 45 (75.0) 96 (68.1) p=0.136 
Ethnicity, N (%)     p=0.027 
White       
British 30 (50.0) 95 (67.3)   
Irish 1 (1.6) 3 (2.1)   
Any other white 0 (0.0) 1 (0.7)   
White and black Caribbean 1 (1.6) 1 (0.7)   
Any other mixed background 1 (1.6) 0 (0.0)   
Indian 11 (18.3) 5 (3.5)   
Pakistani 6 (10.0) 7 (4.9)   
Bangladeshi 1 (1.6) 0 (0.0)   
Black Caribbean 6 (10.0) 7 (4.9)   
Black African 0 (0.0) 1 (0.7)   
Any other black background 0 (0.0) 1 (0.7)   
Other 1 (1.6) 3 (2.1)   
Missing 2 (3.3) 17 (12.0)   
Smoking status, N (%)     p=0.390 
       Ex-smoker 18 (30.0) 50 (35.4)   
       Never smoked 27 (45.0) 66 (46.8)   
       Smoker 15 (25.0) 16 (11.3)   
       Missing 0 (0.0)  9 (6.3)   
Smoking amount (cigs/day)  15 (8.7)  14 (9.3)    
Height (m) 1.6 (0.1) 1.7 (0.1) p=0.026 
Weight (kg) 79.9 (20.6) 78.6 (16.8) p=0.677 
BMI 30.0 (7.4) 28.4 (5.9) p=0.115 
SBP (mmHg) 138.6(22.2) 140 (19.6) p=0.312  
DBP (mmHg) 85.8 (13.6) 84.8 (13.6) p=0.667 
Continuous variables are presented as mean (SD) or median [IQR] 
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Table 12 - Periodontal and rheumatologic outcomes by eligibility   
		 Eligible 
(n=60) 
Not Eligible 
(n=141) p-value 
Oral health data 
    
Median [IQR] number of teeth  23 [19, 26] 24 [20, 27]  p=0.236 
Number of sites with periodontal 
probing depth (PPD) ≥6mm 
6 [1, 8] 1.5 [0, 1] p<0.001 
Proportion of sites/mouth PPD ≥ 3 mm  39 (23) 15 (18) p<0.001 
Proportion of sites/mouth PPD ≥ 5 mm 7 (11) 2 (6) p<0.001 
Proportion of teeth/mouth PPD ≥ 3 mm 68 (23) 32 (26) p<0.001 
Proportion of teeth/mouth PPD ≥ 5 mm 17 (22) 5 (13) p<0.001 
Periodontal Inflamed Surface Area 
(PISA) mm2 
381  
[193, 745] 
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 [42,333] p<0.001 
Cumulative probing depth 64 [50, 89] 25 [12, 41] p<0.001 
Mean periodontal probing depth (mm) 3.4 (0.7) 2.6 (0.6) p<0.001 
Mean bleeding on probing (% of sites) 30 (22) 17 (18) p<0.001 
Mean clinical attachment loss (mm) 3.8 (1.0) 3 (0.9) p<0.001 
Rheumatologic data 
    
DAS28 4.9 (1.1) 3.4 (1.4) p<0.001 
ESR 22 (16) 15 (16) p=0.023 
Visual analogue scale (VAS) 60 (21) 41 (27) p<0.001 
Tender joint count 12.1 (8.0) 6.5 (7.3) p<0.001 
Swollen joint count 2.7 (3.2) 1.6 (2.8) p=0.022 
Questionnaire data 
    
Mean score EuroQuol  12.7 (2.6) 12.0 (2.9) p=0.140 
Mean score Patient Health 
Questionnaire PHQ-9  11.1 (7.6) 7.7 (7.0) p=0.007 
Mean score Oral Health Impact Profile 
OHIP-14  14.5 (12.0) 8.8 (10.5) p=0.002 
Variables are presented as mean (SD) or median [IQR] 
 
Table 11 and Table 12 present the demographic characteristics as well as some of 
the main clinical endpoints for the screened population comparing the 
characteristics of the randomized patients with the non-randomized ones. The age 
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of the participants was relatively balanced between eligible and non-eligible 
patients; the randomized patients group being slightly younger than the not 
randomized one: the median age for the randomized patients was 58 [51, 64] years 
whilst for the non-randomized ones was 60 [49, 67] years of age. The median 
value was the 50% percentile and the interquartile range (IQR) was the 75th 
percentile minus the 25th percentile. 
In terms of gender, women in both groups were representing two thirds of the 
patients. 
In terms of ethnicity, Birmingham area provided a unique opportunity to include 
patients from several different ethnic backgrounds. Although most of the patients 
reported to be white British, the group presented a heterogeneous structure 
encompassing patients from several different ethnic backgrounds. Patients that 
reported Indian ethnicity, constituted the second most represented patient group in 
the cohort, followed by Pakistani and Black Caribbean patients.   
In terms of blood pressure, both groups presented slightly increased values of 
blood pressure.  
There was no significant difference between the groups regarding smoking habits; 
both groups consisting of relatively equal percentages of smokers, ex-smokers and 
patients that reported to be never smokers.  
In terms of number of teeth there were no major differences between the 
randomized vs non-randomized patients.  
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As expected, based on the inclusion/exclusion criteria of the study, the patients 
from the randomized group presented significantly higher rheumatologic disease 
activity and worse periodontal status.  
The randomized group presented a slightly higher BMI value compared to the non-
randomized one with 30.0 (7.4) versus 28.4 (5.9). 
 
5.4 Sample characteristics for the randomized patients at baseline 
Table 13 presents the baseline characteristics for the Immediate treatment and 
Delayed treatment groups. The treatment group allocation was based on stratified 
randomization based on gender, age and anti-citrullinated protein antibody (ACPA) 
status. 
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Table 13 - Baseline patient characteristics by treatment groups  
		
Immediate 
Treatment 
(n=30) 
Delayed 
Treatment 
(n=30) 
Demographic 
characteristics   
Age, years 59 [52,65] 57 [50,61] 
Female, N (%) 20 (67) 25 (83) 
Ethnicity, N (%)   
White     
British 18 (64.3) 12 (40.0) 
Irish 0 (0.0) 1 (3.3) 
Any other white 0 (0.0) 0 (0.0) 
White and black Caribbean 0 (0.0) 1 (3.3) 
Any other mixed background 0 (0.0) 1 (3.3) 
Indian 4 (14.3) 7 (23.3) 
Pakistani 2 (7.1) 4 (13.3) 
Bangladeshi 0 (0.0) 1 (3.3) 
Black Caribbean 3 (10.7) 3 (10.0) 
Black African 0 (0.0) 0 (0.0) 
Any other black background 0 (0.0) 0 (0.0) 
Other 1 (3.6) 0 (0.0) 
Missing 2 (6.7) 0 (0.0) 
Smoking status, N (%)     
Ex-smoker 11 (36.7) 7 (23.3) 
Never smoked 11 (36.7) 16 (53.3) 
Smoker 8 (26.7) 7 (23.3) 
Smoking amount  13.1 (7.9)  17.7 (9.4) 
Height (m) 1.64 (0.08) 1.62 (0.07) 
Weight (kg) 82.8 (22.8) 76.9 (18.1) 
BMI 31.0 (7.9) 29.2 (7.0) 
SBP (mmHg) 142.6 (21.3) 134.8 (22.8) 
DBP (mmHg) 86.8 (14.6) 84.8 (12.8) 
Continuous variables are presented as mean (SD) or median [IQR] 
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Table 14 – Periodontal and rheumatologic outcomes at Baseline by treatment group  
		 Immediate 
Treatment 
(n=30) 
Delayed 
Treatment 
(n=30) 
Oral health data   
Cumulative probing depth 64 [44,80] 64 [56,90] 
Mean periodontal probing depth (mm) 3.4 (0.7) 2.6 (0.6) 
Mean bleeding on probing (% of sites) 30 (22) 17 (18) 
Number of teeth 22 [15, 25] 25 [20, 26] 
Number of sites with PPD≥6mm 5.1 [1, 8] 7 [1, 9] 
Proportion of sites/mouth PPD ≥ 3 mm (%) 40 (22) 38 (24) 
Proportion of sites/mouth PPD ≥ 5 mm (%) 7 (12) 7 (11) 
Proportion of teeth/mouth PPD ≥ 3 mm (%) 71 (20) 66 (21) 
Proportion of teeth/mouth PPD ≥ 5 mm (%) 18 (22) 17 (23) 
Periodontal Inflamed Surface Area (PISA) mm2 374  
[180, 745] 
390 
 [203, 720] 
Rheumatologic data   
ESR 18 (14) 26 (18) 
Visual analogue scale (VAS) 56 (23) 65 (18) 
Tender joint count 11.6 (7.9) 12.6 (8.1) 
Swollen joint count 2.3 (2.8) 3.1 (3.6) 
Mean binarised Power Doppler ultrasound score 3.3 (4.0) 4.7 (4.9) 
Mean binarised Gray Scale ultrasound score  5.8 (3.9) 6.6 (4.6) 
Mean summary analysis Power Doppler ultrasound 
score  5.2 (5.6) 7.2 (8.4) 
Mean summary analysis Gray Scale ultrasound score  10.0 (6.8) 12.1 (9.7) 
Disease-modifying anti-rheumatic drugs (DMARDs), N 
(%) 11 (36.6) 17 (56.6) 
Steroids, N (%) 6 (20) 10 (33.3) 
Nonsteroidal anti-inflammatory drugs (NSAIDs), N (%) 3 (10) 6 (20) 
Biologics, N (%)  10 (33.3) 10 (33.3) 
Mean score EuroQuol 12.5 (2.8) 12.8 (2.5) 
Mean score Patient Health Questionnaire PHQ-9  11.4 (7.6) 10.8 (7.7) 
Mean score Oral Health Impact Profile  
OHIP-14  16.2 (13.3) 12.7 (10.6) 
ACPA positive N (%) 22 (78.5)      24 (88.8) 
ACPA negative N (%) 6 (21.4)     3 (11.1) 
Continuous outcomes are presented as mean (SD) or median [IQR] 
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In terms of age, the two groups were relatively balanced; the patients from the 
Immediate Treatment group presented a median age of 59 years, whilst the 
patients from the Delayed Treatment group had a median age of 57 years. 
The Delayed Treatment group had slightly more females in terms of percentages 
(83% vs 67% in the Immediate Treatment group). 
In terms of race/ethnicity a similar pattern could be identified as in the comparisons 
from Table 11. The patients that reported to belong to the White British ethnicity 
group represented the largest patient population in both arms. They were followed 
in descending order of number of patients by the patients that reported Indian, 
Pakistani and Black Caribbean ethnicity,.  
As per clinical periodontal characteristics the groups were balanced in terms of 
cumulative probing depth with a median of 64 mm for each group.  
No major differences were observed in terms of BMI, blood pressure or smoking 
habits.  
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5.5 Missing data 
Table 15 - Missing data by treatment groups 
 Immediate 
Treatment  
Delayed  
Treatment  
Total  
Periodontal endpoints N (%)    
Baseline 1 (3.33) 0 (0.0) 1 (1.67) 
Visit 2 1 (3.85) 0 (0.0) 1 (1.89) 
Visit 3 1 (4.35) 0 (0.0) 1 (2.04) 
Rheumatologic endpoints N (%) 
(DAS28) 
   
Baseline 1 (3.33) 1 (3.33) 2 (3.33) 
Visit 2 4 (15.38) 5 (18.52) 9 (16.98) 
Visit 3 3 (13.04) 2 (7.69) 5 (10.20) 
Rheumatologic endpoints 
(ultrasonic assessments) 
   
Baseline 2 (6.67) 3 (10.00) 5 (8.33) 
Visit 2 2 (7.69) 0 (0.0) 2 (3.77) 
Visit 3 0 (0.0) 2 (7.69) 2 (4.08) 
EuroQuol  N (%)    
Baseline 5 (16.67) 2 (6.67) 7 (11.67) 
Visit 2 7 (26.92) 5 (18.52) 12 (22.64) 
Visit 3 8 (34.78) 6 (23.08) 14 (28.57) 
Patient Health Questionnaire N (%)    
Baseline 6 (20.00) 5 (16.67) 11 (18.33) 
Visit 2 9 (34.62) 12 (44.44) 21 (39.62) 
Visit 3 11 (47.83) 10 (38.46) 21 (42.86) 
Oral Health Impact Profile N (%)    
Baseline 4 (13.33) 5 (16.67) 9 (15.00) 
Visit 2 7 (26.92) 7 (26.93) 14 (26.42) 
Visit 3 8 (34.78) 9 (34.62) 17 (34.69) 
Medication changes  
Baseline-Visit 2 N (%) 
13 (48.15) 12 (44.44) 25 (46.30) 
Medication changes  
Baseline-Visit 3 N (%) 
15 (59.26) 12 (44.44) 28 (51.85) 
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The missing data is presented only for the randomized patients in Table 15. One 
randomized patient had missing periodontal measurements at Baseline and 
Follow-up visits. 
In terms of rheumatologic endpoints, 2 (1.89%) patients had missing data at 
Baseline, one in each group. Furthermore for Visit 2, there were 4 (15.38%) 
patients for the Immediate Treatment group and 5 (18.52%) for the Delayed 
Treatment group. For Visit 3, there were 3 (13.04%) patients for the Immediate 
Treatment group and 2 (7.69%) patients for the Delayed Treatment group with 
missing data. 
In terms of ultrasonic assessments at Baseline, 2 (6.67%) patients from the 
Immediate Treatment group and 3 (10.00%) from the Delayed Treatment group 
had missing data. Only 2 (7.69%) patients from the Immediate Treatment group 
had missing data for Visit 2 and 2 (7.69%) patients had for Visit 3. 
The EuroQuol questionnaire at Baseline was not completed by 5 (16.67%) patients 
from the Immediate Treatment group and 2 (6.67%) of the patients from the 
Delayed Treatment group. 
For Visit 2 there were 7 (26.92%) patients in the Immediate Treatment group and 5 
(18.52%) in the Delayed Treatment group who failed to complete the 
questionnaire. For the last Follow-up Visit there were 8 (34.78%) patients in the 
Immediate Treatment group and 6 (23.08%) in the Delayed Treatment group with 
missing data from the EuroQuol questionnaires. 
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A similar tendency was present with the Patient Health Questionnaire and the Oral 
Health Impact Profile. 
There is no information regarding medication changes for 25 patients (46.30%) 
from Baseline to Visit 2 and for 28 patients (51.85%) from Visit 2 to Visit 3. 
This is because the information regarding the changes in medications was 
obtained by screening the clinical letters from the rheumatology clinics from all the 
randomized patients from the moment they consented to take part in the trial, until 
the moment they finished the trial. This information was sometimes difficult to 
obtain as some of the patients did not have a large number of clinical appointments 
at the rheumatology clinics and some of the patients were seen by their general 
practitioners. The information that was available was presented in the section – 
Medication changes.   
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5.6 Clinical outcomes 
5.6.1 Periodontal parameters at baseline 
The periodontal endpoints measured at baseline were represented by cumulative 
probing depth (mm), mean periodontal probing depth, (mm) mean bleeding on probing 
(% of sites) and mean clinical attachment loss (mm). Additionally number of teeth, 
proportion of sites per mouth with periodontal probing depth greater or equal with 3 mm 
and proportion of sites per mouth with periodontal probing depth greater or equal with 5 
mm were also calculated to provide a more precise overview about the clinical data. 
For a more generalized overview, proportion of teeth per mouth with periodontal 
probing depth greater or equal with 3 mm and respectively 5 mm were also calculated. 
The Periodontal Inflamed Surface Area (PISA) calculated in mm2 was also considered 
as a clinically relevant outcome. These findings are presented in Table 16 - Periodontal 
parameters at baseline between treatment arms. 
The two groups were relatively balanced at baseline in terms of cumulative and mean 
probing depth. The Immediate treatment group had a larger proportion of active 
bleeding sites compared to the Delayed treatment group (34% vs. 26%).  
In terms of median number of teeth between treatment groups, patients from the 
Delayed Treatment group had a larger number of teeth compared to the Immediate 
Treatment group. Most of the periodontal values measured at baseline were relatively 
balanced between the two treatment arms. 
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Table 16 - Periodontal parameters at baseline between treatment arms 
 Immediate 
Treatment 
(n=30) 
Delayed 
Treatment 
(n=30) 
Cumulative probing depth 64 [44,80] 64 [56,90] 
Mean periodontal probing depth (mm) 3.4 (0.7) 3.3 (0.7) 
Mean bleeding on probing (% of sites) 34 (26) 26 (16) 
Mean clinical attachment loss (mm) 4.0 (1.0) 3.6 (0.9) 
Number of sites with PPD≥6mm 5.1 [1, 8] 7 [1, 9] 
Number of teeth 22 [15, 25] 25 [20, 26] 
Proportion of sites/mouth PPD ≥ 3 mm (%) 40 (22) 38 (24) 
Proportion of sites/mouth PPD ≥ 5 mm (%) 7 (12) 7 (11) 
Proportion of teeth/mouth PPD ≥ 3 mm (%) 71 (20) 66 (21) 
Proportion of teeth/mouth PPD ≥ 5 mm (%) 18 (22) 17 (23) 
Periodontal Inflamed Surface Area (PISA) mm2 374  
[180, 745] 
390 
 [203, 720] 
Continuous outcomes are presented as mean (SD) or median [IQR] 
 
5.6.2 Periodontal parameters at follow-up 
Table 17 - Periodontal parameters between treatment arms at follow-up, illustrates 
all the clinical periodontal endpoints between the two treatment arms between the 
baseline and the follow-up visits. The statistical significance of these mean 
differences was calculated using two-sample t test for continuous variables, which 
were normally distributed, and two sample Wilcoxon (Mann-Whitney) test for. 
Skewed distributions. A summarized overview of the periodontal endpoints from 
Baseline to Visit 3 are presented in Table 17 and Table 18.  
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Table 17 - Periodontal parameters between treatment arms at follow-up (1) 
 Immediate 
Treatment  
Delayed  
Treatment  
p-value  
Cumulative probing depth (mm)    
Baseline 64 [44,80] 64 [56,90] N/A 
Visit 2 42 [22,68] 87 [68,106] 0.002 
Visit 3 33 [21,73] 81 [54,94] 0.002 
Mean probing depth (mm)     
Baseline 3.4 (0.7) 3.3 (0.7) N/A 
Visit 2 3.1 (0.9) 3.5 (0.7) 0.085 
Visit 3 3.1 (0.8) 3.3 (0.6) 0.185 
Mean BOP (% of sites)     
Baseline 34 (26) 26 (16) N/A 
Visit 2 19 (14) 27 (21 0.108 
Visit 3 16 (17 23 (19) 0.189 
Mean CAL (mm)     
Baseline 4.0 (1.0) 3.6 (0.9) N/A 
Visit 2 4.0 (1.4) 3.9 (0.9) 0.646 
Visit 3 4.0 (1.3) 3.7 (0.7) 0.425 
Number of teeth    
Baseline 22 [15, 25] 25 [20, 26] N/A 
Visit 2 23 [15, 26] 25 [19, 27] p=0.059 
Visit 3 21[14, 24] 24 [19, 27] p=0.035 
Number of sites ≥ 6mm    
Baseline 5.1 [1, 8] 7 [1, 9] N/A 
Visit 2 4.5 [0, 1]] 7.9 [2, 9] 0.003 
Visit 3 3.5 [0, 1] 5.8 [0, 3] 0.095 
Continuous outcomes are presented as mean (SD) or median [IQR] 
 
For non-normally distributed outcomes, Mann-Whitney two-sample test tests the 
difference between the two treatment arms in terms of periodontal characteristics 
from Baseline to Visit 3. For normally distributed outcomes, t-test tests the same 
comparison. 
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Table 18 - Periodontal parameters between treatment arms at follow-up (2) 
 Immediate 
Treatment  
Delayed  
Treatment  
p-value  
Proportion of sites/mouth PPD ≥ 
3 mm (%) 
   
Baseline 40 (22) 38 (24) N/A 
Visit 2 29 (27) 43 (21) p=0.006 
Visit 3 27 (23) 39 (21) p=0.028 
Proportion of sites/mouth PPD ≥ 
5 mm (%) 
   
Baseline 7 (12) 7 (11) N/A 
Visit 2 5 (12) 8 (10) p=0.007 
Visit 3 5 (14) 5 (7) p=0.213 
Proportion of teeth/mouth PPD ≥ 
3 mm (%) 
   
Baseline 71 (20) 66 (21) N/A 
Visit 2 48 (28 74 (20 p=0.001 
Visit 3 53 (29 66 (22) p=0.107 
Proportion of teeth/mouth PPD ≥ 
5 mm (%) 
   
Baseline 18 (22) 17 (23)  
Visit 2 13 (25) 20 (19) p=0.008 
Visit 3 13 (21) 15 (17) p=0.170 
Periodontal Inflamed Surface 
Area (PISA) mm2 
   
Baseline 374 [180, 745] 390 [203, 720]  
Visit 2 195 [96, 350] 376 [192, 907] p=0.030 
Visit 3 110 [35, 328] 308 [102, 871] p=0.060 
Continuous outcomes are presented as mean (SD) or median [IQR] 
 
For non-normally distributed outcomes, Mann-Whitney two-sample test tests the 
difference between the two treatment arms in terms of periodontal characteristics 
from Baseline to Visit 3. For normally distributed outcomes, t-test tests the same 
comparison. 
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 Cumulative probing depth 5.6.2.1
The groups were balanced at baseline with 64 [44,80] mm for the Immediate 
treatment group and 64 [56, 90] mm for the Delayed treatment group (Table 17). 
At Visit 2 this value decreased for the Immediate treatment group to 42 [22, 68] 
mm and increased to 87 [68, 106] for the Delayed treatment group. This was 
statistically a significant difference between the groups (p = 0.002). The same 
trend was observed for Visit 3 where the Immediate treatment group presented a 
median value of 33 [21,73] mm and the Delayed treatment group presented 81 
[54,94] mm. In this case as well, the results were statistically significant (p = 0.002) 
and the null hypothesis was rejected. 
Figure 5 presents the median values for cumulative probing depth (mm) between 
treatment groups from Baseline to the Follow-up visits  
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Figure 5 - Median cumulative probing depth (mm) 
 
 
 
Box and whisker plot of the cumulative probing depths between the treatment arms 
and visits 
The median value represents the 50% percentile and the interquartile range (IQR) 
is the 75th percentile minus the 25th percentile. The dots are representing the 
outliers.  
 
 
 Mean periodontal probing depth 5.6.2.2
Figure 6- Median periodontal probing depth (mm) illustrates the effect of 
periodontal treatment in terms of mean periodontal probing depth, between 
baseline and the two follow-up visits, comparing the mean values between the 
Immediate treatment group and the Delayed treatment group.  At visit number one 
(baseline) the two groups presented a mean value for periodontal probing depth of 
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3.4 mm for the immediate treatment group and 3.3 mm for the delayed treatment 
group. 
This value decreased at the follow-up visit for the Immediate treatment group to 3.1 
mm at visit 2 and remained constant for visit 3. In the case of the Delayed 
treatment group, the mean periodontal probing depth presented a slight increase, 
from 3.3 mm at baseline to 3.5 mm for visit 2 and 3.3 mm at visit 3. These values 
were not statistically significant (p = 0.085 for Visit 2 and p=0.185 for visit 3). 
 
Figure 6- Median periodontal probing depth (mm) 
Box and whisker plot of the periodontal probing depths between the treatment 
arms and visits 
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 Mean clinical attachment loss (CAL) 5.6.2.3
Clinical attachment loss was calculated as the difference between periodontal 
probing depth and recession expressed in millimeters. The mean values at 
Baseline were 4.0 (1.0) mm for the Immediate treatment group and 3.6 (0.9) mm 
for the delayed treatment group. This value remained constant for the Immediate 
treatment group 4.0 (1.4) mm at Visit 2 and 4.0 (1.3) mm and Visit 3. For the 
Delayed treatment group the mean CAL presented a slight increase to 3.9 (0.9) 
mm at Visit 2 and 3.7 (0.7) mm at Visit 3. These differences were not statistically 
significant (p = 0.646 for Visit 2 and p = 0.425 for Visit 3). Figure 7 presents a box 
and whisker plot regarding the changes in mean clinical attachment loss from 
baseline to follow-up visits between treatment groups.  
Figure 7 - Median Clinical attachment loss (mm) 
 
Box and whisker plot of the clinical attachment loss between the treatment arms 
and visits 
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 Bleeding on probing (BoP) 5.6.2.4
Mean bleeding on probing was expressed as a percentage of active bleeding sites. 
As presented in Figure 8 and Table 17 this was slightly higher at Baseline in the 
Immediate treatment group (34% of sites bleeding) compared to the Delayed 
treatment group (26% of sites bleeding). The mean values presented a decreasing 
tendency in both groups. The Immediate treatment group mean bleeding on 
probing values decreased to only 19% of sites for Visit 2 and 15% for Visit 3 whilst 
the Delayed treatment group presented a decrease of the mean values to 27% for 
Visit 2 and 23% for Visit 3. None of these, however, was statistically significant (p = 
0.108 for Visit 2 and p = 0.189 for Visit 3). 
 
Figure 8 -Median bleeding on probing (percentage of sites) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box and whisker plot of the bleeding on probing between the treatment arms and 
visits 
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 Number of teeth  5.6.2.5
Patients from the Immediate Treatment group had slightly less teeth present than 
those from the Delayed Treatment group. The differences, where not statistically 
significant at Baseline nor at Visit 2. The data presented statistically significant 
difference for Visit 3 (Table 19). 
Table 19 - Number of teeth by treatment group at each visit 
  Number of teeth, median [IQR] 
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 22 [15, 25] 23 [15, 26] 21 [14, 24] 
Delayed 
Treatment 25 [20, 26] 25 [19, 27] 24 [19, 27] 
p-value p=0.059 p=0.064 p=0.035 
Mann-Whitney two-sample test for the difference in the number of teeth at each 
visit between the two treatment arms  
 
 Number of deep periodontal pockets 5.6.2.6
The number of deep periodontal pockets, or deep sites with periodontal probing 
depth (PPD) ≥ 6 mm decreased after Visit 2 in the Immediate Treatment group. 
This was statistically significant. For Visit 3, difference however the difference lost 
it’s statistical significance (Table 20) 
Table 20 - Number of deep periodontal pockets 
  Number of deep periodontal pockets  
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 5.1 [1, 8] 4.5 [0, 1] 3.5 [0, 1 
Delayed 
Treatment 7 [1, 9] 7.9 [2, 9] 5.8 [0, 3] 
p-value p=0.815 p=0.003 p=0.095 
Mann-Whitney two-sample test for the difference in the number of deep periodontal 
pockets at each visit between the two treatment arms  
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 Proportion of sites/mouth with PPD ≥ 3mm 5.6.2.7
Table 21 presents the mean proportion of sites per mouth with periodontal probing 
depth of 3 mm or more (shallow pockets). The proportion of these sites decreased 
at Visit 2 and Visit 3, compared to Baseline in the Immediate Treatment group. This 
change was statistically significant.  
 
Table 21 -Proportion of sites/mouth PPD ≥ 3 mm by treatment group at each visit 
  Proportion of sites/mouth PPD ≥ 3 mm (%), mean (SD) 
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 40 (22) 29 (27) 27 (23) 
Delayed 
Treatment 38 (24) 43 (21) 39 (21) 
p-value p=0.485 p=0.006 p=0.028 
Two-sample t-test for the difference in the proportion of sites ≥ 3 mm at each visit 
between the two treatment arms  
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 Proportion of sites/mouth with PPD ≥ 5 mm 5.6.2.8
Table 22 presents the mean proportion of sites per mouth with periodontal probing 
depths of 5 mm or more. The patients from both groups had a small proportion of 
pockets that were greater or equal to 5 mm. It can be observed that there is a 
statistically significant decrease of the mean proportion of deep pockets in the 
Immediate treatment group, after Baseline treatment at Visit 2. There was no 
statistically significant change in terms of the mean proportion of deep pockets for 
Visit 3. The Delayed treatment group presented an increase of the mean proportion 
of deep pockets from Baseline 7 (11) % to Visit 2 - 8 (10) %. This was followed by 
a decrease to 6 (7) % at Visit 3 which was not statistically significant.  
Table 22 -Proportion of sites/mouth PPD ≥ 5 mm by treatment group at each visit 
  Proportion of sites/mouth PPD ≥ 5 mm (%), mean (SD) 
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 7 (12) 6 (14) 5 (12) 
Delayed 
Treatment 7 (11) 8 (10) 6 (7) 
p-value  p=0.720 p=0.006 p=0.189 
Two-sample t-test for the difference in the proportion of sites ≥ 5 mm at each visit 
between the two treatment arms  
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 Proportion of teeth/mouth PPD ≥ 3mm 5.6.2.9
The proportion of teeth per mouth with pockets greater than the established 
threshold (shallow pockets) is a less precise measure than the proportion of sites 
per mouth. This, however, contributes to the general description of the clinically 
relevant endpoints. 
Table 23 presents the mean proportion of teeth per mouth with periodontal probing 
depth of 3 mm or more. It can be noticed a consistent reduction of this endpoint in 
the Immediate Treatment group. The statistical significance could be proved only 
for Visit 2.  
 
Table 23 - Proportion of teeth/mouth PPD ≥ 3 mm by treatment group at each visit 
  Proportion of teeth/mouth PPD ≥ 3 mm (%) mean (SD) 
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 71 (20) 48 (28) 53 (29 
Delayed 
Treatment 66 (21) 74 (20) 66 (22) 
p-value p=0.342 p=0.001 p=0.107 
Two-sample t-test for the difference in the proportion of teeth with sites ≥ 3 mm at 
each visit between the two treatment arms  
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 Proportion of teeth/mouth PPD ≥ 5mm 5.6.2.10
Table 24 presents the proportion of teeth per mouth with periodontal probing depth 
of 5 mm or more. As in the previous table, here as well it can be observed a 
statistically significant difference between Immediate Treatment and Delayed 
Treatment at Visit 2.  
Table 24 -Proportion of teeth/mouth PPD ≥ 5mm by treatment group at each visit 
  Proportion of teeth/mouth PPD ≥ 5 mm (%) mean (SD) 
  Baseline Visit 2 Visit 3 
Immediate 
Treatment 18 (22) 13 (25) 13 (21) 
Delayed 
Treatment 17 (23) 20 (19) 15 (17) 
p-value p=0.680 p=0.008 p=0.170 
Two-sample t-test for the difference in the proportion of teeth with sites ≥ 5 mm at 
each visit between the two treatment arms  
  
118 
 PISA (Periodontal Inflamed Surface Area)  5.6.2.11
Table 25 presents the Periodontal Inflamed Surface Area (PISA) as median values 
in mm2 with interquartile range [IQR].  This measure shows the two treatment arms 
being relatively balanced at Baseline with a consistent and statistically significant 
reduction at Visit 2 and Visit 3 for the Immediate Treatment group. 
 
Table 25 -PISA (Periodontal Inflamed Surface Area) by treatment group at each visit 
  PISA (Periodontal Inflamed Surface Area  (mm2), median [IQR]  
 Baseline Visit 2 Visit 3 
Immediate 
Treatment 
374  
[180, 745] 
195  
[96, 350] 
110  
[35, 328] 
Delayed 
Treatment 
390 
 [203, 720] 
376  
[192, 907] 
308  
[102, 871] 
p-value p=0.933 p=0.030 p=0.06 
Mann-Whitney two-sample test for the difference in PISA at each visit between the 
two treatment arms  
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5.6.3 Rheumatologic outcomes – DAS28 
The clinical outcomes that were monitored from a rheumatologic perspective 
consisted of the rheumatoid arthritis disease activity score (DAS28) and 
musculoskeletal ultrasound. The Methods Chapter described in detail the data 
collection process for these clinical endpoints. The mean value of DAS28 was 
higher in the Delayed treatment group. The calculation methods for DAS28 were 
described in more detail in the Methods Chapter. The components of the DAS28 
score are the total number of swollen and tender joints, erythrocyte sedimentation 
rate (ESR) and the 'Patient Global' Visual Analogue Scale (VAS). Each of these 
components are presented below.  
The mean values of DAS28 decreased in both groups between baseline and 
follow-up visits as presented in Table 26 - Mean DAS28 . This, however, was not 
statistically significant. 
Table 26 - Mean DAS28 scores by treatment group at each visit 
DAS28 Immediate 
Treatment , 
mean (SD) 
Delayed 
Treatment, mean 
(SD)  
p-value 
Baseline 4.6 (1.0) 5.1 (1.1) N/A 
Visit 2 4.2 (1.2) 4.8 (1.5) 0.145 
Visit 3 4.2 (1.6) 4.9 (1.3) 0.112 
Two-sample t-test for the difference in the mean DAS28 at each visit between the 
two treatment arms  
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 Erythrocyte sedimentation rate (ESR)  5.6.3.1
Table 27 - presents the mean values for the erythrocyte sedimentation rate (ESR) 
as a component of the rheumatoid arthritis disease activity score (DAS28). The 
Delayed treatment group presented a higher value at Baseline compared to the 
Immediate treatment group. Any difference between the two groups at baseline 
was considered as random; therefore no statistical test was performed. 
Table 27 - Mean ESR by treatment group at each visit 
Two-sample t-test for the difference in the mean ESR at each visit between the two 
treatment arms  
  
ESR Immediate 
Treatment, 
mean (SD) 
Delayed 
Treatment,  mean 
(SD) 
p-value 
Baseline 18 (14) 26 (18) N/A 
Visit 2 16 (12) 19 (15) 0.364 
Visit 3 16 (12) 22 (13) 0.179 
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 Patients Global Visual Analogue Scale (VAS) 5.6.3.2
Table 28 - presents the mean values for the 'Patient Global' Visual Analogue Scale 
(VAS) as a component of the rheumatoid arthritis disease activity score (DAS28). 
Also in this case, the Delayed treatment group presented a higher value at 
Baseline compared to the Immediate treatment group. The differences between the 
treatment groups at follow-up were only significant for visit 3. The interpretation of 
the results was elaborated in the Discussions Chapter.   
 
Table 28-Mean VAS by treatment group at each visit 
Two-sample t-test for the difference in the mean VAS at each visit between the two 
treatment arms  
  
VAS Immediate 
Treatment,  
mean (SD) 
Delayed 
Treatment, 
mean (SD)  
p-value 
Baseline 56 (23) 65 (18) N/A 
Visit 2 56 (20) 66 (18) 0.068 
Visit 3 50 (26) 67 (20) 0.022 
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 Tender joints count 5.6.3.3
The mean value of the tender joint count was calculated for each group of patients. 
Table 29 presents their mean values and their statistical significance.  
 
Table 29 - Mean tender joint count by treatment group at each visit 
Two-sample t-test for the difference in the mean tender joint count at each visit 
between the two treatment arms  
  
Tender joints 
count 
Immediate 
Treatment,  mean 
(SD) 
Delayed 
Treatment, 
mean (SD)   
p-value 
Baseline 11.6 (7.9) 12.6 (8.1) N/A 
Visit 2 8.8 (6.4) 12.5 (8.9) 0.089 
Visit 3 9.2 (7.0) 11.8 (7.9) 0.231 
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 Swollen joints count 5.6.3.4
Table 30 presents the mean values for swollen joints count as a component of the 
rheumatoid arthritis disease activity score (DAS28). Also in this case, the Delayed 
treatment group presented a higher value at Baseline compared to the Immediate 
treatment group. The differences between the treatment groups at follow-up were 
not statistically significant.  
 
Table 30 -Mean swollen joint count from baseline to follow-up visits 
Two-sample t-test for the difference in the mean swollen joint count at each visit 
between the two treatment arms   
Swollen joints 
count 
Immediate 
Treatment, mean 
(SD) 
Delayed 
Treatment, 
mean (SD) 
p-value 
Baseline 2.3 (2.8) 3.1 (3.6) N/A 
Visit 2 1.1 (1.7) 1.8 (2.5) 0.269 
Visit 3 1.8 (2.9) 2.5 (3.9) 0.474 
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5.6.4 Musculoskeletal ultrasonic assessments 
The musculoskeletal ultrasonic assessments were performed as longitudinal 
images of greyscale (GS) and power Doppler (PD) of the following joints bilaterally: 
• Inter-carpal (right and left) 
• Radio-carpal (right and left) 
• Ulnar-carpal (right and left) 
• Metacarpal 1-5 (right and left) 
In total 16 joints were assessed, generating an average of 74 images per patient, 
per visit. This accounted for a total number of 13.383 ultrasound images. The 
scoring system was described more in detail in the Methods chapter. Each joint 
was graded on a scale of severity of synovial inflammation from 0 to 3. Two 
different approaches for data analysis were developed:  
1. For a general assessment: binary allocation of scoring: 0 (no visible sign of 
inflammation) and 1 (visible sign of inflammation) both in Greyscale and 
Power-Doppler.  
2. For a more specific assessment: summary of all grading per patient per visit 
(minimum score = 0; maximum score= 16). 
 Binarised analysis in Power Doppler 5.6.4.1
The binarised mean score analysis in Power Doppler revealed a slightly higher 
score of inflammation for the patients in the Delayed Group at baseline. The only 
statistically significant difference was observed at six months follow-up as 
illustrated by Table 31 - Mean binarised Power Doppler ultrasound scores 
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Table 31 - Mean binarised Power Doppler ultrasound scores by treatment  
group at each visit 
 Immediate 
Treatment, mean 
(SD) 
Delayed 
Treatment, 
mean (SD)  
p-value 
Baseline 3.3 (4.0) 4.7 (4.9) N/A 
Visit 2 2.7 (4.1) 3.1 (3.4) 0.71 
Visit 3 1.8 (1.8) 3.8 (4.2) 0.04 
Two-sample t-test for the difference in the mean binarised Power Doppler 
ultrasound scores at each visit between the two treatment arms  
 
Figure 9 - Binarised Power Doppler ultrasound scores  
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 Binarised ultrasound analysis in grey scale 5.6.4.2
The binarised ultrasound mean scores in grey scale presented a higher value for 
the Delayed Treatment group at baseline compared to the Immediate Treatment 
group. There was no statistically significant difference between the groups at none 
of follow-up visits. This was presented in Table 32 - Mean binarised Gray Scale 
ultrasound scores 
Table 32 - Mean binarised Gray Scale ultrasound scores by treatment  
group at each visit 
 Immediate 
Treatment, mean 
(SD)  
Delayed 
Treatment, 
mean (SD)  
p-value 
Baseline 5.8 (3.9) 6.6 (4.6) N/A. 
Visit 2 4.6 (4.1) 5.1 (3.4) 0.664 
Visit 3 4.3 (2.5) 5.4 (4.1) 0.304 
Two-sample t-test for the difference in the mean binarised Gray Scale ultrasound 
scores at each visit between the two treatment arms  
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Figure 10- Binarised Gray Scale ultrasound scores  
 
 Summarized analysis – total scores in Power Doppler 5.6.4.3
The mean value of the total scores of inflamed joints in Power Doppler at baseline 
visit was higher in the Delayed Treatment group as presented in Table 33 and 
Figure 11. There was no statistically significant difference between the treatment 
arms at none of the follow-up visits. 
Table 33 -Total Power Doppler ultrasound scores by treatment group at each visit 
 Immediate 
Treatment, mean 
(SD)   
Delayed 
Treatment, 
mean (SD)   
p-value 
Baseline 5.2 (5.6) 7.2 (8.4) N/A 
Visit 2 3.2 (3.5) 6.7 (8.2) 0.062 
Visit 3 3.8 (4.4) 6.2 (6.1) 0.141 
Two-sample t-test for the difference in the mean Total Power Doppler ultrasound 
scores at each visit between the two treatment arms  
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Figure 11 - Total Power Doppler ultrasound scores  
 
 Summarized analysis – total scores in grey scale 5.6.4.4
The summarized analysis of the mean values for the grey scale ultrasound at 
Baseline presented a higher value in the Delayed Treatment group, compared to 
the Immediate Treatment group. None of the follow-up visits presented a 
statistically significant difference at none of the follow-up visits as illustrated by 
Table 34 and Figure 12 
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Table 34 - Total Gray Scale ultrasound scores by treatment group at each visit 
 Immediate 
Treatment, 
mean (SD)  
Delayed 
Treatment, 
mean (SD)  
p-value 
Baseline 10.0 (6.8) 12.1 (9.7) N/A 
Visit 2 7.0 (5.4) 10.8 (8.7) 0.073 
Visit 3 9.4 (6.3) 10.2 (7.4) 0.603 
Two-sample t-test for the difference in the mean Total Gray Scale ultrasound 
scores at each visit between the two treatment arms  
 
Figure 12 - Total Gray Scale ultrasound scores  
 
5.7 Medication changes 
The most common medication groups used for the rheumatologic treatment of the 
patients from the OPERA cohort are presented in Table 35 for each treatment arm. 
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Table 35 – Description of classes of rheumatoid drugs for each visit by treatment group 
 
The most common group of medications used in this cohort at Baseline was 
represented by DMARDs with a total of 28 (46.6%) of patients. Of these, 11 
(36.6%) were in the Immediate Treatment group and 17 (56%) were in the Delayed 
Treatment group. At Visit 2 and Visit 3, there were 9 (30%) patients from the 
Immediate Treatment group. For Visit 2 there were 13 (43.3%) patients in the 
Delayed Treatment group and 14 (46.6%) for Visit 3.  
 
 Immediate 
Treatment  
Delayed  
Treatment  
Total 
Disease-modifying antirheumatic 
drugs (DMARDs) N (%) 
   
Baseline 11 (36.6) 17 (56.6) 28 (46.6) 
Visit 2 9 (30.0) 13 (43.3) 22 (36.6) 
Visit 3 9 (30.0) 14 (46.6) 23 (38.3) 
Steroids    
Baseline 6 (20.0) 10 (33.3) 16 (26.6) 
Visit 2 5 (16.6) 8 (26.6) 13 (21.6) 
Visit 3 3 (10.0) 5 (16.6) 8 (13.3) 
Nonsteroidal anti-inflammatory 
drugs (NSAIDs) N (%) 
   
Baseline 3 (10.0) 6 (20.0) 9 (15.0) 
Visit 2 2 (6.6) 3 (10.0) 5 (8.3) 
Visit 3 2 (6.6) 4 (13.3) 6 (10.0) 
Biologics N (%)    
Baseline 10 (33.3) 10 (33.3) 20 (33.3) 
Visit 2 10 (33.3) 8 (26.6) 18 (30.0) 
Visit 3 8 (26.6) 6 (20.0) 14 (23.3) 
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Table 36 - Medication changes by treatment group at each visit 
 Immediate 
Treatment  
Delayed 
Treatment  
p-value 
Baseline – Visit 2 
N (%) 
5  
(16.6) 
6  
(20.0) 
p=0.940 
Visit 2 – Visit 3 
N (%) 
4  
(13.3) 
6  
(20.0) 
p=0.571 
Chi square test for the association between treatment arm and medication change  
 
Some of the data regarding medication change was unavailable as described in 
section 5.5 Missing data. Based on the available data, Table 36 presents statistical 
tests for significance for change in medication between treatment arms. 
5.8 Patient reported outcomes 
5.8.1 EuroQuol  
The EuroQuol (EQ-5D) questionnaire assessed five different dimensions of the 
patient’s self-perceived health and well being with regards to different areas of life. 
Table 37 - EQ-5D mean scores by domains - is presenting the mean scores for 
each of these dimensions with the standard deviation between brackets for each 
treatment arm and visits.  
The highest value for each of the first four dimensions was 3. This represented the 
lowest degree of autonomy and well being . The smallest value for each group was 
1 and this represented the highest degree of autonomy and well being.  
The fifth dimension represented a visual analogue scale (VAS) where the highest 
score represents the best state of self-perceived health. In a majority of the 
dimensions that addressed by this questionnaire, the Delayed Treatment group 
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presented slightly higher mean scores, however none of these was statistically 
significant.  
 
Table 37 - EQ-5D mean scores by domains, mean (SD) by treatment group at 
each visit 
 Mobility Self-care Pain/ 
Discomfort 
Anxiety/ 
Depression 
VAS 
 V2 V3 V2 V3 V2 V3 V2 V3 V2 V3 
Gr 1 1.7 
(0.4) 
1.8 
(0.4) 
1.6 
(0.6) 
1.5 
(0.6) 
2.2 
(0.5) 
1.9 
(0.4) 
1.3 
(0.4) 
1.3 
(0.5) 
6.2 
(2.2) 
6.5 
(2.1) 
Gr 2 1.7 
(0.4) 
1.7 
(0.4) 
1.7 
(0.5) 
1.7 
(0.5) 
2.1 
(0.5) 
2.3 
(0.5) 
1.5 
(0.5) 
1.4 
(0.5) 
6.7 
(2.0) 
6.5 
(2.1) 
p-val. 0.717 0.626 0.613 0.231 0.154 0.132 0.286 0.573 0.443 0.949 
Gr1 = Immediate treatment; Gr2 = Delayed treatment; V2 = Visit 2; V3= Visit 3 
Two-sample t-test for the difference in the mean EQ-5D scores by domains at each 
visit between the two treatment arms  
 
 Mobility (1-3) 5.8.1.1
In terms of mobility the two treatment arms were relatively balanced at both follow-
up visits with no statistically significant difference between the groups.  
 Self-care (1-3) 5.8.1.2
In terms of self-care the two treatment arms were relatively balanced. The Delayed 
treatment group presented a slightly higher value for both visits however this was 
not statistically significant.  
 Pain/ Discomfort (1-3) 5.8.1.3
The highest reported score for both treatment arms was noticed regarding pain and 
discomfort. In this case as well, the Delayed Treatment group presented a slightly 
higher mean score. This was not statistically significant.  
133 
 Anxiety/ Depression (1-3) 5.8.1.4
In terms of anxiety and depression, both treatment groups presented the lowest 
mean scores from all the categories that were addressed. There was no 
statistically significant difference between the groups. 
 Visual analogue scale (VAS) (1-10) 5.8.1.5
The VAS scores were relatively balanced between both groups. The highest 
scores represented better self-perceived general health. There was no statistically 
significant difference between the groups. 
 Total EQ-5D Scores 5.8.1.6
Table 38 - Mean scores of the EQ-5D Questionnaire - presents the mean total 
scores of between the treatment arms from baseline to the follow-up visits. There 
was no statistically significant difference between the treatment groups in terms of 
mean scores from baseline to follow-up visits.  
Table 38 - Mean scores of the EQ-5D Questionnaire, mean (SD) by treatment 
group at each visit 
 Immediate 
Treatment  
Delayed 
Treatment  
P-value 
Baseline 12.4 (2.8) 12.9 (2.6) N/A 
Visit 2 13.1 (2.9) 13.9 (3.1) 0.439 
Visit 3 13.2 (2.5) 13.9 (2.5) 0.467 
Two-sample t-test for the difference in the mean EQ-5D scores at each visit 
between the two treatment arms   
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5.8.2 Patient Health Questionnaire (PHQ-9)  
The Patient Health Questionnaire (PHQ-9) is a depression test questionnaire.  
The total scores represented: 0-6 = mild 6-10 = moderate 11-15 = moderately 
severe 16-20 = severe depression 
Each question had 4 possible choices of answers. The answers were coded with 
zero being the least likely sign of depression and four being the most likely to 
present signs of depression.  
The lower scores represented less evidence of signs of depression, while the 
higher scores could indicate potential signs of depression. These results however 
should be interpreted with caution. The purpose of presenting these results was to 
provide an overview of the data that was gathered through this study and not to 
provide a clinical diagnosis for depression of this patient population.  
Overall, the patient scores pointed towards a higher mean score at baseline and a 
decreasing tendency of these values at the follow-up visits as presented in Table 
39 
 
Table 39 - Mean scores of the Patient Health Questionnaire (PHQ-9) mean (SD), 
by treatment group at each visit 
 Immediate 
Treatment  
Delayed 
Treatment  
P-value 
Baseline 11.4 (7.6) 10.8 (7.7) N/A 
Visit 2 9.1 (7.4) 8.6 (6.5) 0.846 
Visit 3 7.7 (7.2) 8.1 (5.7) 0.895 
Two-sample t-test for the difference in the mean PHQ-9 scores at each visit 
between the two treatment arms  
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In order to provide a deeper understanding of all the different dimensions that were 
analyzed throughout this questionnaire, the mean values for the scores for each 
dimension are presented in Table 40 PHQ-9 mean scores by domains and Table 
41 - PHQ-9 mean scores by domains (continuation). The higher numbers represent 
worse outcomes.  
 
Table 40 PHQ-9 mean scores by domains (1) by treatment group at each visit 
 Anhedonia Depressed 
mood 
Sleep 
problems  
Low energy Appetite 
changes 
 V2 V3 V2 V3 V2 V3 V2 V3 V2 V3 
Gr 1 0.9 
(1.0) 
0.5 
(0.6) 
0.8 
(0.9) 
0.5 
(0.9) 
1.5 
(1.2) 
1.0 
(1.0) 
1.6 
(1.0) 
1.2 
(1.0) 
1.0 
(1.0) 
0.7 
(1.1) 
Gr 2 1.2 
(0.9) 
0.7 
(0.7) 
0.8 
(0.8) 
0.7 
(0.7) 
1.2 
(1.0) 
1.1 
(1.1) 
1.5 
(0.9) 
1.2 
(0.8) 
0.7 
(0.9) 
0.7 
(1.0) 
P-val 0.327 0.443 1.000 0.461 0.418 0.694 0.727 0.988 0.306 0.903 
Two-sample t-test for the difference in the mean PHQ-9 scores at each visit 
between the two treatment arms by domains 
 
 
Table 41 - PHQ-9 mean scores by domains (continuation) by treatment group at 
each visit 
 Low self-
esteem 
Concentration 
difficulties 
Psychomotor 
agitation  or 
retardation 
Suicidal ideation 
 V2 V3 V2 V3 V2 V3 V2 V3 
Immediate 
treatment 
0.6 
(0.9) 
0.6 
(1.2) 
0.7 
(1.0) 
0.7 
(1.0) 
0.7 
(1.0) 
0.7 
(1.0) 
0.4 
(0.8) 
0.2 (0.6) 
Delayed 
treatment 
0.7 
(0.8) 
0.4 
(0.6) 
0.8 
(0.9) 
0.3 
(0.7) 
0.8 
(0.9) 
0.3 
(0.7) 
0.6 
(1.1) 
0.4 (0.9) 
P-value 0.744 0.574 0.773 0.244 0.773 0.244 0.456 0.672 
Two-sample t-test for the difference in the mean PHQ-9 scores at each visit 
between the two treatment arms by domains 
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 Anhedonia and Depressed mood 5.8.2.1
Anhedonia is characterised as the lack of interest or pleasure in fulfilling activities 
that are normally considered enjoyable by the subject [115, 116]. As Table 40 
illustrates, randomized patients from both treatment arms presented a slight 
decrease between follow-up visits with regards to these dimensions. This change 
however, was not statistically significant.  
 
 Sleep problems and low energy  5.8.2.2
The patients from this study provided the highest mean scores for these two 
dimensions. Considering the demographic characteristics of the participants, this 
result is in line with the scientific literature. As Table 40 presents, for both treatment 
groups, there was a decrease of this indicator over the follow-up visits but it was 
not statistically significant.  
 
 Appetite changes 5.8.2.3
This aspect did not present change in the Delayed treatment group and only a 
small decrease in the Immediate treatment group. None of these changes was 
statistically significant as described in Table 40. 
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 Low self-esteem, Concentration difficulties and Psychomotor 5.8.2.4
agitation or retardation  
There was no change of the mean scores of these dimensions in the Immediate 
treatment group while the Delayed treatment group presented a decrease for all 
the three measures as presented in Table 41. 
 
 Suicidal ideation 5.8.2.5
Table 41 illustrates that both groups presented a decrease of this measure 
between the follow-up visits. This was, however, not statistically significant. 
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5.8.3 Oral Health Impact Profile (OHIP-14) baseline, 3 months, 6 months 
The Oral Health Impact Profile (OHIP-14) is a self-administered questionnaire of 14 
items classed in seven dimensions of health assessing the impact of oral health on 
the quality of life of the patient.  
The higher scores mean worse self-assessed oral health status, meanwhile the 
lower scores mean a better self-assessed oral health. The patient’s lowest score 
was 0 and the highest score was 48. Table 42 - Total scores of the OHIP-14 and 
Table 43 - Mean scores of the OHIP-14 by dimensions of health. None of the 
differences between groups was statistically significant.  
 
Table 42 - Total scores of the OHIP-14 
 Immediate 
Treatment  
Delayed 
Treatment  
P-value 
Baseline 16.2 (13.3) 12.7 (10.6) N/A 
Visit 2 16.6 (15.0) 12.9 (11.9) 0.375 
Visit 3 12.7 (14.4) 8.2 (9.3) 0.332 
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Table 43 - Mean scores of the OHIP-14 by dimensions of health 
 Immediate 
Treatment  
Delayed 
Treatment  
P-value 
Functional 
limitation 
V2 1.1 (1.1) 0.7 (0.8) 0.282 
V3 0.4 (0.6) 0.3 (0.5) 0.951 
Physical pain 
 
V2 1.4 (1.1) 1.2 (1.0) 0.638 
V3 1.2 (1.0) 0.9 (0.9) 0.398 
Psychological 
discomfort 
 
V2 1.6 (1.4) 1.3 (1.1) 0.430 
V3 1.5 (1.4) 0.8 (0.8) 0.135 
Physical 
disability 
 
V2 1.7 (1.2) 0.8 (1.1) 0.326 
V3 0.8 (1.2) 0.5 (0.9) 0.507 
Psychological 
disability 
 
V2 1.3 (1.2) 1.2 (1.0) 0.699 
V3 1.0 (1.2) 0.6 (0.9) 0.394 
Social 
disability 
 
V2 0.7 (1.1) 0.6 (1.0) 0.755 
V3 0.6 (1.2) 0.2 (0.5) 0.311 
Handicap 
 
V2 0.8 (1.1) 0.7 (0.9) 0.630 
V3 0.6 (0.9) 0.3 (0.5) 0.252 
 
 Functional limitation (0-4) 5.8.3.1
As presented in Table 43 the area of functional limitation encompasses the first two 
questions of the OHIP-14 questionnaire and refers to the inability of a person to 
pronounce words or to sense taste. The Immediate treatment group presented a 
slightly higher mean score compared to the Delayed treatment group at Visit 2 and 
the two groups presented similar mean values at the follow-up Visit number 3. The 
change was not statistically significant.  
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 Physical pain (0-4) 5.8.3.2
Physical pain was the third highest rated indicator by the patients, immediately 
after physical disability and physiological discomfort. This dimension refers to pain 
and discomfort localized in the oral cavity. Both groups presented a not statistically 
significant decrease of these mean values at follow-up visits. This can be observed 
in Table 43. 
 Psychological discomfort (0-4) 5.8.3.3
This dimension was the second highest rated by the patients. Self-consciousness 
and tensed state caused by oral health problems were the defining characteristics 
of this area of investigation. Neither of the two groups presented a statistically 
significant decrease between visits (please see Table 43). 
 Physical disability (0-4) 5.8.3.4
This was the highest rated dimension by the patients in the questionnaires as 
presented in Table 43. The questions relating to this field were describing episodes 
of inability to eat properly caused by functional impairment of the dentition. In this 
case as well, the Immediate treatment group presented a higher mean value, 
compared with the Delayed treatment group and both groups presented a 
decreasing tendency over visits which was not statistically significant.  
 Psychological disability (0-4) 5.8.3.5
The questions referring to psychological disability were related to patient’s 
difficulties to relax and sense of embarrassment – both caused by oral health 
problems. The tendency, in this case as well, was decreasing between visits, with 
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slightly higher mean values for immediate treatment group. This can be seen in in 
Table 43. 
 Social disability (0-4) 5.8.3.6
This dimension aimed to assess the extent to which the patients’ encountered 
difficulties in performing their daily activities or if they felt irritable with regards to 
their social interactions because of oral health problems. Both treatment groups 
presented a decreasing mean score between the follow-up visits that was not 
statistically significant (please see Table 43). 
 Handicap (0-4) 5.8.3.7
The last dimension of the Oral Health Impact Profile, presented in Table 43 
explored the patients overall level of satisfaction and capacity to fulfill their tasks in 
relation to their oral health status. This domain as well, did not present a 
statistically significant decreasing tendency between the follow-up visits.  
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5.9 Results of the Qualitative Interviews 
5.9.1 Overview  
In the followings, the reader will be guided through the demographic characteristics 
of the study population and the results of the qualitative data analysis. The main 
themes that emerged from the discussions are related to the patients personal 
experiences regarding the way rheumatoid arthritis affected their quality of life, the 
role and place of oral health as a health priority and encouraging or hindering 
factors to take part in the clinical trial (Figure 15). 
Some of themes that emerged from the discussions were difficult to set in clearly 
distinctive categories as these themes were crossing over several different topics. 
For example “Oral health” could be included both in “Periodontitis and oral health” 
as well as “Comorbidities and health priorities” 
 
5.9.2 Demographics 
The demographic characteristics of the patients who consented to take part in the 
qualitative interview process are presented in Table 44. The median age for the 
patient population was 60 [57,64], whilst the median number of years spent since 
they were diagnosed until the time of the interviews was 19 [12,25] years (Table 
44). 
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Table 44- Demographics of the patient population (qualitative interviews) 
Pt	#	 Gender	 Age	 Observations	 Years	since	diagnosis	
1	 F	 60	 Randomized	-	delayed	 19	
2	 M	 86	 Unconsented	 20	
3	 F	 83	 Unconsented	 60	
4	 F	 37	 Unconsented	 9	
5	 M	 52	 Randomized	-	delayed	 13	
6	 F	 59	 Unconsented		 20	
7	 F	 68	 Unconsented		 22	
8	 M	 65	 Randomized	-	delayed	 30	
9	 F	 60	 Unconsented	 67	
10	 F	 65	 Randomized	-	delayed	 6	
11	 F	 55	 Randomized	-	immediate	 12	
12	 F	 59	 Unconsented		 2	
13	 M	 54	 Unconsented	 14	
14	 M	 64	 Not	eligible	 10	
15	 F	 62	 Randomized	-	delayed	 36	
16	 F	 47	 Randomized	-	delayed	 15	
17	 F	 61	 Randomized	-	delayed	 15	
18	 F	 62	 Randomized	-	immediate	 25	
19	 F	 62	 Randomized	-	delayed	 30	
20	 M	 57	 Randomized	-	immediate	 20	
21	 F	 57	 Randomized	-	immediate	 1	
Median	[IQR]	 60	[57,64]	 	 19	[12,25]	
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As can be seen in Table 44, there were 21 participants in the qualitative part of the 
research project. In term of gender representation, 15 participants were females 
and 6 were males.   
Females had a higher proportion in the participant group as rheumatoid arthritis 
has a higher prevalence in females than males [117-119].  
More than half of the participants (13) consented for periodontal screening in the 
study, while the remaining participants did not. The main objective of the qualitative 
component of this study was to provide a better understanding of the reasons why 
certain participants choose not to take part in this clinical trial. 
Another major question was to understand how study participants feel about being 
in a control group and receiving a delayed treatment of their periodontal disease. 
Therefore, a large proportion of the randomized participants (67%) were in the 
delayed treatment group. 
Figure 15 presents the main 3 categories of merging themes: RA and Quality of 
Life, Oral Health and The Study. Each of these main themes presented a number 
of sub-themes that evolved as the dynamics of the interviews progressed.  
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Figure 13 - Qualitative interview themes 
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5.9.3 Results of the interviews 
In the followings, the results of the interviews are presented together with the 
relevant quotes from the participants for each one of the topics.  
Besides the initial topics, the main themes that emerged from the interviews were 
related to the effects of rheumatoid arthritis on the quality of life of the patients, 
their health priorities, the issues related to the delayed treatment of the control 
group, financial compensation and patient oriented outcomes of the study. 
 
 History of the condition 5.9.3.1
The first topic was represented by the history and onset of rheumatoid arthritis. The 
reason for this was to set the scene for the patients and to facilitate the recall of 
their experiences related to their condition, as well as the psychological impact of 
this experience. 
The study participants were diagnosed on average 21 years ago with rheumatoid 
arthritis. Patient 3 was diagnosed 60 years ago and patient 21 was diagnosed 1 
year ago. A number of participants described the onset of their condition as a very 
distressing moment, illustrated by the following statement: 
“I remember going to pick my son up from school and walking up  
 high street and just with tears rolling down my face because 
I was in such pain and I am not a baby when it comes to pain, I 
think I have got quite a high pain threshold, but it was just I had 
never known anything like it and then it just got worse from there...”  
(PATIENT 1 p5) 
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"It started badly.  It started with my shoulder and then it just gradually 
started to go to my hands and you know and physio wasn’t 
helping." (PATIENT 11 p1) 
 
Several patients reported similar problems to Patient 1. They were feeling severe 
pain of unknown origin and were seeking out help from their general practitioner. 
Comments included: 
 
"I got worse and worse and then I did sort of erm have an episode 
where I couldn’t move, I couldn’t get out of bed or anything and I 
managed to get a neighbour eventually." (PATIENT 17 p2) 
 
“I must have been suffering in agony because I was missing time from 
work and I was ringing them up.” (PATIENT 20 p1) 
 
There was a very strong level of consensus amongst the participants in terms of 
the impact of the onset of rheumatoid arthritis has had on their lives. They describe 
experiencing severe pain, non-responsive to common analgesics that were 
available over the counter. The pain did not diminish in time in terms of intensity 
but it was getting gradually stronger and harder to resist, as follows: 
 
“I do you remember the little girls used to wear long white socks, I 
couldn’t put them on my children.  That was a…  big problem… 
Distressing and depressing." (PATIENT 3 p2) 
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“Oh my God, what’s happening to me”.  All I could move was my eyes, 
couldn’t move anything else.  I just went into a complete erm, I 
don’t know what you would call it.  It’s like when I do get down the 
side, I do get where I lock where I go into really bad pain, I get a 
flare-up and I will lock all down the side.” (PATIENT 1 p5) 
 
The onset of rheumatoid arthritis was a highly traumatizing event for most of the 
participants both physically and emotionally. Sometimes it took a while until they 
received the correct diagnosis and medication and afterwards they had to learn to 
live with a chronic condition for the rest of their lives. The patients were unaware of 
their situation of being in an early phase of a chronic inflammatory condition and 
found themselves distressed with severe pain and trying to understand what this 
meant to them. Comments included: 
 
"The children thought I was going to die.  I heard them talking to my wife 
and er the er they said “Is dad going to die?” and I though, blimey, 
I must look bad, but I was so thin me bones were sticking out all 
over the place.” (PATIENT 14 p2) 
 
"I mean remember on more than one occasion getting stranded half way 
home with the buggy, I just couldn’t walk any further, so I would 
have to stop for about fifteen, twenty minutes to try and build a bit 
of energy and wait for the pain to subside before I could carry on.  
So yeah, it was really restrictive." (PATIENT 5 p2) 
 
“The difficulty I was facing whilst I was working was the inability to hold a 
pen properly ….. And work and a computer. Erm, sitting down 
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meant that my joints got really stiff, my knee joints and my back… 
And my feet and as a consequence mobility as I say became very 
bad… I couldn’t get upstairs to the upstairs offices."  
(PATIENT 10 p2) 
 
"You know, where before I used to think nothing of it, I would go off and 
do what I needed to do.  Now, I can’t do that, if I’m in pain I have 
think right I can only do one shop today, or I can’t walk that far 
today." (PATIENT 12 p4) 
 
In some of the cases, there was a delay in starting the correct treatment because 
the symptoms were not recognized as specific for rheumatoid arthritis. This was 
the case for several patients. Patient 12 reports that it went undiagnosed for nearly 
18 months.   
 
“I have had a lot of other treatments that haven’t helped a great deal I 
didn’t respond, the blood tests showed that I didn’t response very 
well to those treatments that I was having.  Until I can’t think how 
many years ago now, quite a few years now I have started on 
infusion antiTNF infusion, which I take Rituximab.”  
(PATIENT 15 p1) 
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 Rheumatoid arthritis and quality of life 5.9.3.2
 
Figure 14 – Theme: Rheumatoid arthritis and quality of life 
 
There were several similarities in the stories presented by the patients regarding 
the impact of rheumatoid arthritis on their quality of life. Having to learn to live with 
a chronic condition there was a common pattern in the stories presented by the 
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patients: in the beginning there is frustration and depression, which later will 
develop into acceptance and finally coping strategies. As a result, a number of sub-
themes emerged from the discussions that described this shared experience of this 
group of patients.  
The way the quality of life of patients suffering of rheumatoid arthritis is affected, 
seems to present a number of similar stages that are presented below. 
The following sub-themes emerged:  
• Frustration/Depression 
• Acceptance 
• Coping strategies  
• Impact on work life  
• Impact on social life 
• Flare-ups 
• Interactions with other medications and side effects 
 
 Frustration/Depression 5.9.3.2.1
Several participants described rheumatoid arthritis on their overall quality of life as 
having a strongly emotional, quite traumatizing impact. The onset of the condition 
was accompanied by feelings of frustration and even depression.  
“Everyday things that I would have done without blinking an eye just 
became totally impossible to do because I had no grip in my hands, 
no strength then to actually get myself up in the bed.” 
 (PATIENT 1 p3) 
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"So it can be frustrating, erm.  If you know because people can’t see it 
and “Oh yeah, you’ve got arthritis, well other people manage” but 
every person is different.  You know, the arthritis, you know people 
deal with it differently." (PATIENT 12 p5) 
 
As rheumatoid arthritis has a higher prevalence in females than in males, in case 
the patients were also mothers, they often developed feelings of frustration caused 
by the new barriers in parenting duties. These feelings augmented the general 
level of depression that accompanied the onset of severe, chronic pain.  
 
 “I do you remember the little girls used to wear long white socks, I 
couldn’t put them on my children.  That was a…  big problem… 
Distressing and depressing." (PATIENT 3 p2) 
 
“Cooking, cleaning, going out shopping, I don’t go shopping anymore… 
Because I can’t walk, so my husband does all this.”  
(PATIENT 19 p1) 
 
Each patient is unique and reports a unique experience about the effects of 
rheumatoid arthritis on their quality of life. However, a common pattern can be 
found in all the stories they have related. These can refer to the sense of loss of 
utility in their family but also about the gratitude for the help that they received from 
their family members. “Completely my life is changed. I can’t do anything now, I 
have to rely on other people, my husband or my children. (PATIENT 19 p1)” 
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Some of the patients are also mothers. They always tend to mention the impact 
that rheumatoid arthritis had on their life as parents. "In the morning my joints are 
quite bad so I need help with things like getting dressed, my husband helps me in 
and out of the shower, even though we have an adapted bathroom he helps me in 
and out the shower in the mornings.  I have a baby now so that together has a lot 
of complications I need help, you know, putting her in and out the highchair and 
feeding her." (PATIENT 4 p1) 
 
 Acceptance 5.9.3.2.2
After the start of treatment and finding the correct dosage, the symptoms of 
rheumatoid arthritis diminished in most of the cases. The patients managed to 
learn to live with their condition. Patients reported that acceptance comes easier 
once the patients managed to discover new ways of doing things that they used to 
do before the onset of their condition.  
“Because I’ve had the condition for so long I’ve learned to adapt but I 
would say it’s changed my life and the career I would have 
pursued I haven’t pursued now because of the problems with my 
arthritis and I have taken a job that it less, less, perhaps less 
intellectually demanding but it’s less physically demanding so I 
haven’t got the stress and I can, you know cope with that." 
(PATIENT 4 p1) 
 
“I have to accept that there is not a lot, you know, physically, I am not 
capable of doing an awful lot.”  (PATIENT 1 p5) 
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"Because of the medication and also I find it difficult to erm, sit at any 
given time ….. I can’t sit and I cant stand so I can’t see what kind 
of job I can do as an engineer and I I managed to get about and do 
stuff, but I do have to erm sort of put my feet up quite a lot on the 
sofa, so I sit, I sit up..." (PATIENT 17 p2) 
 
 Coping strategies 5.9.3.2.3
From daily routine activities like personal hygiene, dressing up in the morning or 
driving a car, most of the patients had to develop new ways to learn how to live 
with their condition.  
 
“I sort of use the palm of my hand when changing gear instead of 
holding with my fingers.” (PATIENT 21 p3) 
 
This topic has a crucial importance for understanding the patient’s experiences 
with rheumatoid arthritis. Their personal experiences are shaping their priorities 
every day and these priorities are shaping their choices for healthcare.   
"It has it has changed the way I have to live now because it rules what I 
do now." (PATIENT 12 p4) 
 
"If I had to have teeth out, I have to have them out and that’s the end of 
it." (PATIENT 4 p7) 
 
Almost all the patients had to retire early or reduce their workload because of their 
diagnosis. This affected their socio-economic status, their independence and their 
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self-confidence as it was evidenced from this sample. Things that they were doing 
routinely on a daily basis became important challenges and some of them had to 
rely on the help of their family members and friends.  
 
 Impact on work life  5.9.3.2.4
Some patients are reporting the impact that rheumatoid arthritis had on their work 
life and socio-economic status was incredibly high. In some cases, this went as far 
as the patients had to change their living arrangements and make compromises in 
order to find ways to adapt to their new situation. 
 
“I did retire early yes as a consequence and I had to give my home up 
because I couldn’t get up the stairs any more… So within a very 
short space of time from 2010 to 2014 I retired early and I lost my 
home… I am living in a bungalow now, which has been adapted for 
my needs. I’ve got a wet room as opposed to a bathroom.” 
(PATIENT 10 p3) 
 
"I was made redundant er in 2009 that was the second time, I was made 
redundant in in ..  the year before as well erm and then I has 
another episode where I had to go into hospital and from then I 
have not really been able to sort of work…" (PATIENT 17 p2) 
 
Except for Patient 8 and Patient 14, all the other patients had to retire earlier or had 
to reduce their work schedule from full time to part-time because of the impact of 
rheumatoid arthritis on their work life. Patients reported that this had a major 
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negative impact on their socio-economic status. This is illustrated more in detail at 
the Financial compensation theme. 
As rheumatoid arthritis does not always present visible signs, some patients were 
facing difficulties explaining what they are going through and why their condition 
impairs their ability to work. 
 
 “This is it, it’s very hard to make people understand. Obviously people 
like job centres and people like that, if they can’t actually see your 
illness... you know, it’s awful to say but sometimes they might think 
that your swinging it or you’re… Because if you’ve got a cut on 
your head, they can see that you’ve cut your head, but with arthritis 
because they can’t see it. And you look healthy, they think “Well 
you’re alright”. But they don’t see the pain that you suffer inside." it 
can be really frustrating. (PATIENT 12 p4) 
 
Some patients report that they had to attend several medical appointments for 
consultation and treatment and this made it for them difficult to continue working. 
As a consequence they had to retire early which represented an economic burden 
both for the individual and the society. 
 
“I had to take early retirement from work and the first few years my 
knees were very swollen and very painful and my joints became 
and there was a time when because of the swelling and the fluid 
on my knees, I had to have quite a bit of fluid withdrawn and 
steroid injections as well, walking, a few years back was very slow 
and very painful and I still have the walking stick.  Well I don’t use it 
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now, but there was a time when I had to use the aid of the walking 
stick…" (PATIENT 15 p1) 
 
 Impact on social life 5.9.3.2.5
Besides work, rheumatoid arthritis affected also the ability of the patients to enjoy 
their hobbies and social activities. The pain and swelling made it difficult for them 
to visit their friends and family members. Some patients reported that they enjoyed 
gardening or swimming and that they had to stop also these activities, because of 
their condition.  
 
 “It was just before my fortieth birthday.  I was considering starting to 
play football for the veterans and do my first marathon, so it was 
quite a sad year for me really." (PATIENT 5 p1) 
 
Patients are remembering their leisure activities often nostalgically and relate 
stories of regret caused by the barriers imposed by their condition to further enjoy 
these hobbies. As the patients work life was affected by their condition, they would 
be able to enjoy more leisure time but this is not the case, because the disease 
also affected their leisure activities. 
 
“I used to enjoy football, fishing, things like that.  I couldn’t go fishing cos 
I couldn’t hold the rod any longer in that one position holding the 
rod.” (PATIENT 20 p2) 
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Sometimes, patients reported feelings of isolation because of their condition. 
Loneliness at advanced age can have a major impact on people’s mental health. 
 
 "Oh yes, I mean I would have worked til I was a hundred I think if I 
hadn’t of been unwell.  I love my job.  I love the interaction with 
people, but the rheumatoid arthritis…..Prevented that.  I don’t do 
the walking.  Erm, socially I’ve become a tiny bit isolated... 
Because I’m not with work colleagues anymore.  I am not meeting 
people so there isn’t structure to my life so it’s, the impact has 
been quite profound." (PATIENT 10 p4) 
 
 Flare-ups 5.9.3.2.6
One of the other factors that were reported by the patients as difficult to cope with 
in terms of the impact of rheumatoid arthritis was the number and intensity of flare-
ups. Comments included: 
"Yeah, I need longer in the morning, erm, I need a bit of time to warm up 
as well, because it is quite stiff in the mornings, my hands and feet 
particularly and you just have really strange like shocks and things 
like that.  Last night was a really strange one, erm, I woke up in the 
middle of the night and I had the most severe pain in my knee I 
had had, I have had in years.  It lasted for about twenty minutes 
and then it was totally gone.  I thought when I get up this morning I 
am not going to be able to walk, the knee is going to be really 
painful, but nothing." (PATIENT 7 p3) 
 
“And I was rushed into hospital for a week and I have had some sort of, 
they don’t really know what happened, but it was a massive, 
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massive flare-up. And I was poorly and that’s happened to me 
twice.” (PATIENT 17 p4) 
 
“The first proper flare-up was pretty bad, yeah and for about, for about 
two years afterwards.  I was really lucky because within six months 
I was given a biological drug, but there was all the other stuff like 
Methotrexate and quite a lot of other medications …. Steroids I 
was taking at the time as well, but yeah it is quite restrictive.  My 
children were really young at the time as well.  My son was three 
coming on four and my daughter was erm just two so …and my 
partner working full time at that time.  So yeah it was quite 
restrictive, especially when I was trying to take the kids out 
shopping and things.” (PATIENT 1 p5) 
 
 Medications and side effects 5.9.3.2.7
As patients can sometimes have other comorbidities, regardless if it’s an acute or 
chronic condition, they always have to balance the new medication with the 
potential interactions and side effects that this has with their existing arthritis 
medication. Also, some patients sometimes report about the side effects of the 
medications that they are taking for controlling the symptoms caused by 
rheumatoid arthritis . 	
"They put me on Methotrexate, and gradually increased the dose until it 
had some effect.  I was on 25 mg a week, which I think is the top 
dose that they can give me, erm so I was on that for about four 
years and then I had … for some reason I had a very bad reaction 
to it, and I couldn’t keep anything down or in, you know I was either 
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being sick or diarrhoea with it, so they … I stopped the tablet." 
(PATIENT 14 p2) 
 
 Periodontitis and oral health 5.9.3.3
Figure 15 – Theme: Periodontitis and oral health 
 
 
Patients discussed their oral health status, perceptions about oral health and 
previous experience that they had with dental care professionals. Few participants 
self-reported having a good oral health status, despite the fact that most of them 
self-reported having good oral hygiene habits: most of them reported about 
brushing their teeth twice a day. This however, was not possible on the days when 
they had a flare-up of their arthritis.  As illustrated by: 
 
“Right, when, if I have a bad flare-up of arthritis, I can’t … and I miss it 
and I am not able, I don’t have the strength to hold a erm my 
electric toothbrush, because it is quite heavy compared to a 
manual, so I have to go to a manual toothbrush just temporarily.” 
(PATIENT 9 p5) 
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“Erm, yes, if my shoulder hurts then it’s it can be a bit difficult to brush.” 
(PATIENT 13 p4) 
 
(Regarding brushing while having a flare-up) "Oh no, no, it’s er very 
awkward to hold and brush my teeth.” (PATIENT 18 p7) 
 
A large number of participants reported to be unable to use dental floss because of 
the difficulties they encountered in grabbing small objects. Some of the patients in 
a more advanced age reported about experiences from their youth, with dental 
care professionals that were not the most positive. These past experiences 
influenced to some degree their attitudes and behaviours towards oral health in 
general and dental care professionals in particular.  
 “I will be honest I do need to see a dentist, because I have got gum 
disease. And my gums are receding and I do need to, I do 
seriously need to have treatment. But I am that frightened the fear 
is taking over me going to see a dentist. I just can’t do it." 
(PATIENT 12 p8) 
 
The past experiences that the patients were reporting shaped their perception 
regarding oral health. However, patients acknowledge the importance of good oral 
health and they try to help their children to prevent the occurrence of oral 
conditions. 
"Then you never used to go to the dentist, they used to come round the 
school, this is going back a long time nineteen fifties and sixties. … 
And then most of the time they just pulled your teeth out (laughs).  
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That was, they never did any fillings or anything they just looked at 
your teeth and if they didn’t like the look of it, they just pulled out 
your teeth.  They were sort of your your initial teeth anyway not 
your adult ones, but that was all you would see was rows and rows 
of children sitting with things in their mouth where they had had 
teeth pulled out, but that was quite good really because that was 
the only time that people looking at your teeth because your, my 
parents and I think most parents at the age didn’t bother with the 
children ('s oral health) …. My wife was had, used to have terrible 
problems with the fear of going to the dentist, but now she is she is 
much better…  Whereas I think a lot of people don’t go because 
they are frightened of something that has either happened in the 
past, or something they think is going to happen."  
(PATIENT 14 p5) 
 
“Yeah, I, I think I woke up under the gas. And er, I was there was blood 
all over the place and I was only about this high. At school. And I 
never went again. I stopped going for a long time.”  
(PATIENT 20 p7) 
 
“I did when I was younger. Yeah, I did. I was I think about, I don’t know, 
about 17 and I used to go to a dentist in  way. That I can 
remember vaguely from when I was little and he was quite abrupt 
and rough. And I think that’s right from the beginning that I was 
scared of a dentist really. You know, there was no “Oh tell when to 
stop if I’m hurting” or anything like that. It was just “Open your 
mouth and let’s get on with it.” (PATIENT 21 p5) 
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Participants mentioned the importance of developing a relationship based on trust 
with their dental care provider. This plays an important role on their attitudes 
towards oral health and their behaviours in seeking oral health care services.  
 
“It was quite bad before I came to you. My gums were always inflamed 
and bleeding. But really and truly I didn’t get that much help from 
my dentist. It was always just really antibiotics. You know to the 
point where I didn’t have a lot of faith in them.“ (PATIENT 21 p4) 
 
Patient 2 reports being afraid of needles and consequently being afraid of dentists. 
Teeth are not so important to him anymore and he would rather choose to have 
them all extracted instead of restorative treatments, in case it is needed.  
 
“If I’m in pain I get there, it’s the thought of the needle. The needle, 
yeah… When inquired about his preference for restorative 
treatment or extraction: “I suppose out would be the best at my age 
I suppose out, you know.” (PATIENT 2 p5) 
 
Another factor that needed to be addressed is represented by the comorbidities of 
the participants. Having multiple chronic health problems. This was further 
developed in paragraph 5.9.3.8 Comorbidities, health priorities. 
Some patients reported that the medication they take for rheumatoid arthritis might 
have had negative side effects towards their oral health.  
"I don’t know if that drug would make you a bit more prone to the 
inflammation of the gums, but since I have stopped that and I have 
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gone on a different one, they have calmed down…. "When I was 
on Rituximab, I would have a terrible lot, I had only got to eat 
anything and mouth had got blood in it." (PATIENT 6 p2) 
 
The participants also mentioned the oral health services delivery system as 
important. Patients consider that dental treatments in a private setting are more 
thorough and better quality, compared to dental care supported only by the NHS.   
"He, it’s a private practice...  And I would love him not to be, but because 
of the time and the care and attention I get … It is quite noticeable.  
How much more time I can take doing things and him explaining 
things to me and the precision with which he makes my false teeth 
and how he puts new ones on when I lose another one that I 
wouldn’t, if I could find a national health dentist that gave me that 
much time and care…" (PATIENT 9 p5) 
 
Other patients shared this opinion as well. They believe that the quality of care in a 
private setting is superior compared to publicly fund dental services. 
 
"I have had to change from a private dental care to a NHS dental care 
and I am not saying that there is any difference but I found that the 
speed with which the NHS dental hygienist did their work was in 
my opinion it wasn’t as thorough as when I was paying for it 
privately… And erm, I wasn’t sort of getting the feedback where I 
would have with the hygienist before... Where I have been asked 
certain questions there just didn’t seem to be the time with the 
NHS." (PATIENT 10 p5) 
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Having to live with a chronic condition already, some patients reported the 
importance of having a sense of control over their own bodies and over their own 
health.  
“Yeah, because when your rheumatoid is bad you know about it, you 
can’t do anything and when my ITP is bad.  I’m having to control 
nose bleeds all the time and dental health if it’s not causing you a 
problem it’s like, it’s a bit like the osteoporosis that I don’t know it’s 
there.  I know it’s something I need to be aware of but because it’s 
managed with a calcium tablets and, you know, and everything 
else I don’t need to you know I’m dealing with it I’m controlling it 
and I have to.  My priorities are things that aren’t so controllable.  
My dental health as far as I’m concerned is controlled, I’m 
controlling it." (PATIENT 4 p7) 
 
When participants were asked about the way they feel regarding their oral health, 
and how they regard the visit to their dentist patients reported mainly using 
negative attitudes towards these experiences: 
 
“I suppose out would be the best at my age I suppose out, you know.” 
PATIENT 2 p3) 
 
“It wouldn’t be my favourite day out you know.” (PATIENT 3 p4) 
 
"If I had to have teeth out, I have to have them out and that’s the end of 
it." (PATIENT 4 p7) 
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These were mainly the attitudes of the patients that were more elderly. Younger 
patients reported that they would prefer to keep their natural teeth and have them 
treated.  
So yes, I did give them a nice brush this morning before I came though, 
but it is easy I think to erm to, you can brush your teeth, but if you 
don’t er try and keep your gums healthy as well the your teeth will 
eventually just fall out anyway, so you need to keep the two stuck 
together so there.” (PATIENT 14 p11) 
 
Because I wouldn’t like to lose my teeth. I mean until this time.” 
(PATIENT 15 p9) 
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 The study 5.9.3.4
 
Figure 16 – Theme: The study 
 
 Satisfaction about the study and reasons for taking part 5.9.3.4.1
 
Most of the participants who consented to take part in the study considered it being 
a positive experience overall. They reported that the project was a good 
opportunity for them to become aware of their oral health status, specifically in 
terms of periodontitis. 
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"I’m really pleased actually that erm doing this study because erm had it 
not been for that, this could have gone on and on and it might have 
got to a really bad situation with my gums and I wouldn’t have 
known so I am really pleased." (PATIENT 11 p2) 
 
The professionalism of the research team was considered being very positive 
experience for the participants. 
 
"Yeah, they have been good, I think the experience has been good.  
You staff have been really helpful and I am aware of what is 
happening every time I come and see you.  The hygienist was 
great, she explained what she was going to do and what she 
expected to do in future, so I think it has been a really good 
experience as well and eye opening as well." (PATIENT 5 p4) 
 
Several consented patients that were randomized to one of the treatment arms 
expressed their special gratitude for the high quality of care that they received from 
the hygienist assigned for this project.  
 
 “She made me feel so comfortable and it’s embarrassing as well when 
you go to dentist... I find I get embarrassed. And because of the 
state of my teeth. I didn’t feel at bit like that from the moment I met 
the hygienist and I felt quite confident that she was confident. She 
knew what she was doing. She explained everything. And she told 
me if anything hurt or to stop, to stop her. I just felt so comfortable 
with her.” (PATIENT 21 p7) 
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The patients reported that they felt appreciated and treated with respect during 
their visits at the Dental Hospital. They related stories enthusiastically about each 
step that they took during their trial participation, regarding both their research 
visits and treatment appointments. 
“They were very inform informative and very kind... And they answered 
any questions I had and you yourself reassured me and made 
everything perfectly erm plain to me what I was undertaking and 
why I was undertaking... The significance of the tests so I found all 
of that to be very beneficial, yeah, very courteous, very kind, not a 
problem at all and I came away with a raised awareness... From 
being with the hygienist and she showed me how to use the 
interdental brushes or the floss whichever I preferred and  a 
different way of maybe tackling the problem areas."  
(PATIENT 10 p7) 
 
Some of the patients were reporting with enthusiasm about their experience at the 
screening visit. This was a new type of experience and the patients quite positive 
about the process. However, some aspects of the screening visit that were 
considered exciting by some participants, were less pleasant for others. The 
negative experiences are described in the following chapter. 
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“Excellent, very, very professional… every step of the er the 
examination that they did they explained in detail before they did it 
and showed me all the different things that they were going to use, 
the instruments they were going to use and then when they going 
to do the saliva tests they showed me you know, all the equipment 
and everything they were going to use they showed me, so very 
good.” (PATIENT 14 p6) 
 
The screening process triggered the curiosity of some participants and with this 
occasion they also requested follow-up information about the results of the study. 
 
“Well I find it very interesting, especially with the collecting of the saliva I 
would like to know what that entails.  Erm. the plaque from my 
teeth and erm the blood tests what all the the connections with all 
those tests the findings how it erm.” (PATIENT 15 p4) 
 
Through this interview process we aimed to gather information about the views and 
personal values of each participant. Since every participant is unique, his or her 
priorities and motivations might be quite different. However, this being a relatively 
heterogeneous group in terms of age, gender as a consequence of their chronic 
condition a certain number of common denominators were extracted from these 
interviews, reflecting factors that they considered to be encouraging for their study 
participation. 
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A large number of participants reported that their main reason to take part in the 
trial was altruism. More specifically, they were hoping that by their participation 
they could help future patients to avoid the same amount of pain and suffering that 
they went through themselves.  
 
“The purpose of my agreeing to this study is erm any type of study with 
regards to improvements in future developments for people with 
rheumatoid arthritis and gum disease… People in the future 
…hopefully won’t so that won’t have to suffer hopefully quite as 
much.“ (PATIENT 10 p7) 
 
This opinion was shared by most of the participants. Altruism towards fellow 
patients seems to be an important motivational incentive for patients suffering with 
rheumatoid arthritis.  
 
"So yeah you know anything that is going to help or or help people in the 
future in going to be better really.” (PATIENT 17 p6) 
 
However, some participants considered that this trial, being offered at the Dental 
Hospital, will make them benefit of a good oral care without significant effort, and in 
the same time they reported a certain level of curiosity about the results. 
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"No, that’s, that’s one of the reasons I joined this study was also a 
selfish reason.  The appointments are there.  I can come and see a 
dentist, I can just come and see a hygienist and you know that’s 
great for me.  Whereas with my own dentist, it’s left to me to go 
and do the footwork then, if it was left to me, I wouldn’t do it, so this 
is quite good for me and as I say, it is a bit selfish, but . "I mean 
that has always been one of the main reasons I have taken part in 
trials , I have taken part in quite a few and one of the main reasons 
is always to find out what the outcome is and what you and I have 
learnt from it.  That is why it has always been of interest to me." 
(PATIENT 5 p7) 
 
Patient 13 refused to consent for screening unless he was guaranteed to receive 
complete and free of charge dental treatment for all his oral health problems.  
Some patients recommended financial compensation as a potential incentive to 
increase the level of interest of the potential participants of the trial. 
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“And perhaps compensating patients financially for taking part is 
important because for me it’s not such a big thing but for some 
people, you know, they do incur costs and you know some people 
are carers you know or you know for me child if if I could pay 
somebody to look after my child rather than asking a favour you 
know it would be more feasible. I would look into it as to how much 
time it was and whether I was being compensated for that in any 
way.  Because, if it was, let’s say, let’s say for example it was 2 
hours a month for 5 years and I wasn’t getting anything for it.  I 
was just doing it, I was just doing it for the, you know, I’d I’d look in, 
you know, I’d look into it.” (PATIENT 4 p7) 
 
A few patients were involved in other clinical trials before. This was a positive 
experience for them; therefore they decided to participate in our study as well.  
Some patients expressed their desire to participate but the logistics of getting to 
the Dental Hospital were too difficult for them to manage. Therefore arranging 
transportation to the Dental Hospital helped significantly their willingness to 
participate in the study. This was the case for Patient 4 and Patient 7. 
A few participants expressed their interest in finding out the results of the study and 
mentioned this also as an incentive for their participation.  
Some patients believed that it would have been easier if they would have been 
invited to participate in the trial by the clinician from the rheumatology clinic.  
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“I think that my rheumatologist should have sort of, they don’t tell you to 
be sort of extra special careful with your teeth and I think they 
should.” (PATIENT 17 p4) 
 
 Dissatisfaction about the study and barriers for study participation 5.9.3.4.2
Providing an accurate and potentially negative feedback seemed to be one of the 
most challenging parts of the interview process due to potential cultural bias. 
Certain groups of patients seem to find it easier to provide positive feedback than 
criticism about their experiences in a study. This finding can be also linked to the 
CONSORT statement presented in the previous chapter where it has been 
demonstrated that one third of the patients consented to take part in the study but 
never attended their screening visit. The patients were encouraged to provide 
genuine feedback about anything that they felt that could have been done better. In 
certain instances, the patients were asked to imagine that they would be running 
the project and to try to suggest what things they would do differently. 
The patients overall did not report any major negative experiences regarding their 
participation in the study however, a few issues did emerge, for example the saliva 
sampling process, which was described by one of the patients as follows: 
“a little awkward and embarrassing.” (PATIENT 1 p5) 
 
Furthermore, periodontal probing was reported to be unpleasant by one of the 
participants. Other participants shared this opinion, but they all reported that they 
expected this to be the situation and it did not represent a major problem for them. 
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"The only thing that I dislike but I cope well with is when you put the little 
and you are measuring the depth of the gums?" (PATIENT 15 p4) 
 
It was important to explore the reasons why some patients would be reluctant to 
participate in the study in order to better understand their perceptions and if there 
are potentially barriers that could be removed by the research team. A large 
number of patients reported having negative experiences with dentists in the past 
and this discouraged them to participate in our trial.  
 
“Well I am concerned that my dentist hasn’t done what needed to be 
done to save my teeth from breaking." (PATIENT 13 p4) 
 
The location of the Dental Hospital was mentioned as a hindering factor by several 
patients. 
That was because it was the Dental Hospital and I find it difficult to get 
from my part of the town to the Dental Hospital.” (PATIENT 2 p5) 
 
This opinion was shared by a number of different patients. Due to classic signs and 
symptoms of rheumatoid arthritis like mobility problems, fatigue, morning stiffness 
and logistic issues with the traffic from their homes to the city centre, they found 
that without help, they could not attend their research appointments. 
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“It is a bit far away, you know the other side of town but they are moving 
to a new hospital shortly which will be more accessible, yes.” 
(PATIENT 18 p3) 
 
Besides the location of the Dental Hospital, patients mentioned forgetfulness and 
overlap with other medical appointments for rheumatology clinic or for other 
comorbidities as being important hindering factors for study participation. 
 
“I completely forgot.” (PATIENT 3 p5) 
 
Patient’s comorbidities that lead to other hospital appointments were also 
mentioned by a number of patients as being a reason not to participate.  
 
“But the other thing to remember is for patients like me who have got 
rheumatoid, they’ve probably got other going ongoing conditions 
as well.  There is so many things you have to try and focus on." 
(PATIENT 4 p6) 
 
This opinion was shared by several patients as a hindering factor for their study 
participation. 
 
"No, no I probably haven’t been to the dentist, it has got to be a year 
now, so but part of that is that I have so many appointments for 
different things at the moment, that unless I am reminded of an 
appointment, or given an appointment they tend to slip away." 
(PATIENT 5 p6) 
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 Financial compensation 5.9.3.5
This topic was also a new theme that emerged from the interviews and was added 
to the final topic guide. It was reported being important by some patients and less 
important by other patients. 
A few patients mentioned that financial compensation could be a fair and 
reasonable stimulus to participate in the study.   
“That always seems to help I did a lot of groups and the financial side of 
it isn’t a big thing to me.  When I did the conferences it was all 
about expenses I was happy for my expenses to be paid, but a lot 
of the groups I also did erm, it would be like an interview, but there 
would be ten of us and we would sit around and the discussion 
would be recorded and you usually found that all those groups 
would be full because people were getting financial….. they were 
being paid for it basically, but you would find that they were all full, 
all of them.” (PATIENT 5 p7) 
 
 Removal of barriers 5.9.3.5.1
This topic was composed of suggestions and feedback from the patients 
perspectives about the solutions that could be arranged by the research team in 
order to facilitate patients study participation. Some of these hindering factors were 
addressed by the research team, as the project was going on: patients received 
phone call reminders about their appointments and those patients that required 
assistance for getting to the Dental Hospital, received support in arranging the 
logistics around getting to their appointments.  
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"Because as I say I wouldn’t have been able to undertake the study 
unless I’d have had payment for transportation." (PATIENT 10 p10) 
 
Financial incentives were set in place to compensate for the loss of time and 
logistics for the research and treatment visits. As all patients are unique and so is 
their situation, some patients did not feel that financial incentives should encourage 
patients study participation. 
 
“I never give it a thought, no, no. Well you go for yourself really don’t you 
so I don’t think money or that would be you know .... Yeah... I 
always think if you are suffering and if you think you can find an 
easier way to help yourself, that’s what I would do.”  
(PATIENT 6 p7) 
 
Some patients that reported to suffer of dental anxiety suggested that the only way 
they would participate in the study would be if the screening and treatment would 
be done under general anaesthesia. 
 
"I mean I did say to my son because he keeps telling me off he says, 
“Mom, you really need to go and get your teeth sorted… And I said, 
I will go if they can put me to sleep” (laughs). If they can knock me 
out …. Yeah. I said that’s the only way I would have it done.” 
(PATIENT 12 p9) 
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 Delayed treatment 5.9.3.6
This topic was one of the new topics that emerged as a result of the interviews. It 
was important to understand the feelings and perceptions of the patients about the 
topic of being in the delayed treatment group and how this would affect their study 
participation and adherence to the study protocol. 
 
Regarding the topic of being in the delayed treatment group, most of the 
participants expressed their desire of being treated as soon as possible after 
diagnosis.  
The opinions regarding the delay of treatment range from some patients 
considering that there should be no delay at all: 
 
"I think it should be done straightaway." (PATIENT 6 p6) 
 
To patients that believe that six months is a reasonable waiting time: 
 
“6 months would be reasonable for the delay of the treatment in the 
control group.” (PATIENT 2 p8) 
 
To some patients agreeing in theory to go as far as 18 months of delay.  
 
"I am not really fussed.  I will leave that for the experts, but personally I 
would say eighteen months would probably be you know, but I 
agreed to take part in the trials, so you know so I agreed to take 
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part in the timescale as well, which I am quite happy to do." 
(PATIENT 5 p5) 
 
However, the upper threshold of most patients seem to go towards six months 
delay of treatment. The delay is easier to accept to participants that expressed a 
great level of confidence in the research team. 
 
“I was hoping not to be in the delayed group, but as I am in the delayed 
group then I leave it to you to help me as best you can.”  
(PATIENT 15 p6) 
 
This idea is reflected in the opinion of other participants as well, but consider the 
easiest acceptable waiting time being six months.  
 
I would have preferred to have been into the first group… So I don’t 
think there is a problem because you are looking after me.  I mean 
I was just a little bit worried because if there was an abscess or 
something like that, but I hadn’t and there was no decay it was just 
sort of like the receding gums that were causing the problems… 
So I wouldn’t want to go any longer than that because erm you 
know a lot can happen in six months can’t it?" (PATIENT 17 p6) 
 
In case of a longer delay, some of the participants reported that they would seek 
help outside the trial. 
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 Interview notes about participants 5.9.3.7
This topic was reserved for any comments or observations made by the interviewer 
regarding factors that might play be playing a role in the interpretation of the results 
from the interviews. For example this could be the body language of the 
participants, anything unusual that can be observed and noted by the interviewer.  
Some of the patients, were trying to show a strong and independent attitude. They 
sometimes had very short answers, often only one-word answers, and it was very 
difficult to stimulate them to elaborate on their thoughts.  
When speaking about the onset of rheumatoid arthritis and the impact of the 
disease on their quality of life, some patients answered along the line of: 
 
“I didn’t stay in and weep and mope." (PATIENT 3 p2) 
 
The same patient who reported that has no difficulties in gripping small objects like 
a toothbrush because of the join deformities, however at the end of the interview, 
the patient struggled to grip the door handle to open the door. 
One of the respondents was actively involved in the National Rheumatoid Arthritis 
Society as a patient’s representative (Patient 5). 
Some of the stories related by the patients carry very high emotional charge and 
the way patients relate about the impact that rheumatoid arthritis had on their 
quality of life are sometimes very sensitive topics. One of the patients had to give 
up her home and work as a consequence of her condition (Patient 10). 
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One patient conditioned study participation by receiving free dental care for other, 
non-periodontal oral health problems (Patient 13). 
 
 Comorbidities, health priorities 5.9.3.8
As the average age of the participants is around sixty years of age, some of them 
might be suffering from comorbidities. In order to get a better insight in the reasons 
why they might or might not participate in the study, it was considered important to 
understand their healthcare priorities and the impact their comorbidities have on 
their life and as a consequence on their healthcare choices. Another factor was to 
understand where is oral health situated on their list of healthcare priorities. 
Although several patients declared oral health as a main priority in the beginning of 
the interview, as the discussions evolved and they reported on comorbidities, they 
presented a tendency to prioritise other comorbidities compared to oral health.  
 
“So I have rheumatoid arthritis and I have asthma/COPD, so I have 
breathing problems, but again somebody at the QE is looking after 
me there, so they are helping me with that. And that is linked to 
what used to be a constant round of chest infections, but they now 
seem to have this under control and then oral health is the third 
most important thing in my life.“ (PATIENT 9 p5) 
 
As most of the patients have multiple comorbidities, they tend to place oral health 
as the last one on the scale of importance: vascular disease, rheumatoid arthritis, 
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Chron’s disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, 
high blood pressure. 
"I think, erm, probably the second most important oral health, because I 
don’t think that oral health is taken into consideration of other that 
can cause other health problems…" (PATIENT 15 p2) 
 
These health priorities have to take into consideration the age of the participants, 
their level of health literacy, socio-economic status and length of time since they 
have been diagnosed with rheumatoid arthritis.  
“My chest really, my chest is first then my rheumatoid. My teeth, round 
about third I think to be honest.“ (PATIENT 7 p2) 
 
One participant mentioned a list of five comorbidities with rheumatoid arthritis on 
the top of the list of health priorities. When asked about oral health, one of the 
patients reports that it is:  
“Not really one of them.“ (PATIENT 4 p2) 
 
 Other 5.9.3.9
This topic was always kept free by the interviewer for any new topics that might 
emerge from the discussions. As the patients mentioned new topics, these new 
topics were noted in the “Other” column. When no more new topics emerged for 
three consecutive patients, the research team agreed that saturation was reached. 
The new topics that emerged from the interviews and were added to the initial topic 
guide were: 
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• Comorbidities/Health priorities 
• Delayed treatment 
• Financial compensation 
Some of the topics and themes were merged between each other or reformulated 
as the discussions shaped the results of interviews. The full list of themes was 
presented in Figure 13 - Qualitative interview themes 
Several patients reported that they would like to receive a report with the results at 
the end of the study. 
 
5.10 End summary of qualitative results 
The main findings of this interview process can be summarized by taking into 
consideration the specificities of this particular patient population. The sample that 
consented to take part in the interview process was fairly representative for the 
patient population with RA in terms of gender, age, time since diagnosis with 
rheumatoid arthritis, etc. The patients expressed their personal experiences 
regarding rheumatoid arthritis and the impact of this condition on their quality of life. 
Rheumatoid arthritis presented a direct effect on the patient’s physical health 
(through pain, swelling, morning stiffness) and indirect effect through the side 
effects of the medications. Furthermore besides the impact that RA had on the 
patient’s physical health, the patients reported on how the condition affected their 
emotional well being as well as the influence it had over their socio-economic 
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status as a consequence of reduction of work and/or early retirement based on 
disability. 
Several patients related their experiences about developing coping strategies and 
trying to find new ways of doing the things that they used to do before being 
diagnosed.  
Although many participants acknowledged the importance of good oral health and 
its potential impact on general health, when compared to rheumatoid arthritis and 
the other comorbidities that they have to manage to live with, oral health seemed to 
fall back on their list of healthcare priorities.  
The patients identified a number of hindering factors that might impact their ability 
for study participation and some of these factors were addressed by changes of 
the research protocol.  
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6 Discussions  
6.1 Feasibility 
The OPERA study was developed with the main objective of assessing the 
feasibility of an interventional trial that would aim to assess the effectiveness of 
periodontal treatment in patients with rheumatoid arthritis. The outcomes presented 
in this study are related mainly to the feasibility findings, including but not limited to 
patients’ compliance, recruitment, dropout rate, logistic challenges and the values 
and perceptions of patients with regards to study participation.  
 
Any analysis of the clinical endpoints, must take this into consideration especially 
in terms of statistical power calculation of the population sample. Mainly descriptive 
statistics were presented. Results of statistical tests including the p-values should 
be interpreted with caution.  
 
As with any interdisciplinary research, one of the main challenges was to 
successfully manage the effective communication, leadership and project 
management related issues with all the different stakeholders involved at all levels: 
rheumatology consultants, periodontology consultants, patients, patients 
representatives, dental hygienist, etc.  
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6.1.1 Methodology  
The OPERA study has a number of advantages compared to other similar studies. 
The sample size of 60 patients and the six months follow-up period makes it the 
largest study on the effects of periodontal treatment on rheumatoid arthritis 
outcomes. 
 
Table 45 – Associations between periodontitis and RA in interventional follow-up studies  
Studies	 Sample	size	
Follow-up	 Results	
Treatment	 Control	
Al-Katma,	et	al	2007	
[9]	
17	 12	 2	months	 Decrease	severity	RA	
Ortiz,	et	al	2009	[8]	 10	 10	 2	months	 Symptoms	and	signs	
improved	
Okada	et	al	2013	[6]	 26	 29	 2	months	 Lower	DAS28	and	Pg	serum	
levels	
Ribeiro	et	al	2005	[5]	 26	 16	 3	months	 Decreased	ESR	
Pinho	et	al	2009	[120]	 15	 15	 6	months	 Unclear	results	
 
Table 45 presents a brief overview of several interventional studies that assessed 
the effect of periodontal treatment in rheumatoid arthritis disease markers [70, 121, 
122] It can be observed that the results of these five studies were not always very 
clear, the sample sizes were small and the follow-up period was maximum six 
months [5, 6, 8, 9, 120]. This could lead towards highlighting the potential 
challenges of an interventional trial with this type of research design.  
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6.1.2 Recruitment procedures  
In the beginning of the recruitment process standard recruitment letters were 
designed for patients’ recruitment. This was requested by the clinical team from 
Queen Elizabeth Hospital Birmingham. A number of issues were identified 
regarding this approach. Some patients sent back empty response letters without 
marking any option; meanwhile other patients ticked both available options. Other 
letters were returned late to Birmingham Dental Hospital or were lost in the post. 
Another problem was represented by the fact that these standard letters were sent 
out to the patients that were booked for the following weeks clinics. Often these 
lists suffered alterations over one week time, having some patients rescheduling 
their clinical appointments to a later date and other patients moving them forward 
to the week in discussion.  
After a trialing period of three months, based on the experiences, the research 
team decided that there is no added advantage in using the standard letters.  
Another challenge was represented by the limited allocation of human resources in 
research as well as potentially conflicting trials that were recruiting patients in the 
same period. 
This was evidenced at City Hospital Birmingham where only one research 
administrator allocated for patients recruitment for all the clinical trials that were 
running in parallel in the Rheumatology Department. This led to having one or two 
patients consented each week. Having a clear deadline set in place for the 
financing of this project, the time constraint was considered as one of the key 
aspects in running the trial as efficiently as it was possible. The solution to speed-
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up recruitment was to involve the author of this thesis to personally recruit patients 
across all the recruitment sites. This approach led to a dramatic increase of study 
participation with over 10 recruited patients per week.  
Ultimately, a member of the research team directly involved in the trial was 
required to be present and directly consent patients for efficient recruitment.  
 
6.1.3 Sample characteristics at Screening 
The patient population was represented mainly by women at postmenopausal age. 
This finding was consistent with the scientific literature as two thirds of the patients 
with rheumatoid arthritis are women [122, 123] 
 
In terms of ethnicity, the cohort was represented by an ethnically diverse 
population. This can be due to the fact that Birmingham area is home for a 
multiethnic and multicultural population. This can be considered one of the 
strengths of the study in terms of generalizability of the findings.  
 
6.1.4 Sample characteristics at Follow-Up 
The basic demographic characteristics of the randomized patient population are 
consistent with those of the screened population. 
Both the Immediate Treatment and Delayed Treatment groups presented 
consistently higher values for blood pressure. This finding was to some extent 
surprising as all the screened and randomized patients were in long term care of a 
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rheumatology specialist. After discussing with the members of the research team, 
regarding this finding, the clinical consensus was that this was attributable to the 
“white coat syndrome” and the potential levels of anxiety represented by the dental 
visit. All the patients were being treated and monitored by specialist 
rheumatologists on a regular basis and consistently high values of blood pressure 
would have been noticed on the occasion of these visits. This information can be 
corroborated with the clinical data from the rheumatology clinics. 
 
6.1.5 Logistics and follow-up appointments 
The protocol for the OPERA study (Appendix 1: Study Protocol) established that 
the intervention for the Immediate Treatment Group is carried out at maximum 
three weeks after randomization. This however was not possible in most of the 
cases. The reasons for the delay were either technical or patient driven. 
 
The technical reasons for the delay were represented by the challenges in assuring 
communication and logistics between the several stakeholders involved: OPERA 
was a trial that was led by the Oral Surgery Department from Birmingham Dental 
Hospital however the treatments for the patients were delivered by the Hygienist 
from the Periodontology Department. This raised a number of challenges in 
booking the patients list. A different procedure was set in place for booking patients 
for the Screening Visit, a different one for the Follow-up Visits and a different one 
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for the Treatment Visits. Timely and effective communication was key for success 
between all the factors involved. 
 
Birmingham Dental Hospital was moved into a new building in March 2016. This 
did not have a major impact on the running of the OPERA Study. It affected some 
of the latest appointments but most of the patients finished the study before the 
move. 
Another reason for delays was also represented by the delays requested by 
patients. As several patients had ongoing clinical appointments for several 
numbers of comorbidities, occasionally these appointments overlapped with the 
appointments from the Dental Hospital. In a large majority of occasions the 
appointments from the Dental Hospital were postponed, giving priority to the 
clinical appointments from the other hospitals. On other occasions, the patients 
were unable to attend their appointments because of flare-ups of their rheumatoid 
arthritis or just simply feeling generally unwell. Holidays or other types of 
commitments of personal nature also had an impact on delivering the study 
between the given time limits.  
 
The patients were consented on Mondays at Queen Elizabeth Hospital 
Birmingham and Tuesdays at City Hospital Birmingham. Wednesdays to Fridays 
the screening and follow-up appointments were taking place at Birmingham Dental 
Hospital.  
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There was also a limitation of the logistic capacity of the number of patients that 
were possible to be seen on a day. The clinics at Birmingham Dental Hospital 
started every morning at 09:00 however one of the characteristics of rheumatoid 
arthritis is represented by morning stiffness. As a consequence the majority of 
patients requested for their appointment to be booked only after 10:00 am. 
The appointments on the dental clinic lasted approximately one hour, being 
followed by the ultrasonic assessment, which lasted for approximately half an hour. 
In the dental clinic, the patients received all the clinical examinations and the 
biological samples were collected as described in the Methods Chapter. 
The biological samples that were collected were processed in the Biology 
Laboratory of The University of Birmingham School of Dentistry. The processing of 
the samples took approximately one hour therefore the last patient had to be 
booked for no later than 15:00 hours to allow enough time for the clinical 
assessments and the processing of the biological samples. 
 
Several patients presented significant delays in their appointments. The study 
protocol established that after consenting for treatment, the patients were 
randomized to one of the treatment arms and they received their first appointment 
with the Dental Hygienist two weeks after the screening visit. In practice this was 
not always feasible as often patients were not free in the exact given time frame. 
Furthermore other delays were caused by issues relating to staffing and waiting 
times at Birmingham Dental Hospital or patients cancelling appointments on short 
notice without being able to find a new appointment on a close enough time scale. 
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This was especially the case for the first appointment with the Dental Hygienist. In 
case a patient fails to attend the appointment with the Dental Hygienist, 
Birmingham Dental Hospital’s policy is to discharge the patient and send a letter to 
the referring dentist. As the referring dentist for this study was also from the Dental 
Hospital, if a patient failed to attend the appointment with the Hygienist it often took 
a long time until the information was forwarded to the members of the research 
team and they managed to book a new appointment for the patient. This has led to 
significant delays for the first appointment with the Hygienist and as a 
consequence for the first follow-up appointment in the study.  As the first follow-up 
appointment (Visit 2), according to the study protocol should have taken place at 
three months after the final treatment performed by the Dental Hygienist (for the 
Immediate Treatment Group) and three months after the one appointment with the 
Hygienist (for the Delayed Treatment Group) this often took place much later. As 
illustrated by Table 10 - Time spent between follow-up appointmentsit took a 
median of 1.5 months for the patients to see the Hygienist for the first time. The 
protocol required for this period to be no longer than 2 weeks. The treatment for 
the Immediate treatment group took approximately 2 weeks. These delays lead to 
an average waiting time of 5 months from Baseline to Visit 2. For the final visit 
(Visit 3) the delays were less severe with a median of value of 2.9 months for the 
Immediate treatment group and 3.2 months for the Delayed treatment group.  On 
average a patient spent over 8 months as part of the study, instead of the minimum 
of 6 months.  
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6.1.6 Loss to follow-up 
The number of patients that was lost to follow-up was greater in the Immediate 
Treatment arm, compared with the Delayed Treatment Group. The first follow-up 
visit which took place at 3 months from the end of treatment was attended by 26 
patients in the Immediate Treatment group and 27 in the Delayed Treatment group 
For the last follow-up visit that took place 3 months from Visit 2 there were only 23 
patients in the Immediate Treatment group compared to 26 in the Delayed group. 
To sum-up, by the end of the study there 7 patients were loss to follow-up in the 
Immediate Treatment group and 4 patients in the Delayed Treatment group. 
It would be reasonable to hypothesize that once the patients received the 
periodontal treatment, their interest in study participation decreased or, based on 
the findings from the qualitative interviews the treatment experience discouraged 
the patients for further study participation. This would be in line with some of the 
patient’s dental phobia on one hand and the discomfort created by the multiple 
attendances in the Dental Hospital which on the other hand, as reported by some 
of the participants in the qualitative interviews. 
 
6.1.7 Medication changes 
Several patients from both treatment groups had changes in their rheumatologic 
treatments during study participation. This could have potentially influenced the 
outcomes in terms of rheumatologic disease activity (DAS28 and ultrasounds) from 
Baseline to the Follow-up visits.  
195 
There was an ethical dilemma in requesting no change in medication for the study 
participants, especially considering the fact that this was a feasibility study that 
aimed to assess the feasibility for a larger trial, in a real world setting with multiple 
participating study sites. The frequency for medication changes is something that 
reflects the realities of this patient population and it would have been ethically and 
logistically unfeasible to restrict this for the purposes of a study with this design. 
 
6.1.8 Missing data 
Paragraph 5.5 reports on the missing data from the randomized patients. The 
missing data can be divided into clinical and non-clinical data. 
In terms of clinical data there are two groups of clinical information relevant to this 
project: periodontal data and rheumatologic data.  
In terms of periodontal endpoints, one patient had missing data at randomization. 
This was due to the fact that the patient presented gingival overgrowth and the 
research dentist performing the clinical examination could not finish the full mouth 
probing as per protocol. The patient was referred to the Periodontology 
Department from Birmingham Dental Hospital where the diagnosis for periodontitis 
was confirmed. 
In terms of rheumatologic endpoints the two main clinical areas of interest were for 
DAS28 and ultrasounds.  
For Baseline there were 2 patients (3.33%) – one for each treatment arm with 
missing DAS28 data. This came from the way DAS28 is being calculated. The 
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methodology for calculating DAS28 was presented in paragraph 4.7.3 Disease 
Activity Score (DAS28). 
The Baseline DAS28 was calculated using the tender and swollen joint scores 
obtained at the Baseline visit together with the patient’s visual analogue scale 
score (VAS) and the value of the ESR. The ESR value was obtained either from 
the results of the blood tests from the rheumatology clinic – when the patient was 
consented – either from the blood tests performed during the Baseline screening – 
if there was no ESR test at the rheumatology clinic.  
Occasionally, with some of the patients, there were technical difficulties in 
collecting blood during visits in the dental clinic. In a number of occasions the blood 
tubes were mislabeled and the results were lost between the laboratory and the 
hospital. The research team aimed to place measures for quality control to prevent 
most of these situations but in a number of occasions this was not possible. 
The other clinical rheumatologic endpoint with missing data was represented by 
the ultrasound scores. In a number of occasions the ultrasound was not possible to 
be performed due to technical issues represented either by the unavailability of the 
ultrasound machine or the lack of an appropriate room to perform the examination. 
Furthermore as the ultrasound assessment was done on a different clinic than the 
periodontal examination, occasionally the patients opted to leave before the 
ultrasound assessment started because of lack of available time. 
Some of the patients complained regarding the large amount of questions from the 
questionnaires or the fact that occasionally the questions overlapped or felt 
repetitive. Furthermore, some patients expressed their preference to complete the 
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questionnaires at home and post them to the research team but occasionally they 
failed to do so. This could potentially explain the reasons for the missing data from 
the questionnaires.  
 
6.1.9 Qualitative methodology  
Some of the disadvantages of the one to one interviews are related to the potential 
recall bias and the patients answers can be influenced to some extent by their level 
of and health literacy. Level of income and the social economic gradient could also 
play a role in the responses provided by the subjects of the study.  
In order to insure methodological consistency for the interviews, an independent 
researcher with expertise in qualitative research methods observed and provided 
feedback for some of the interviews that were conducted.  
To control for the potential bias from the author of this thesis in terms of data 
analysis and interpretation, an independent researcher reviewed the transcripts 
and the framework analysis and the results were compared and agreed by 
consensus. 
The framework analysis for this study was conducted manually. For further 
research it might be worth exploring the option of using software such as NVIVO 
and compare the results with the manual work [124]. 
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6.1.10 Qualitative results  
The qualitative sample for this study was diverse and heterogeneous in terms of 
demographics and clinical characteristics. Furthermore it was also comprehensive 
in terms of representing patients who did not consent to take part in the clinical trial 
as well as patients who consented to take part in the trial; as well as patients from 
the immediate treatment and the delayed treatment groups. 
Their views were varied and could be influenced by their age, time spent since 
diagnosis with rheumatoid arthritis, socio-economic status, level of education and 
health literacy. 
Despite these differences, most of the patients seemed to agree on the idea that 
rheumatoid arthritis is a condition that had a major impact on their quality of life. 
The stories are extremely rich with personal views and emotions reflecting the very 
personal and unique ways in which RA had an effect on their quality of life, level of 
income, emotional and psychological health. One of their main concerns seems to 
be represented by the ability to have a “normal life” as much as possible - to live 
independently, autonomously and pain free.  
In many cases, they have to balance their life around the treatment they receive for 
RA as well the treatments for a set of comorbidities: this involving several 
medications, hospital visits, etc. 
Considering all these factors, it can be easier to understand that most of these 
patients did not report on having oral health as a priority. This finding, however, 
can be adjusted for different age groups as well as for length of time that a certain 
patient has spent since the RA diagnosis. 
199 
In the light of these results, a future clinical trial should take into accounts the 
priorities and preferences that are driving this particular patient population. An 
interventional trial with a design involving multiple clinical follow-up appointments 
should target the specific segments of the patient group that would most welcome 
this design. This would increase the chances for a higher patient compliance and 
lower dropout rate.  
6.1.11 Technical aspects  
One of the most interesting lessons learned through this trial was related to the 
complexity of handling all the logistical and technical aspects of a study that 
involves several NHS Trusts and specialists from different clinical backgrounds. 
From rheumatology consultants to dentists and research nurses, everybody’s 
commitment and willingness of cooperation was necessary to implement the study 
in an efficient way. 
One of the nurses involved in the study, mentioned the fact that the hospital is an 
NHS Hospital and that patient’s treatment takes priority before research. This has 
led to a discussion that highlighted the importance of understanding the values, 
motivations and priorities that are driving each member of the research team. It is 
crucial to understand these in order to be able to deliver a high quality service.  
Regular follow-up meetings with the research team were held in order to assure 
that everybody is well informed about the progression of the study and in case 
there are any problems identified by any member of the research team, the 
solutions can be identified and implemented together. Clinical research is by its 
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very nature teamwork. One of the ideas that emerged from those meetings was 
related to the fact that the NHS Constitution states that the “NHS aspires to the 
highest standards of excellence and professionalism… through its commitment to 
innovation and to the promotion, conduct and use of research to improve the 
current and future health and care of the population” [125]. 
In line with this idea, it would be worth mentioning the concept that clinical research 
could also be analyzed as part of health services research. Using Donabedian’s 
concept in health services research relating to Structure, Process and Outcome it 
would be worth further developing a framework to assess clinical research capacity 
from the same perspective [126, 127].  That analysis would be beyond the aims of 
this thesis but it is an anecdotal finding that is in line with the previous research 
conducted by the author of this thesis.  
 
6.2 Clinical outcomes 
The type of clinical endpoints that are assessed has important implications for the 
design of the protocol of any interventional trial. The endpoints determine also the 
sample size and any statistical analysis has to be sufficiently powered in order to 
be able to assess these endpoints.  
One of the most important clinical endpoints to evaluate the effects of rheumatoid 
arthritis on the long term is represented by radiological assessments of the bones. 
This however, implies that the patients have to be followed-up for a long period of 
time to be able to detect changes in the shape and structure of the bones. Setting 
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up a clinical study that would have a control group that would not receive treatment 
for periodontal disease for a long period of time would likely be considered 
unethical.  
Time spent since diagnosis with rheumatoid arthritis could also play a role in 
determining the potential benefit of periodontal treatment. The patients that were 
interviewed as part of the qualitative part of the project, spent on average 21 years 
since the moment they were diagnosed with rheumatoid arthritis until the moment 
they were interviewed in the OPERA Project. The range of years spent since RA 
diagnosis starts from 1 year to 60 years in the qualitative patient sample. 
Evaluating the effects of an intervention over six months for a patient that suffered 
of a condition for over 20 years can be difficult. 
 
6.2.1 Surrogate endpoints vs hard endpoints 
It is common practice in clinical research to use surrogate endpoints as a measure 
for chronic conditions as in most of the situations it would be unethical or 
unfeasible to use “hard endpoints” to evaluate the effect of exposure over the 
outcome. This problem was raised also in 2012 in an official statement of the 
American Heart Association (AHA) regarding the associations between periodontal 
disease and atherosclerotic vascular disease (ACVC) [128]. The statement called 
for further, high-quality research and highlighted the weaknesses of several studies 
focusing on surrogate endpoints and the lack of evidence for the sustainability of 
the response to treatment over time. 
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There can be several reasons for having a large number of studies focusing on 
surrogate, short-term endpoints instead of those that are clinically more relevant. 
These reasons can be ethical, financial or even related to feasibility for a long-term 
follow-up.  
6.2.2 Rheumatologic endpoints 
 DAS 28 6.2.2.1
Although widely used across research studies and clinical assessments, the 
rheumatoid disease activity score (DAS28) has certain limitations [129]. It is a 
score that can fluctuate from one day to another. Also, the visual analogue scale 
(VAS) can play an important role in the results of the final score. The calculation 
methods of the DAS28 score were presented in the Methods Chapter. The VAS is 
prone to some bias in terms of how every person perceives pain in a different way. 
Pain can be perceived differently depending on the patient’s age, gender, culture, 
ethnicity, or time spent since diagnosis with rheumatoid arthritis. Patients that 
spent a long time with the condition, could present a lower sensitivity to pain as 
their get more accommodated with the sensations of pain than patients that are 
newly diagnosed.  
 
 Ultrasound 6.2.2.2
Ultrasonic assessments were considered a non-invasive and convenient method of 
monitoring the levels of inflammation from the joints. Over 13.000 images were 
recorded in Gray Scale and Power Doppler for the randomized patients in the two 
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groups. Initially were taken longitudinal images of the wrists knuckles and toes,- all 
of these bilaterally. The ultrasonic assessment of the toes proved to provide certain 
difficulties. The patients had to remove their shoes, socks and/or tights and get on 
a bed. This was not very comfortable for most of the patients, especially in 
wintertime when they had difficulties in removing the winter shoes/boots and 
several layers of clothing. Most of the patients did not present any significant 
ultrasonic activity in their toes, which is why it was decided, together with the 
rheumatology specialists to record and assess the ultrasound images of the wrists 
and knuckles only – without the toes.  
The large number of ultrasounds made it logistically difficult to perform a separate 
grading for each and every patient for each visit to assess the inter-observer 
validity and reliability. It was decided instead to create separate assessments for 
different grading of joints and compare the findings between the author of this 
thesis and a consultant rheumatologist with expertise in ultrasonic assessments. 
To improve validity and reliability, training sessions were held periodically between 
the author of this thesis and the consultant rheumatologist as described in section 
4.12 Ultrasound 
A number of randomized patients received intra-articular steroid injections as part 
of their rheumatologic treatment during study participation. This was a factor that 
could potentially have a high influence on the level of synovial inflammation visible 
on the ultrasound images.  
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6.2.3 Periodontal endpoints 
There is a lack of consensus in the scientific literature regarding the definition of 
periodontal diagnosis and universal criteria for successful periodontal treatment 
[23, 28, 29]. In terms of clinical practice, patients who receive periodontal treatment 
are required to be compliant and have a good oral hygiene to maintain periodontal 
health [130-132]. This leads towards skewed results and potential selection bias in 
the general population in terms of success rates for periodontal treatment. The 
patients in this project were offered periodontal treatment and education about the 
importance of good oral hygiene as well as specific methods of maintenance that 
are designed specifically for patients that have mobility problems or problems 
regarding the grip of small objects – caused by the joint damage in rheumatoid 
arthritis. 
 Plaque  6.2.3.1
One of the limitations of this study was represented by the lack of recording of the 
plaque levels. As this was a feasibility study and the clinical endpoints are not 
considered to be primary outcomes, the decision to not record plaque was taken in 
the beginning of the study as to not increase even longer the duration of the clinical 
appointment in the dental chair and to avoid the need and inconvenience of using 
revelator. Without recording the plaque index, the appointment was already 
approximately one hour long and sitting for too long in the same position was a 
cause of complain for several patients as this caused them discomfort because of 
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their condition. From a clinical perspective, any further trial should consider 
recording longitudinal data on plaque levels.  
The hygienist that performed the periodontal treatment reported that several 
patients presented a poor level of oral hygiene and difficulties in maintenance as 
illustrated at their follow-up appointments.  
This is reflected by the clinical data presented in paragraph 5.6.2 Periodontal 
parameters at follow-up. Clinical endpoints like: Proportion of sites/mouth with PPD 
≥ 3mm, Proportion of sites/mouth with PPD ≥ 5 mm, Proportion of teeth/mouth 
PPD ≥ 3mm, Proportion of teeth/mouth PPD ≥ 5mm and PISA (Periodontal 
Inflamed Surface Area) all presented a statistically significant decrease in the 
Immediate treatment group from Baseline to Visit 1 but in lack of maintenance this 
decrease was not sustained for Visit 3.  
The effectiveness of periodontal treatment in patients with chronic conditions is 
becoming a source of more and more intense debate in the scientific community. 
While randomized controlled trials are considered the “gold standard”, the 
methodological dilemmas faced by the field are getting increasingly complicated in 
todays’ research environment. Engebretson et al presented the results of a 
randomized controlled trial of 514 patients with diabetes and periodontal disease 
[133]. The study design was similar to the OPERA study with half of the patients 
receiving intense non-surgical periodontal treatment while half receiving only oral 
hygiene instructions. The patients were followed-up at three months and six 
months from baseline. After the six months follow-up the authors concluded that 
‘‘nonsurgical periodontal therapy did not improve glycemic control in patients with 
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type 2 diabetes and moderate to advanced chronic periodontitis” and that the 
results “do not support the use of nonsurgical periodontal treatment in patients with 
diabetes for the purpose of lowering levels of HbA1c.’’  
This study has led to a response authored by 21 of the most respected and 
acknowledged authorities in the field of periodontology [134] where they provided a 
series of concerns regarding the findings of the study published by Engebretson et 
al. 
The first concern raised by the group of the authors was related to the fact that 
patients at Baseline had already a good level of glycemic control, therefore it would 
be difficult to expect a significant treatment effect after the periodontal treatment 
was delivered. Similar problems were faced by the OPERA study (in terms of 
inclusion/exclusion criteria). Although the patients needed to have some extent of 
disease activity in order to be randomized for treatment, they also have been on an 
ongoing effective background treatment. In general, all the trials encounter a 
similar challenge whereas the treatment is executed against a background of 
effective medical treatment available.  
The second concern was that the conclusions of the study are not valid because 
the periodontal treatment failed to reach the accepted standard of care, more 
precisely the mean probing reduction was not significant.  
This conclusion could potentially be applied also in case of OPERA as presented in 
Table 17 and Table 18. The mean (SD) probing depth for the Immediate treatment 
group at Baseline was 3.4 (0.7) mm followed by 3.1 (0.9) mm at Visit 2 and 3 (0.8) 
mm at Visit 3.  
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This however, does not reflect the results of the cumulative probing depth in the 
OPERA study where the values were 64 [44, 80] mm at Baseline and decreased to 
42 [22, 68] mm at Visit 2 and 33 [21, 73] mm at Visit 3 (p =0.002 for both visits). 
When treatment is being delivered to a population that is not selected for 
compliance with oral health measures, the treatment results may be less than 
ideal.  
The third concern of the review group was that “pronounced obesity would mask 
any decrease of inflammatory response caused by successful periodontal 
treatment.” The mean BMI of the patients in the study delivered by Engebretson et 
al, was 34.7. The reviewers suggest that there is evidence to support the 
hypothesis that systemic inflammation persists in obese patients after non-surgical 
periodontal treatment [135]. 
The mean (SD) BMI of the patients from the Immediate treatment group in the 
OPERA study was 31.0 (7.9) (Table 13). 
 Optimal periodontal treatment 6.2.3.2
A large number of professional societies around the world, created specific 
guidelines to describe the optimal care pathway for periodontal treatment.  
The British Society of Periodontology (BSP), the American Academy of 
Periodontology and The Scottish Dental Clinical Effectiveness Program (SDCEP) 
are the main professional organizations to provide these guidance in the English-
speaking world. 
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The guidelines of the British Society of Periodontology (BSP) and the American 
Society of Periodontology (ASP). 
According to these guidelines the treatment plan for periodontal treatment is 
structured as follows: 
 
• Assessment and Diagnosis 
• Patient behavior change 
• Non-surgical therapy 
• Management of Local Plaque-retentive Factors 
• Periodontal surgery 
• Long Term Maintenance and support 
The professional organizations for periodontology in the UK and the US agree that 
optimal levels of treatment can only be achieved in patients that are fully compliant 
with oral hygiene instructions [136-138]. Furthermore it has been also highlighted 
that prior to periodontal surgery, patient’s access for cleaning has to be maximized 
by removing any potential restorative/orthodontic work that could hinder optimal 
access for cleaning.  
As these factors constitute increasing practical difficulties in a patient population 
with chronic systemic conditions such as RA, it raises the questions regarding the 
feasibility of larger interventional studies that could assess treatment effectiveness.  
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6.3 Patient reported outcomes 
When examining patient reported outcomes, reporting bias is one of the possible 
factors that need to be taken into account. The patients completed a 17 pages 
questionnaire at each visit (Baseline, 3 Months Follow-up and 6 Months Follow-up). 
Most of the patients reported that it was a burden because of the large number of 
questions, some of which were repetitive. Also, as most of the patients were elderly, 
they reported difficulties in reading the print without glasses or holding the pen for 
too long – because of joint damage. 
Also, as illustrated by the qualitative interviews and the findings from the literature 
the patient relevant endpoints can be sometimes different than the clinician driven 
endpoints [92, 97, 98]. In terms of rheumatoid arthritis – one of the most important 
endpoints for the patients was lack of pain and freedom for mobility and autonomy. 
Whilst disease activity score and markers of inflammation represent the clinical 
endpoints from the specialist’s perspective, the patient reported outcomes play at 
least an equally important role that needs to be taken into account when designing 
a trial. In the same way, whilst periodontists argue about establishing a gold 
standard for diagnosis of periodontal disease as well as criteria for success of 
treatment, the patient group from the OPERA study did not consider oral health an 
absolute health priority considering all the comorbidities that they have to struggle 
with.  
"If I had to have teeth out, I have to have them out and that’s the end of it." 
(PATIENT 4 p7) 
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On the other hand, those patients that do consider oral health as a priority reported 
that once diagnosed with periodontitis they would prefer to get treatment as soon 
as possible and the maximum delay that is acceptable for them would not be 
longer than six months.  
 
6.4 Contamination 
As described through the section 5.9 some of the patients that were diagnosed 
with periodontal disease and were assigned to the control group, reported that did 
not wish to wait until they would have received delayed periodontal treatment as 
part of the study but seek help elsewhere in case the delay would have been for 
too long.  
This could potentially contaminate the results of a future interventional study. One 
of the challenges of this pilot study, and any further interventional study with a 
similar design are represented by the fact that once the patients are revealed their 
periodontal diagnosis, they could potentially seek help outside the study in case 
they are allocated to the control group. The likelihood of this could increase by the 
increase of the length of the waiting time for treatment for the delayed patient 
group.  
This topic leads the reader to the feasibility and ethical dilemma of running a larger, 
multicenter randomized controlled trial that aims to assess the effectiveness of 
periodontal treatment in reducing RA disease parameters.  
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6.5 Feasibility/Ethical dilemma  
The results of this pilot study are crucial for the development of the protocol and 
methodologies for a larger clinical study. As most of the patients were diagnosed 
with rheumatoid arthritis several years ago, a change in their disease activity level 
over a six months period of the study is difficult to evaluate. A longer observation 
period would be desirable from a methodological perspective; however setting up a 
control group that receives a delay of the periodontal treatment for longer than six 
months would not be ethical. Once diagnosed, most of the patients desired to be 
treated as soon as possible. Although some patients expressed their confidence in 
the research team and the advantages of the close, periodical monitoring, the 
longest period of waiting from the patients perspective would be around six months 
to one year.  
 
6.5.1 Delay of treatment  
The higher numbers of drop outs in the Immediate treatment group presents one of 
the methodological challenges of such a study - to keep all the patients, from both 
treatment groups engaged and motivated for study participation for the duration of 
the entire study.  
As illustrated by personal correspondence with members of the Rheumatology Unit 
from the Karolinska University Hospital from Stockholm, the delay of treatment is 
an important ethical conundrum – a topic that requires further investigation. The 
delay of periodontal treatment for a patient that is diagnosed with the condition is 
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considered unethical in Sweden. This is the reason why a similar project to OPERA 
would have not received ethical approval in Sweden, as reported in the 
correspondence (Serban, ST. 08 august 2016, correspondence with Karin 
Lundberg, PhD Senior Scientist Rheumatology Unit, Karolinska Institute, 
Stockholm). 
The patients’ waiting list for periodontal treatment in Birmingham Dental Hospital 
could be longer than six months, which is why delaying the treatment in the control 
group, was considered ethical in this setting.  
Cluster randomization of different hospitals (or NHS Trusts in the case of the UK) 
would represent a possible research design for a larger study that would avoid this 
problem. If the prevalence of periodontitis is considered normally distributed across 
the clusters and the patients were not diagnosed for periodontitis at baseline in the 
control clusters but only in the intervention clusters. The clusters would be 
compared in terms of RA disease activity over time. This approach could avoid the 
ethical conundrum of delay of treatment. However this design would create other 
challenges such as the number of possible confounding factors that could influence 
the outcomes. 
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7 Conclusions and recommendations 
 
7.1 Conclusions  
When designing the protocol for an interventional clinical trial that involved a 
vulnerable population, there can be many unforeseen challenges. The findings 
from the qualitative part of this study are highlighting several potential challenges 
as well as solution that should be taken into account when designing a larger, 
interventional study to assess the effectiveness of periodontal treatment in patients 
with rheumatoid arthritis. 
 
While analyzing these results, they should be regarded in a corroborative manner 
with the feasibility findings from the CONSORT flowchart and the quantitative 
results from the clinical data. Considering the relatively advanced age group of this 
population, their healthcare priorities are in line with the status of their general 
health. The patients highlighted the importance of independence, mobility, lack of 
pain as factors that shape their decision-making processes in terms of the 
healthcare services that they choose to access.  
 
As presented in section 6.2.3.2 Optimal periodontal treatment, professional 
organizations in periodontology like the British Society of Periodontology (BSP) 
and American Academy of Periodontology (AAP) highlighted the importance of 
behavior change and maintenance to achieve optimal levels of success for 
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periodontal treatment. For future directions of research it would be desirable to 
investigate how feasible would be behavior modification for a patient population 
that already is suffering with a chronic debilitating condition and potentially with a 
large number of comorbidities, besides periodontitis.  
 
7.1.1 Mobility 
Mobility is one of the main barriers for access for patients from this population 
group. As the gender balance is more inclined towards females who are more 
advanced in age, their ability to get to dental care service providers might be 
impaired. As some of them had to take early retirement because of their condition, 
their income level was also affected which subsequently influenced their choices 
and priorities regarding the healthcare services that they would access.   
 
7.1.2 Health priorities 
As several patients reported a number of comorbidities besides rheumatoid arthritis, 
this is also one of the factors that influenced study participation. When asked to list 
in order of importance their health priorities, most of the patients listed 
cardiovascular disease, respiratory conditions or problems regarding mobility and 
pain. In most of the cases, oral health was not considered an important health 
priority compared to the other conditions that the patients are suffering with. 
Moreover because of the mobility problems, the patients reported difficulties to 
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include an additional dental appointment to their on-going several hospital 
appointments for their existing comorbidities.  
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7.2 Recommendations  
 
• The planning of a larger, interventional trial should take into account the 
findings from this pilot, feasibility study. 
• The qualitative and quantitative findings are reflecting some very specific 
problems of the patient group of interest such as access to care, 
comorbidities and health priorities. These factors might play an important 
role in the recruitment process as well as patients adherence to the study 
protocol.   
• Some of the endpoints need to be evaluated both from patient’s perspective 
and from the feasibility of monitoring perspective during the trial. 
Rheumatoid Disease Activity Score (DAS28) is prone to fluctuations in a 
short period of time and can be influenced by subjective measures. “Hard 
endpoints” that could be more objective are difficult to monitor over short 
period of time. 
• The outcomes that the patients mentioned as most relevant for them were 
related to their ability to perform unhindered their day-to-day activities, which 
contribute to a good quality of life and that are driven by values such as 
autonomy and self-confidence. Patients often mentioned the “pain-free” life 
as a very important outcome. The patients seemed to express strong views 
regarding their desire to live their lives as independently as possible, like 
they were before they have been diagnosed with rheumatoid arthritis.  
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• Delaying treatment for longer than six months for the control group would 
not be ethical nor acceptable from the patients perspective. A possible 
solution for this would be cluster randomization of Rheumatology Clinics or 
Hospitals in case of a larger, multicenter study. Other issues however could 
arise in this situation regarding data collection and analysis.  
• Patients who did not have a long time since their RA diagnosis could 
potentially present better compliance with the study protocol and present 
easier to monitor clinical endpoints.  
• One of the key logistic solutions is to create a specially allocated research 
and treatment clinic. Patients should be screened, randomized, treated and 
monitored on the same clinic by clinical study personnel that are allocated 
full-time for the project. Potentially this clinic would include also the 
rheumatology consultation and treatment clinic in order to reduce any 
potential discomfort for the patients whilst maximizing efficiency of the 
resources from the research team.  
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1) Introduction: 
 
Rheumatoid arthritis (RA) is common chronic inflammatory disease that is 
characterised by inflammation in the joints ultimately leading to joint destruction 
and consequently functional impairment and disability. In addition, patients with RA 
are more likely to develop cardiovascular diseases such as heart disease and 
stroke and are therefore at an increased risk of premature death. Several studies 
now indicate that chronic periodontitis, a common inflammatory disease of the 
gums surrounding the teeth caused by bacteria in the mouth, can initiate and 
worsen inflammation in RA. A small number of small clinical studies in patients with 
RA have indicated that periodontal therapy aimed at eliminating gum infection can 
reduce joint and systemic inflammation in patients with RA. We therefore propose 
this clinical pilot study to study the effects of intensive periodontal therapy 
administered by a dental hygienist in a secondary care setting to patients with RA 
who also suffer from moderate to severe periodontitis. We will measure the effect 
of this intervention on several clinical and blood measures of RA and RA activity as 
well as on overall and oral health related quality of life. We will also assess how 
easy or difficult it is to recruit patients into such a study and how easy and 
acceptable patients find participation and compliance with the periodontal therapy 
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and the study procedures. We plan to evaluate this intervention in a larger 
definitive study, provided that the proposed pilot study is successful and shows 
promising results. If successful, treatment of gum disease in patients with RA could 
be an inexpensive and safe, non-pharmacological treatment with direct benefit for 
patients with RA in terms of RA severity and progression. 
 
2) Scientific Summary 
 
2.1 Background  
RA is a chronic immune-mediated inflammatory disease associated with significant 
morbidity and, primarily due to cardiovascular disease, increased mortality. More 
than 500,000 people in England suffer from rheumatoid arthritis, with 
approximately 26,000 new cases being diagnosed every year. Chronic periodontitis 
is arguably the most prevalent chronic inflammatory disease of humans and 
several lines of evidence indicate that periodontitis may be a causal risk factor for 
RA. Effective and safe treatments for chronic periodontitis exist and a small 
number of preliminary studies have indicated that successful treatment of 
periodontitis may benefit patients with RA in terms of RA disease activity. 
 
2.2 Plan of Investigation  
We plan to conduct a randomized parallel-group randomized controlled clinical pilot 
trial of the short term effects of non-surgical periodontal therapy on RA disease 
parameters. Patients with established rheumatoid arthritis and moderate to severe 
chronic periodontitis will be eligible for inclusion. The intervention group will receive 
intensive non-surgical periodontal therapy with rigorous periodontal maintenance; 
the control group will receive oral hygiene instructions for the duration of the trial, 
and full therapy at the end of the study. Patients will be followed for 6 months. 
Outcome measures include clinical and serological markers of RA and disease 
activity, and general and oral health related quality of life. 
 
3) Study aims 
Our mid-term goal is to evaluate the effectiveness, cost-effectiveness and safety of 
intensive periodontal therapy and maintenance administered by dental hygienists 
in an intermediate/secondary care setting to reduce disease activity and improve 
function in RA. Our main hypothesis is that control of periodontal infection and 
inflammation by means of intensive non-surgical therapy administered by a dental 
hygienist will result in improved disease activity, function and QOL.  
In order to be able to evaluate this hypothesis in a definitive trial, the present pilot 
trial will randomise RA patients who also suffer from moderate to advanced chronic 
periodontitis to intensive non-surgical periodontal therapy or delayed therapy. The 
objectives of this pilot trial are to assess the feasibility of the proposed protocol, to 
establish recruitment and retention rates, to gauge the acceptability of the 
intervention and study procedures to patients and to gather pilot data on the effect 
size and variability of the effect of the intervention. We plan to accomplish these 
objectives by pursuing the following specific aims: 
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3.1 Establish recruitment and retention rates 
We will establish the proportion of RA patients in the target population that  
(a) Meet inclusion criteria in terms of RA disease activity. 
(b) Meet periodontal inclusion criteria. 
(c) Are willing to undergo periodontal treatment.  
This is important not only to assess the feasibility of the protocol and screening 
requirements for a larger definitive study, but also to gauge the potential impact of 
the intervention in terms of the size of the potential target population (note that this 
will only be determined by what proportion of RA patients meet periodontal criteria, 
the RA inclusion criteria only apply to the specifics of a clinical trial). 
 
3.2 Gauge the relevance and acceptability of the intervention and study to 
patients 
We will conduct semi-structured qualitative interviews with participants recruited 
into the study, as well as with participants who refused to participate even though 
they were eligible. The results of these interviews will directly inform the design of a 
future definitive study by identifying barriers for recruitment, issues related to 
acceptability of the study procedures as well as factors important to be included in 
quantitative assessments in a definitive trial. 
 
3.3 Refine study protocol and logistics 
Our experiences from this pilot study as well as feedback from patients will inform 
the design and planning for a potential definitive trial. This includes not only the 
study design itself in terms of eligibility criteria and study procedures, but also 
logistic aspects such as recruitment procedures and the coordination and timing of 
visits between rheumatology and periodontal clinics. 
 
3.4 Gather pilot data on effect size and variability of outcome measures 
Data on the effectiveness of non-surgical periodontal therapy on RA disease 
activity will be collected 3 months after treatment. Patients who do not respond 
after 3 months of treatment will be offered ‘rescue’ treatment as per standard of 
care (adjustment of DMARD therapy or treatment with biologics). All patients will 
be followed for 6 months to assess ‘maintenance of benefit’. Collection of these 
data is crucial to evaluate if the intervention shows any promise to affect the 
outcomes of interest in the proposed NHS setting and if so, for sample size 
estimation for a definitive trial. 
 
4) Study background 
 
4.1 Link between chronic periodontitis and RA 
We have recently reviewed the literature linking RA and chronic periodontitis [2], 
showing a large number of studies that have indicated a positive association 
between the occurrence of periodontitis/tooth loss and RA, i.e., RA patients are 
more likely to have chronic periodontitis and have lost more teeth compared to 
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individuals without RA. In our own population-based study [1], having RA was 
associated with a four-fold increase in the odds of having periodontitis, after 
adjusting for potential confounders. Another recent longitudinal study from the US 
has, for the first time, shown an increased incidence of RA in individuals with 
periodontitis [7]. Interestingly, the recent recognition of the importance of anti-
citrullinated protein antibodies in RA and the discovery that the major periodontal 
pathogen Porphyromonas gingivalis expresses peptidyl arginine deiminase (PAD), 
provides a plausible potential pathobiologic mechanism by which periodontitis may 
cause or sustain the inflammatory response in RA. PAD is an enzyme responsible 
for post-translational citrullination of peptide antigens on arginine residues [8], and 
microbial PAD deiminates arginine in fibrin found in periodontal tissue [9]. 
Individuals with periodontitis are exposed, therefore, to citrullinated antigens that 
might become systemic immunogens.[8] Interestingly, patients with periodontitis 
might have anti-citrullinated protein antibodies (ACPA) in the absence of any signs 
of RA.[7, 10] The levels of antibodies against P. gingivalis have been correlated 
with levels of ACPA in patients with RA.[11] Antibodies to citrullinated α-enolase 
are specific for RA [12, 13]; an immunodominant epitope in this protein that shows 
sequence similarity and cross-reactivity with P. gingivalis enolase could indicate a 
role for P. gingivalis infection in priming the autoimmune response in RA.[13] 
Autoantigens modified by citrullination through exposure to periodontal pathogens 
[8] might sustain synovial inflammation in the context of untreated periodontitis. 
Given the high prevalence of chronic periodontitis in the UK population, chronic 
periodontitis may thus represent an important modifiable factor leading to 
increased RA incidence and severity. To date, three small intervention studies 
have indicated that periodontal treatment in patients with RA may have a beneficial 
effect on RA disease parameters, including the erythrocyte sedimentation rate [3-5] 
and an improvement in the Disease Activity Score (DAS28) [3, 4]. However, 
whether such benefits can be achieved by providing periodontal care in an NHS 
setting is unclear. 
 
4.2 Current periodontal care 
Currently periodontal care is provided within the General Dental Services (GDS) 
under the new dental contract (2006) and comprises oral hygiene instruction, 
scaling and root surface debridement and supportive care. It is categorised as a 
“band 2” procedure and amounts to 3 units of dental activity, with patients 
contributing approximately £42.00 to the cost of care. The Clinical Audit Committee 
of the Royal College of Surgeons of England classified periodontal diseases into 3 
codes of complexity [14]. Under these guidelines, general dental practitioners are 
advised to only refer patients with relatively rare aggressive forms of periodontitis 
to specialist care. However, chronic periodontitis is underdiagnosed and under-
treated in the GDS, for a variety of reasons including the limited availability of 
dental hygienists in NHS general dental practices [15]. Furthermore, specialist care 
is more intensive than that performed within the GDS [15] and the greater time 
spent and expertise employed within specialist environments results in greater 
periodontal stability [16]. Hence, we strongly believe that an 
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intermediate/secondary care setting employing dental hygienists is most 
appropriate for periodontal treatment of patients with RA in order to achieve 
successful outcomes. If periodontal care results in improved RA outcomes, then 
there would be significant patient benefit to be gained by including periodontal 
therapy within the RA-patient care pathway, and such treatment would have to be 
commissioned rather than referred to the GDS. 
 
5) Research Plan & Methodology 
 
5.1 Overview: 
To address the objectives and specific aims of this study, we propose to conduct a 
6-month two-arm parallel group randomised controlled clinical trial. 60 RA patients 
with moderate to advanced chronic periodontitis will be randomly allocated to 
receive either non-surgical periodontal therapy with intensive maintenance therapy 
delivered by a dental hygienist (intensive therapy), or no therapy. Periodontal 
parameters and RA disease activity parameters will be assessed at baseline, three 
and six months. At the end of the 6-months study, patients in the control arm will 
be offered non-surgical periodontal therapy as per intervention group. Outcome 
evaluations will include measures of RA disease activity and disability, periodontal 
measures, as well as overall and oral-health related quality of life. 
 
5.2 Study population and recruitment procedures: 
Patients with established rheumatoid arthritis (RA) attending the outpatient 
Rheumatology services at City Hospital and Queen Elizabeth Hospital (scheduled 
to be moved from Selly Oak Hospital) will be contacted. General medical and 
rheumatologic eligibility criteria will be assessed and dentate patients meeting 
eligibility criteria will attend an outpatient periodontology clinic at Birmingham 
Dental Hospital. Dental eligibility criteria will be assessed and patients who qualify 
will be enrolled and randomised to the intervention or control group. 
There are several challenges to evaluating the efficacy of a novel intervention to 
reduce disease activity of RA [17]. With the availability of effective treatments in RA, 
‘pure’ placebo trials have become unethical. Hence, testing a new intervention 
against background therapy and early rescue have become standard practice. 
However, to be able to demonstrate efficacy of the new intervention, patients on 
background therapy have to have sufficiently active disease. We therefore propose 
an ‘addon’ design, whereby patients who have been on a stable DMARD regimen 
for at least 2 months and who have active disease (DAS28 score>=3.2) will be 
offered participation in the trial. If the disease is still active after 3 months of 
experimental treatment, patients will be offered ‘rescue’-treatment as appropriate. 
We will also offer trial participation to patients with higher disease activity that 
would qualify for biologics according to NICE guidelines but who decline biologic 
therapy. Patients who are currently on a stable biologics regimen are eligible, 
because even though treatment with biologics itself may have beneficial effects on 
periodontitis [18], RA disease activity may be reduced by additional periodontal 
treatment [4]. 
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5.3 Inclusion Criteria 
• Able and willing to give written informed consent and comply with the 
requirements of the study protocol. 
• Age 18+ years 
• Patients with rheumatoid arthritis (RA) diagnosed according to the revised 
1987 ACR criteria for the classification of RA 
• DAS28 score ≥3.2 
• DAS28 score >5.1 only if patient on biologics or patient unwilling to take 
biologics 
• Treatment with DMARD for ≥ 3 months and stable dose for ≥ 2 months 
• Generalized moderate to severe chronic periodontitis as evidenced by 
pocketing with clinical attachment loss (CAL>=4 mm on at least 2 non-adjacent 
teeth AND cumulative probing depth>=40mm). The threshold based on CAL is 
consistent with a recently proposed case definition [19]. Cumulative pocket depth is 
the sum of the deepest probing depths of at least 4mm on each tooth [20].The 
proposed threshold ensures a minimum number of teeth with deep periodontal 
pockets, e.g., a patient who has 8 teeth with 5mm pockets would meet this criterion. 
 
5.4 Exclusion Criteria 
• Rheumatic autoimmune disease other than RA, or significant systemic 
involvement secondary to RA (including but not limited to vasculitis, pulmonary 
fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome or secondary limited 
cutaneous vasculitis with RA is permitted. 
• History of, or current, inflammatory joint disease other than RA (including, 
but not limited to, gout, reactive arthritis, psoriatic arthritis, seronegative 
spondyloarthropathy) or other systemic autoimmune disorder (including, but not 
limited to, systemic lupus erythematosus, inflammatory bowel disease, 
scleroderma, inflammatory myopathy, mixed connective tissue disease or any 
overlap syndrome). 
• Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis 
(JRA) and/or RA before age 16. 
• Any surgical procedure, including bone/joint surgery/synovectomy (including 
joint fusion or replacement) within 12 weeks prior to baseline or planned during 
study 
• Significant concomitant disease, which would preclude patient participation 
in the investigators’ opinion. 
• Intra-articular or parenteral glucocorticoids within 4 weeks prior to baseline 
• Any dental condition that would preclude, in the investigator’s opinion, 
participation in the trial (including but not limited to restorations impairing oral 
hygiene or instrumentation, need for extractions or extensive restorative work) 
• Periodontal treatment (surgical or non-surgical, excluding supragingival 
cleanings) within 12 months prior to baseline 
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5.5 Recruitment 
The outpatient Rheumatology departments at City Hospital and Selly Oak Hospital 
together care for approximately 5000 RA patients annually, with a mean age of 
approximately 50 years. We estimate that at least 20% will satisfy rheumatologic 
eligibility criteria. 94% of UK adults aged 45-54 years are dentate, of which 52% 
have CAL >3.5 mm and 61% have at least one pocket (PD > 3.5 mm) [21]. 
These figures demonstrate that the prevalence of chronic periodontitis in the UK is 
high, and it is expected to be even higher among patients with RA. However, it is 
difficult to predict what proportion of RA patients will meet dental eligibility criteria, 
and establishing this proportion is therefore one specific aim of this pilot study. 
Based on these data we would estimate that 10% of eligible RA patients will fulfil 
periodontal eligibility criteria. Thus, we expect to be able to recruit 60 patients into 
the study within 12 months. 
 
5.6 Intervention 
Patients randomised to the intervention group will receive a course of non-surgical 
periodontal therapy, completed in 2-3 sessions within 3 weeks of the baseline 
rheumatologic assessment. Non-surgical periodontal therapy will be delivered by a 
dental hygienist at Birmingham Dental Hospital. Following oral hygiene instruction, 
scaling and root surface debridement (RSD) will be performed under local 
anaesthesia using ultrasonic scalers and hand instruments as appropriate. At three 
and six months following scaling and RSD, supragingival scaling and prophylaxis 
will be performed and all sites with 4+mm probing depth and bleeding on probing 
or sites with 5+ mm probing depth will be reinstrumented. 
The control group will receive oral hygiene instructions only during the study period. 
In the event of an increase in probing depth or clinical attachment loss of more 
than 2 mm (active site) between baseline and 3 month visits, site-specific rescue 
treatment will be performed. All patients in the control group will be offered the 
same periodontal therapy as the intervention group after study completion (6 
months after baseline). 
 
5.7 Treatment allocation 
Treatment allocation will be  based on stratified randomization by ACPA status 
(positive or negative).. The randomization list will be generated by the Birmingham 
Clinical Trials Unit (BCTU). Following confirmation of eligibility for the intervention 
and informed consent, patients will be randomised when they attend the first 
treatment appointment with the hygienist. The hygienist will phone the 
randomisation service run by BCTU and the patient will be randomised in either the 
control or the intervention arm. 
 
 
5.8 RA management during trial 
In line with current recommendations for clinical trials in RA [17], patients will be 
required to have been on DMARD medication for at least 3 months (stable DMARD 
dose for at least 2 months) before study enrolment to be eligible. Periodontal 
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treatment will then be added to the existing background treatment in patients 
randomised to the intervention arm. Medical treatment (DMARDs and/or biologics) 
should not be modified until the 3 months follow-up. If the DAS28 remains >=3.2 at 
the three months follow-up, modification of DMARD regimen or treatment with 
biologics will be discussed as appropriate. 
 
5.9  Outcome measures 
All measures described below will be taken at baseline (before periodontal 
treatment) as well as 3 and 6 months after treatment. We will assess standard 
measures of disease activity that are routinely used in clinical trials of RA, including 
DAS28 and ACR criteria (ACR20, ACR50, ACR70) [22]. While these composite 
scores are established outcome measures that are routinely used in RA drug 
clinical trials, they have several limitations in evaluating the efficacy of periodontal 
therapy. Firstly, DAS28 as well as ACR criteria include serum concentrations of 
acute-phase reactants (ESR, CRP) as one of their components. However, in the 
context of a concomitant inflammatory disease such as periodontitis, a reduction in 
the acute-phase component of the DAS28 or the ACR criteria afforded by 
successful periodontal treatment may not reflect a ‘true’ reduction in disease 
activity, that will lead to reduced structural damage. Indeed, inflammatory 
biomarkers have been shown to decrease in response to periodontal therapy in 
some studies [23] and reductions in serum levels of acute-phase reactants in 
patients with RA may therefore solely reflect elimination of periodontal 
inflammation and occur independently of RA disease activity. Secondly, both 
DAS28 and ACR criteria include patient global assessment of disease activity, 
which is obviously a highly subjective measure. Because it is impractical to blind 
the patient with regards to the periodontal intervention, DAS28 and ACR criteria 
are outcomes particularly susceptible to placebo effects. We therefore propose 
joint ultrasonography as a sensitive and more objective, non-invasive and relatively 
inexpensive primary outcome measure. 
 
5.10 Ultrasonography 
Ultrasonography is rapidly becoming the tool of choice to assess changes in the 
joint in response to therapy, based upon high sensitivity to subclinical active joint 
disease [24], improved reliability versus clinical counts [25], and the ability to 
predict joint damage using power doppler detection techniques [26]. We propose to 
use a 12 joint count assessing bilaterally wrist joints and metacarpophalangeal 
joints for greyscale synovitis and power doppler enhancement. Individual joint 
scores will be summed 
to provide overall ultrasound indexes for greyscale and power doppler. Ultrasound 
scans will be performed by an experienced operator blinded to participants’ clinical 
or treatment details, using one of the University of Birmingham’s two dedicated 
high resolution ultrasound machines. The proposed scan takes no more than 30 
minutes to complete. 
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5.11 Other outcome measures 
Other outcomes measures to be assessed at baseline and 3 and 6 months include: 
DAS28, ACR20, ACR50, ACR70 (including the components of these composite 
scores), physical function using the Health Assessment Questionnaire (HAQ), 
periodontal and general (EQ-5D-5L, PHQ9, MAF), rheumatologic ( AIMS2) [27] 
and oral health related quality of life (OHIP). In addition, venous blood samples will 
be taken at baseline, 3 months and 6 months, frozen in aliquots and stored for 
further laboratory analyses.  
 
5.12 Periodontal measures 
Periodontal assessments will be made to confirm eligibility and monitor periodontal 
treatment response. A trained and calibrated examiner, will performfull mouth 
probing and clinical attachment levels at four sites per tooth. 
 
5.13 Other measures (covariate data) 
We will collect baseline data on age, gender, race/ethnicity, socio-economic status 
(postcode), education, marital status, smoking history, height and weight, 
comorbidities and concomitant medications, disease duration, ACPA and RF status, 
background treatment, and joint damage (radiographs of hands and feet). 
 
5.14 Qualitative Interviews 
We will conduct semi-structured interviews with patients randomised to either the 
intervention or control groups, as well as with patients who refused to participate 
even though they would have been eligible for the study. Data from the first five 
patients in these groups will be used to design the topic guide for the semi-
structured interviews. It is anticipated that questions will be asked in relation to the 
following areas: oral health maintenance, treatment preferences (dental and 
medical), access to dental care, priorities/values placed on oral health, quality of 
life issues, acceptability of the intervention and, if applicable, reasons for non-
participation. The interviews will be conducted at Birmingham Dental Hospital, or, 
for patients unwilling to participate, over the phone. They will be audio recorded 
and, subsequently, will be fully transcribed. Because of the small sample size to be 
recruited into this pilot study, we do not propose to use purposive sampling based 
on predefined population characteristics. Instead, we will sample consecutive 
patients and conduct the interviews until saturation is reached, which will ensure a 
broad range of views and yield of the most comprehensive understanding of the 
subject. 
A framework approach to data analysis will be adopted in the manner suggested 
by Pope et al. [28] A preliminary framework, based on the research questions, will 
be developed. The transcripts will be read and, following familiarisation with the 
data, the initial framework will be expanded to reflect themes emerging from the 
interviews. The data will then be indexed according to the framework and further 
refined. To guard against bias, the transcripts will be analysed independently by 
another researcher. Subsequently, consensus will be achieved on emergent 
themes and issues. 
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5.15 Statistical considerations 
This is a pilot study and no formal sample size calculation is presented. However, 
this feasibility study will also need to establish that the periodontal treatment as 
delivered in this study is achieving a minimum standard in terms of periodontal 
healing (pocket probing depths reduction at 3 and 6 months). A reasonable 
minimum threshold criterion is to expect an effect size of 1 for reduction of mean 
probing depth. The feasibility study will have >90% power to detect such an effect 
size, even allowing for 20% loss to follow-up. 
 
5.16 Analysis Plan 
Endpoints to be evaluated will include: 
• ultrasound joint scores 
• DAS28 and ACR20, ACR50, ACR70 
• tender and swollen joint counts 
• HAQ,  
• OHIP 
• AIMS2 
• EQ-5D-5L 
• PHQ9 
• MAF 
• ESR,  
• hsCRP 
• Proportion of patients who reach DAS28 <3.2 
• Proportion of patients who receive rescue treatment/upward dose 
adjustment during study 
 
5.17 Statistical Analysis 
Summary statistics will be calculated as appropriate. To test for between group 
differences at 3 and 6 months, parametric and non-parametric methods will be 
used as appropriate. For continuous outcomes, differences between groups at 3 
and 6 months will be tested using ANCOVA adjusting for baseline. For proportions, 
relative risks and risk differences will be calculated, and logistic regression 
adjusting for baseline will be used as appropriate. 
 
6. Patient & Public Involvement 
Patient/public involvement will not be a ‘stand-alone’ activity but rather an integral 
part of all workpackages. Indeed, the rationale and design of this research have 
already been discussed with the Patient User Group from Sandwell and West 
Birmingham Hospitals NHS Trust and two representatives of the group will be 
members of the steering committee of the study (see letters of support). 
Discussions with the Patient User Group have already resulted in changes to the 
study design. The initial plan was to follow patients for 12 months and use a 
‘community care’ control group. However, members of the Patient User Group felt 
that the control group should receive specialist periodontal treatment at the end of 
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the study and the duration of the study (i.e., the ‘delay’ in treatment for the control 
group) was reduced to 6 months in response to their concerns. Importantly, this 
trial duration is still consistent with current recommendations for trials on RA 
disease activity [17]. 
 
Direct patient/public involvement will contribute to: 
a. Initial project development. 
b. Project approval via the NRES system. 
c. Project management 
d. Interpretation of the findings and the development of plan for larger definitive 
study 
e. Dissemination of the findings of the project. 
 
7.  Project Plan 
We anticipate being able to complete this pilot study over 2 years. The project will 
be delivered in the following three workpackages (WP): preparatory work (WP1), 
conduct of clinical trial (WP2) and data analysis and interpretation, preparation of 
reports and dissemination (WP3). 
 
WP1 – preparatory work: 
This will include finalization of the protocol and study materials, gaining ethical as 
well as R&D approval, and recruitment of study personnel. 
 
WP2 – conduct of clinical trial: 
This will include screening and recruitment of patients, baseline assessments, 
randomization and intervention delivery and follow-up assessments. 
 
WP3 – data analysis and dissemination: 
This will include statistical analysis, data interpretation, presentation of results and 
manuscript preparation. 
 
8. Dissemination of research findings 
Dissemination of the results will take place through oral and poster presentations at 
national and international scientific conferences, and the results will be published in 
peer-reviewed scientific journals. Data will also be disseminated at internal seminar 
series at which specialist audiences with both a scientific and clinical background 
attend. 
The Patient User Group and Patient representatives will also provide input and 
determine on how to best disseminate the results to a wider audience, if 
appropriate. However, it is important to note that specific dissemination plans will 
depend on the results of this pilot study and dissemination of preliminary results to 
a wider audience may not be appropriate. 
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10 Appendix 4: Recruitment letter  
 
Name and address 
 
Date as postmarked 
 
Dear Patient, 
 
Re – Invitation to join Research study looking at the link between chronic 
periodontitis (gum disease) and rheumatoid arthritis 
 
The Rheumatology Department at the Queen Elizabeth Hospital in Birmingham is 
involved in a research study into the link between gum disease and rheumatoid 
arthritis. The study is funded by the Department of Health. We are writing to you 
and other patients on our list that may be suitable to join this study and to help with 
our research. 
 
To enter this study you must be over 18 years old and have rheumatoid arthritis. 
The study will involve an examination of your teeth and gums and may also involve 
treatment of gum disease by a specialist at Birmingham Dental Hospital, if this is 
appropriate for you.  
 
You do not need to take any new medication to help with this research.  You will 
continue to take your medicines as before. Your participation in our research is 
entirely voluntary and you may opt out at any time should you choose.  
  
We would be very grateful if you would consider helping with this important 
research project. In order to express your interest or decline please reply using the 
attached page and the stamped addressed envelope or contact us on the phone 
Department of Rheumatology 
Queen Elizabeth Hospital 
Birmingham  
B15 2WD 
 
Tel: 0121 627 8314 
Fax: 0121 371 6826 
http://www.uhb.nhs.uk 
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number or email address below. We will send more detailed information to those 
who are interested in our research. 
 
Thank you for taking the time to read this.   
 
Yours sincerely, 
 
Dr. Paresh Jobanputra     Dr. Simon Bowman    
Consultant Rheumatologist   Consultant Rheumatologist 
& Clinical Service Lead 
 
Dr. Andrew Filer     Dr. Elizabeth Justice 
Consultant Rheumatologist   Consultant Rheumatologist 
 
Dr. Alison Jordan     Dr. Ben Fisher 
Consultant Rheumatologist    Consultant Rheumatologist  
 
 
Dr. Elizabeth Rankin    Dr. Ben Rhodes    
Consultant Rheumatologist    Consultant Rheumatologist  
 
Dr. Paola de Pablo  
Consultant Rheumatologist   
Clinical Lecturer 
 
Response Form for Arthritis Study (OPERA) 
For attention of: [name of study doctor/research nurse] 
 
 
Please complete this reply slip and return it in the attached envelope or phone the 
surgery to register your response. Do please note that your reply does not commit 
you under any obligation whatsoever, and you will have the opportunity to have 
any questions answered before entering this study. 
     
Name  
 
Address 
  
 
Date of Birth  
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Please register your response as follows: 
 
[ ] Yes! Please contact me with further details about this study. I understand that I 
will be given further information and fully informed before making any decision.  
 
[ ] No, sorry I am not interested in taking part. 
 
 
Or contact me by telephone on the following number(s).  
  
 
 
<< insert phone number >> 
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11 Appendix 5: Patient Information Sheet (PIS) 
Screening 
 
 
 
 
 
Patient Information Sheet SCREENING V1.4, 
12/01/2015 
 
Title of study:   
Outcomes of Periodontal Therapy in 
Rheumatoid Arthritis (OPERA, 11/WM/0235) 
 
 
Invitation to take part 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
What is the purpose of the study? 
Chronic periodontitis (gum disease) is a chronic inflammation of the gums around 
the teeth. This inflammation can ultimately result in loosening and loss of teeth. 
Gum disease is common in the UK population with about 10-15% of the population 
suffering from this condition. Recent research has suggested that gum disease is 
seen more often in patients with rheumatoid arthritis and may also be a factor in 
the development and progression of this disease. Effective and safe treatments for 
gum disease exist, and some initial studies suggest that successful treatment of 
periodontitis may benefit patients with rheumatoid arthritis. 
The aim of this study is to study the link between gum disease and rheumatoid 
arthritis and to find out if treating gum disease can help control disease activity in 
the joints of patients with rheumatoid arthritis. 
 
Why have I been chosen to take part in the study? 
You have been selected because you have rheumatoid arthritis and attend 
outpatient clinics at one of the centres taking part in this study. If you agree to 
participate, we will check whether you are eligible to participate in this study 
according to your rheumatoid health status. 
Specialist Division 
Birmingham Dental Hospital 
St Chad’s Queensway 
 Birmingham  
B4 6NN 
 
Tel: 0121 466 5000  
Fax: 0121 466 5151 
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Do I have to take part in the study? 
It is your choice as to whether you wish to take part in the study. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign a 
consent form which you will be given a copy of. If you do not want to take part your 
care will not be affected in any way. If you do take part you are still free to withdraw 
at any point without giving a reason. 
 
What will happen to me if I take part? 
If you decide to take part we will need to record some details about your symptoms 
and type of arthritis. These assessments will be made with your standard 
outpatient assessments.  
We will then ask you to attend an appointment at the Dental Hospital where a 
dental specialist will perform an examination of your teeth and gums, which will 
take about 30 minutes. This is a non-invasive and generally painless procedure 
routinely performed during a dental examination, although some patients may find 
it slightly uncomfortable. In addition to these routine dental examinations, we would 
like to take samples of blood (less than 50ml), dental plaque, gum fluid (a fluid 
found naturally between your teeth and gums) and saliva. Sampling of plaque, gum 
fluid and saliva is all non-invasive and has long been established in clinical gum 
disease research. Your blood, saliva, dental plaque and gum fluid samples will be 
stored and analysed for markers of inflammation relevant to chronic periodontitis 
and/or rheumatic disease, including genetic markers. Furthermore, these samples 
may be used for future, currently unforeseen, medical research projects in the UK 
and Europe, subject to approval by an Ethics Committee (no personal information 
would be released from Birmingham). 
 
If the detailed dental examination reveals that you do not have moderate or severe 
gum disease, your study participation will end and you will continue to receive your 
standard care for your rheumatoid condition. If however, the dental examination 
reveals that you have moderate or severe gum disease and meet the study criteria 
you will then be eligible to continue in the study. If so, a dental specialist will 
explain to you in more detail the treatment of gum disease and you will have the 
opportunity to ask any questions. You will be given another patient information 
sheet which explains the further course of the study and you will again be asked to 
sign a consent form which you will be given a copy of. If you do not want to 
continue to take part in the study your care will not be affected in any way. Again, if 
you do take part you are still free to withdraw at any point without giving a reason. 
 
At any time during the course of the study you may be approached by a health 
psychologist for an interview about your experience with this study and the study 
procedures and your experiences and opinions regarding your oral health and 
healthcare. Topics may include: your experience with this study in terms of 
acceptability of the study procedures and logistics or your reasons to not 
participate in this research; your previous experience with visits to the dentist, 
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barriers to receiving dental care and/or maintaining oral health and your attitude 
and expectations with regards to dental health. The interviews will last about 20-30 
minutes in a private room at the dental hospital. These interviews will be 
audiotaped and then typed out on paper from the recording. This will be explained 
in detail to you by the health psychologist and if you agree to be interviewed, you 
will be asked to sign a separate consent form. You may of course refuse to 
participate in the interviews and this would not affect your participation in all other 
aspects of the study. 
 
What do I have to do? 
In order to take part in the study you will need to be able to attend appointments 
both at the Rheumatology outpatient clinic and those at Birmingham Dental 
Hospital. 
 
Will my taking part in the study be beneficial? 
Screening of your gum condition may find undiagnosed gum disease; treatment of 
such disease is important for your oral health. If you have moderate to severe gum 
disease and are enrolled in the study, you will receive treatment of the condition in 
a specialist clinic at Birmingham Dental Hospital.   
 
Will my taking part in this study be kept confidential? 
All information given by you and all results obtained will be treated in the strictest 
confidence. You will be allocated a study number, so your name will not be 
disclosed to anyone except the clinical people treating you during the study. Using 
the study number, it will be possible for the researchers to link the results of the 
research tests back to you as an individual. However, you will never be identified 
individually in any publications. 
 
Are there any side effects of the treatment? 
You may develop a bruise on the arm where the blood is taken; this will settle 
within a few days. 
 
What are the possible disadvantages and risks of taking part? 
Other than the possible side effects described above and the inconvenience 
caused by the additional time required for the study procedures, there are no 
disadvantages with participation in this study. 
 
What happens when the research study stops? 
You should continue to attend your general dentist for maintenance of your oral 
health, and you will continue to be reviewed in the outpatient Rheumatology clinic. 
 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds for a legal action but you may have to pay for it. Regardless of this, if 
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you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms will be available to you.  
 
Who is organising or funding the research? 
The study is organised by a team of investigators at the University of Birmingham 
College of Medical and Dental Sciences. The study is funded by the Department of 
Health via the Research for Patient Benefit Programme of the NHS National 
Institute for Health Research. Funding is also available from a research grant by 
the European Union. 
 
Who has reviewed this study? 
This study has been reviewed by the funding body as well as by the South 
Birmingham Research Ethics Committee. 
 
Contact for further information? 
If you require any further information please telephone  and ask to 
speak to Professor Thomas Dietrich.  
 
If you have any concerns about the study and wish to contact someone 
independent, you may contact the Patient Advice and Liaison Service (PALS) 
(0121 507 5169 – City Hospital, 0121 371 3280 – Queen Elizabeth Hospital, 0800 
917 2855 - Dental Hospital). 
 
A copy of this information sheet and a signed consent form will be given to you to 
keep. 
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12 Appendix 6: Informed Consent Form (ICF) 
Screening 
 
 
 
Accessible, Responsive Community Healthcare 
 
  
 
 
  
 Consent Form (Version 1.3, 24/NOV/2014, 11/WM/0235) 
SCREENING 
Title of Project: Outcomes of Periodontal Therapy in Rheumatoid Arthritis (OPERA) 
Name of Investigator: Professor Thomas Dietrich 
                                                                                               Please initial box 
 
1. I agree to take part in this study and confirm that I have read and understood the 
information sheet SCREENING, dated 12/JAN/2015 (Version 1.4) for the above study 
and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason. 
 
3. I understand that the data collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my data.   
4. I agree to have my blood, saliva, dental plaque and gum fluid taken, stored and analysed 
for research into markers of inflammation, including genetic markers, relevant to 
chronic periodontitis and/or rheumatic disease. 
5.  I agree to have my blood, saliva, dental plaque and gum fluid taken, stored and analysed 
for future, currently unforeseen, medical research projects in the UK and Europe, 
subject to approval by an Ethics Committee (no personal information would be released 
from Birmingham). 
6. I agree to be contacted in the future regarding consent to future use of my blood, saliva, 
dental plaque and gum fluid samples. 
7.   I agree to my general practitioner (GP) and general dental practitioner (GDP) being 
informed about my participation in this study.   
 
 
 
 
_______________ ________________ ____________________ 
Name  Date Signature 
 
_________________________ ________________ ____________________ 
Investigator Date Signature 
 
1 for patient;  1 for site file; 1 for hospital notes 
Specialist Division 
Birmingham Dental Hospital 
St Chad’s Queensway 
 Birmingham  
B4 6NN 
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13 Appendix 7: Patient Information Sheet (PIS) 
Treatment 
 
 
 
 
 
 
Patient Information Sheet TREATMENT V1.4, 
12/01/2014 
 
Title of study:   
Outcomes of Periodontal Therapy in Rheumatoid Arthritis (OPERA, 
11/WM/0235) 
 
 
Invitation to take part 
You are being invited to continue to take part in this research study. Before you 
decide, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this. 
 
What is the purpose of the study? 
Chronic periodontitis (gum disease) is a chronic inflammation of the gums around 
the teeth. This inflammation can ultimately result in loosening and loss of teeth. 
Gum disease is common in the UK population with about 10-15% of the population 
suffering from this condition. Recent research has suggested that gum disease is 
seen more often in patients with rheumatoid arthritis and may also be a factor in 
development and progression of this disease. Effective and safe treatments for 
gum disease exist, and some initial studies suggest that successful treatment of 
periodontitis may benefit patients with rheumatoid arthritis. 
The aim of this study is to find out if treating gum disease can help control disease 
activity in the joints of patients with rheumatoid arthritis. 
 
Why have I been chosen to take part in the study? 
Specialist Division 
Birmingham Dental Hospital 
St Chad’s Queensway 
 Birmingham  
B4 6NN 
 
Tel: 0121 466 5000  
Fax: 0121 466 5151 
 
 
 
254 
You were initially selected because you have rheumatoid arthritis and attend 
outpatient clinics at one of the centres taking part in this study. During your recent 
dental examination you have been found to have moderate or severe gum disease 
(chronic periodontitis). 
 
Do I have to continue to take part in the study? 
It is your choice as to whether you wish to continue to take part in the study. If you 
do decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form which you will be given a copy of. If you do not want 
to take part your care will not be affected in any way. If you do take part you are 
still free to withdraw at any point without giving a reason. 
 
What will happen to me if I take part? 
If you decide to take part some details about your symptoms and type of arthritis 
will need to be updated at 3 and 6 months after your entry into the study. These 
assessments will be made with your standard outpatient assessments in the 
Rheumatology clinic.  
 
We will use ultrasound to look at your joints. This will take about 30 minutes and is 
an entirely harmless procedure. The detailed dental examination and the 
ultrasound scan will be repeated at 3 and 6 months and will be conducted at the 
Dental Hospital. If you hadn’t had x-rays of your hand and feet within the past 6 
months, we would also like to take such x-rays to assess how much damage there 
is to the joints of your hands and feet.  
 
You will be seen by a dental hygienist who will give you detailed instructions on 
home cleaning techniques for your teeth. You will then be allocated into one of two 
groups by a random procedure (similar to the flip of a coin). Both groups will 
receive standard therapy for gum disease which consists of a thorough ‘deep 
cleaning’ of the teeth by the study hygienist with or without local anaesthesia as 
necessary. One group will have this treatment done immediately; the other group 
will have treatment deferred for 6 months. However if we find deterioration of your 
gum condition during this time, treatment of the affected teeth will be provided 
immediately. Depending on the severity of your gum disease and the number of 
teeth you have, this treatment may take 2 to 3 visits to complete. The periodontal 
treatment provided will be a standard treatment which has been routinely used for 
the treatment of periodontitis for many decades. No surgery or drug treatment will 
be involved. Following the completion of treatment you will be re-examined 3 and 6 
months afterwards. In addition to the treatment procedures and routine dental 
examinations, we would like to take samples of blood (less than 50ml), dental 
plaque, gum fluid (a fluid found naturally between your teeth and gums) and saliva 
at all visits to the Dental Hospital. Sampling of plaque, gum fluid and saliva is all 
non-invasive and has long been established in clinical gum disease research. We 
also request permission to take a small biopsy from your inflamed gum tissue 
during the treatment. This will only be done from sites under local anaesthesia and 
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will therefore not lead to any additional discomfort. Some samples will be analyzed 
immediately and some stored for analysis at a later date. 
Furthermore, we would like to ask you to complete a series of questionnaires that 
will assess to what extent your daily life is affected by your oral and general health.  
The study will finish following the 6 month assessment and completion of 
periodontal treatment for those patients allocated to the deferred treatment group. 
Please see the study diagram which summarises the course of the study. 
 
What do I have to do? 
In order to take part in the study you will need to be able to attend all appointments 
both at the Rheumatology outpatient clinic and those at Birmingham Dental 
Hospital. 
 
Will my taking part in the study be beneficial? 
You will receive treatment for your gum disease in a specialist clinic.  If indeed 
treatment of gum disease is beneficial for rheumatoid arthritis (this is what we are 
trying to find out with this study), then participation in this study may also have a 
positive impact on your rheumatoid arthritis. 
 
Will my taking part in this study be kept confidential? 
All information given by you and all results obtained will be treated in the strictest 
confidence. You will be allocated a study number, so your name will not be 
disclosed to anyone except the clinical people treating you during the study. Using 
the study number, it will be possible for the researchers to link the results of the 
research tests back to you as an individual. However, you will never be identified 
individually in any publications. 
 
Are there any side effects of the treatment? 
Treatment of gum disease may cause your gums to shrink a little, but these are 
accepted consequences of managing this disease. Following the treatment, you 
may also experience some increased sensitivity of your teeth to hot and cold 
temperatures. This is a temporary side effect and your treating hygienist will be 
able to advise you on how to minimise it. You may develop a bruise on the arm 
where the blood is taken; this will settle within a few days. 
 
What are the possible disadvantages and risks of taking part? 
Other than the possible side effects described above and the inconvenience 
caused by the additional time required for the study procedures, there are no 
disadvantages with participation in this study. 
 
Expenses/Payments 
You will not be charged for any treatment costs or any other procedure done as 
part of the study. If you are eligible and participate in the study we will pay you £50 
upon completion of the study.  
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What happens when the research study stops? 
On completion of your treatment you should continue to attend your general dentist 
for maintenance of your condition, and you will continue to be reviewed in the 
outpatient Rheumatology clinic. 
 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may 
have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms will be available to you.  
 
 
Who is organising or funding the research? 
The study is organised by a team of investigators at the University of Birmingham 
College of Medical and Dental Sciences. The study is funded by the Department of 
Health via the Research for Patient Benefit Programme of the NHS National 
Institute for Health Research. 
Funding is also available from a research grant by the European Union. 
 
Who has reviewed this study? 
This study has been reviewed by the funding body as well as the South 
Birmingham Research Ethics Committee. 
 
Contact for further information? 
If you require any further information please telephone  and ask to 
speak to Professor Thomas Dietrich.  
 
If you have any concerns about the study and wish to contact someone 
independent, you may contact the Patient Advice and Liaison Service (PALS) 
(0121 507 5169 – City Hospital, 0121 371 3280 – Queen Elizabeth Hospital, 0800 
917 2855 - Dental Hospital). 
 
A copy of this information sheet and a signed consent form will be given to you to 
keep. 
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14 Appendix 8: Informed Consent Form (ICF) 
Treatment 
 
 
 
Accessible, Responsive Community Healthcare 
 
  
 
 
  
 Consent Form (Version 1.3, 24/NOV/2014, 11/WM/0235) 
TREATMENT 
Title of Project: Outcomes of Periodontal Therapy in Rheumatoid Arthritis (OPERA) 
Name of Investigator: Professor Thomas Dietrich 
                                                                                               Please initial box 
 
1. I agree to take part in this study and confirm that I have read and understood the 
information sheet TREATMENT, dated 12/JAN/2015 (Version 1.4) for the above study 
and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason. 
 
3. I understand that the data collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my data.   
4. I agree to have my blood, saliva, dental plaque, gum fluid and gum biopsy taken, stored 
and analysed for research into markers of inflammation, including genetic markers, 
relevant to chronic periodontitis and/or rheumatic disease. 
5.  I agree to have my blood, saliva, dental plaque and gum fluid and gum samples taken, 
stored and analysed for future, currently unforeseen, medical research projects in the 
UK and Europe, subject to approval by an Ethics Committee (no personal information 
would be released from Birmingham). 
6. I agree to be contacted in the future regarding consent to future use of my blood, saliva, 
dental plaque, gum fluid and gum samples. 
7.   I agree to my general practitioner (GP) and general dental practitioner (GDP) being 
informed about my participation in this study.   
 
 
 
 
_______________ ________________ ____________________ 
Name  Date Signature 
 
_________________________ ________________ ____________________ 
Investigator Date Signature 
 
1 for patient;  1 for site file; 1 for hospital notes 
Specialist Division 
Birmingham Dental Hospital 
St Chad’s Queensway 
 Birmingham  
B4 6NN 
 
258 
15 Appendix 9: Case report form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening number INTERVIEW Pag. 1/6 
Patient screening number 
 
 
Patient initials: 
 
 
Alcohol How often do you have a drink containing alcohol? 
 
 
 

 
 
Never 
 
 
 
 
 
 

 
 
Monthly or less 
 
 
 
 
 
 

 
 
2-4 times a month 
 
 
 
 
 
 

 
 
2-3 times a week 
 
 
 
 
 
 

 
 
4 or more times a week 
 
 
 
Alcohol (Units/week) 
 
 
Smoking 
Have you ever smoked? 
 
 
 

 
 
Yes 
 
 
 
 
 
 

 
 
No 
 
 
 
If yes, have you smoked more than 100 cigarrettes in your life? 
 
 
 

 
 
Yes 
 
 
 
 
 
 

 
 
No 
 
 
 
If yes: 
If former/current: age started 
 
   
 
 #cigs/day 
   
If former:           age 
stopped 
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Screening number 
Pag. 4/6 
GENERAL EXAMINATION 
Height (cm-only at initial visit) 
 
 
 
 
Sistolic BP (mmHg) 
 
 
Weight (kg) 
 
 
Diastolic BP (mm Hg) 
 
 
Blood taken 
    
 

  

 
 
  
 
Yes 
  
No 
 
  
 
Time blood taken 
 
 
GCF 
    
 

  

 
 
  
 
Yes 
  
No 
 
  
GCF 1-upper right 
premolar 
 
 
 
 
GCF 2-upper right 
molar 
 
 
 
 
 
GCF 3-upper left 
premolar 
 
 
 
 
GCF 4-upper left 
molar 
 
 
 
 
Saliva sample taken 
    
 

  

 
 
  
 
Yes 
  
No 
 
  
 
Time saliva 
 
 

 
 
5 min 
 
 
 
 

 
 
10 min 
 
 
 
Volume (ml) saliva 
 
 
FLORIDA PROBING 
    
 

  

 
 
  
 
Yes 
  
No 
 
  
 
DAS 28 
    
 

  

 
 
  
 
Yes 
  
No 
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Screening number 
Pag. 5/6 
DAS 28 
DAS 28 
 
 
LEFT-tender 
 
LEFT-swolen 
 
RIGHT-tender 
 
RIGHT-swolen 
 
 
 
 
Shoulder 
         
 

  

  

  

 
    
 
 
 
Elbow 
         
 

  

  

  

 
    
 
 
 
Wrist 
         
 

  

  

  

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Patient Global Assessment of Disease Activity 
CONSIDERING ALL THE WAYS YOUR ARTHITHIS AFFECTS YOU, RATE HOW WELL YOU 
ARE DOING ON THE FOLLOWING SCALE: 
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Screening number 
Pag. 6/6 
How to score de DAS 
 
 
 
Tender joint score (0-28) 
   
  
 
 
 
Swolen joint score (0-28) 
   
 
 
 
ESR 
   
 
 
 
VAS disease activity (0-100mm) 
   
 
 
 
TOTAL SCORE 
   
 
 
Have you been taking DMARDs since > or = 3 
months ago? 
 
 
 

 
 
yes 
 
 
 
 
 
 

 
 
no 
 
 
 
Has the dose been stable for > or = 2 
months? 
 
 
 

 
 
yes 
 
 
 
 
 
 

 
 
no 
 
 
 
Eligibility 
 
 
Yes 
 
No 
 
 
 
 
DAS 28 > or = 3,2 
     
 

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DAS 28 > 5,1 only if patient on biologics 
or patient unwilling to take biologics 
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
 
  
 
 
 
DMARD > or = 3 months  
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DMARD stable dose > or = 2 months 
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CAL > or = 4 mm on at least 2 adjacent 
teeth 
     
 

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Cumulative probing depth > or = 40 mm 
     
 

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ELIGIBLE 
     
 

  

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16 Appendix 10: Euro-Quol 
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Patient Health Questionnaire (PHQ-9)
Screening number
Over the last 2 weeks, how often have you been bothered by any of the following problems?
More than half 
the days
Nearly every 
dayNot at all Several days
Little interest or pleasure in doing things
Feeling down, depressed, or hopeless
Trouble falling or staying asleep, or sleeping too much
Feeling tired or having little energy
Poor appetite or overeating
Feeling bad about yourself or that you are a failure or
have let yourself or your family down
Trouble concentrating on things, such as reading the
newspaper or watching television
Moving or speaking so slowly that other people could
have noticed. Or the opposite being so figety or
restless that you have been moving around a lot more
than usual
Thoughts that you would be better off dead, or of
hurting yourself
If you checked off any problems, how difficult have these problems made it for you to do your work, take care of 
things at home, or get along with other people?
Not difficult at all Somewhat difficult Very difficult Extremely difficult
Pg. 7/16
17 Appendix 11: Patient Health Questionnaire 
(PHQ-9) 
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Screening numberPg. 14/16
18 Appendix 12: Oral Health Impact Profile (OHIP) 
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19 Appendix 13: Recruitment poster 
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20 Appendix 14: The ultrasound grading sheet 
used for OPERA 
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21 Appendix 15: Example from the Qualitative Data 
Analysis 
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22 Appendix 16: Topic guide for the qualitative 
interviews 
 
22.1 Initial topic guide framework 
The initial topic guide framework was composed of the following topics: 
22.1.1 Introduction  
• Introduction about the purposes of the study 
• Explanation about confidentiality issues and tape recording 
22.1.2 Rheumatoid arthritis and systemic health 
• Discussion regarding the way that rheumatoid arthritis affects the patient’s 
quality of life 
• The patients were asked to describe their top 5 health priorities? 
22.1.3 Periodontitis and oral health 
• The patients were asked to describe their dental health 
• The patients were asked to describe any steps they take to maintain their 
dental health 
• The patients were asked to describe their cleaning/flossing habits  
• The patients were asked to describe the frequency of their oral hygiene habits 
• The patients were asked to describe if they experienced any influence of their 
rheumatoid arthritis on their dental health 
• The patients were asked to describe their relationship with their general dental 
practitioner 
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22.1.4 The Study 
• The patients were asked to describe the reasons why they decided to 
participate or not participate in the study 
• The patients that took part in the study, were asked to describe their 
experiences regarding the screening visit: 
• What represented a positive experience 
• What factors they considered positive or encouraging for a dental visit, based 
on their previous experiences with their dental care provider  
o Surgery 
o Staff 
o Modern equipment 
o Communication skills 
• The patients were asked to describe if they had any negative experiences in the 
past with their dental care provider 
• What they liked or disliked about the study 
• The patients were asked to imagine what they would do differently if they were 
in charge with organizing the study 
22.1.5 Factors influencing participation in the research project 
• The patients were asked to describe the factors that encouraged or would 
encourage them to participate in the study 
o Pain free assessments 
o Gender of the dentist 
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• The patients were asked to describe the barriers that they felt that would 
hinder their participation in the study 
• If they had any (dental) anxiety related issues 
• If they encountered any barriers to care  
• Language or cultural difficulties 
• Fear or embarrassment 
• The patients were asked to describe their dental anxiety or fear related 
experiences 
• The patients were asked to describe types/cause/experiences  
• Specific fears  
• The patients were asked to talk about the onset of these fears 
• Coping strategies  
• Any history of non-dental anxieties 
• The patients were asked to talk about the removal of barriers 
• What would encourage better attendance in their opinion 
• What action should the profession or the government take to promote better 
attendance in their opinion 
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22.2 The final topic framework. 
The first three topics: Introduction, Rheumatoid arthritis and systemic health and 
Periodontitis and oral health did not suffer significant changes 
22.2.1 The Study 
The following topics emerged and were added to the final topic guide: 
• The patients described how they would feel being in the control group and 
getting treatment with a delay.  
• The patients discussed about the length of time for which they would agree 
to be delayed and not seek treatment elsewhere  
22.2.2 Factors influencing participation in the research project 
The following topics emerged and were added to the final topic guide: 
• The patients described how financial compensation would encourage 
participation in the project. 
• The patients described how often and how much would represent a fair 
amount of financial compensation for study participation. 
• What types of outcomes would the patients find interesting to enhance study 
participation 
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23 Appendix 15: Standard operating procedures for 
biological sample collection  
 
SOP - OPERA 
1. ACPA - QE   
• Check on Patient Portal in QE/City Hospital if the patient has already the 
ACPA  
• If not, request them to be done after the patient signs the consent form 
 
All the following samples are collected at screening visit and for the randomized 
patients, it is repeated at 3 months and 6 months follow-up 
 
2. ESR – QE 
• Check on Patient Portal in QE/City Hospital if the patient has any recent 
ESR done 
• If not, request them to be done after the patient signs the consent form 
 
3.  Venous blood samples in frozen in aliquots 
• Clinic 
• A qualified phlebotomist will collect the blood samples, during the screening 
and the follow-up visits 
• Quantity ≤ 50 ml in 4 red + 4 green tubes 
 
• Lab: 
• Prepare tubes (Star Lab 1.5 ml (E1415-2227) screw top tubes – red/white 
(E1480-0304) top for serum, green/white (E1480-0302) for plasma) – Label 
with sample name, visit number and type (cryo stickers provided).  
• Fill in form with Date, patient number and visit, sample type. 
• Receive bloods – fill out time in form and in comments box fill out how many 
vials you received 
• Centrifuge (2680rpm at 4 degrees for 30mins) – this is usually on setting 1 – 
fill in form with time [NB serum may need to be left to clot] 
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• Remove tubes without disrupting the separation.  
• Aliquots of 1.5 ml (2 x750ul per tube) 
• Keep the plasma packed blood sediment for the DNA isolation (see below) 
• Put samples in the appropriate OPERA box order serum, plasma, saliva, 
DNA  
• add sticker or write on to the top of box 
• Fill out form to show where the samples are stored in the box plan 
• Return all paperwork back to the purple OPERA folder 
 
• DNA 
• Prepare tubes (Star Lab 1.5 ml screw top tubes – Amber with lilac top) – 
Label with sample name, visit number and type (cryo stickers provided). Pre 
prepare in molecular lab hood with 500ul of trireagent. 
• Fill in form with Date, patient number and visit, sample type. 
• PEG300 located in blood spill kit. Double glove and Face Mask for this 
procedure. 
• Collect pre-prepared tube from flammable cupboard in molecular biology 
lab, ensuring it stays upright. – If at all concerned, replace tube and use 
another. 
• Return to main lab and place in rack 
• Label tubes 
• Aliquot 500ul of blood sediment from the green plasma tubes into the trizol 
tubes, replace cap tightly. 
• Invert to mix 5 times 
• put into -80 freezer – time on form 
 
4. GCF sample  
• Clinic 
• Sampling with Periopaper strips  
• Unwrap sterile set of Periopapers (n=16) and mount on holder provided. 
Take care not to touch paper section of strips (contamination occurs).  
• Set holder down on bracket top.  
• Isolate site to be sampled carefully with sulcus cotton rolls and saliva 
ejector.  
• Blow air from triple syringe x 5 blasts buccal and palatal/lingual. The 
direction of the blast should be from gingivae to occlusal surface, i.e. away 
from gingival crevice and not into the crevice.  
• Check interproximal contacts to ensure they are dry. If not, re-dry 
interproximal areas as above.  
• Pull Periopaper from holder using college tweezers holding the orange 
section only. Take care not to touch adjacent strips on the holder.  
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• Insert the paper portion of the strip so its leading edge is parallel to the line 
of the gingival margin, try not to bend the strip.  
• Insert until gentle resistance is felt and guard strip from cheek/lip contact or 
contamination during collection (patient must NOT speak).  
• The entire leading edge of the strip should enter the crevice, i.e. not just a 
corner.  
• Time for 30-seconds and remove.  
• NB. If the strip comes out during sampling, it is often not possible to re-sit it.  
• If failure occurs sampling a site, it cannot be re-sampled, the site is lost.  
• Blood contamination may invalidate the sample, depending on what is being 
analysed.  
• If there is doubt about saliva contamination, note “? saliva contamination” on 
CRF.  
 
• Lab 
• Prepare tubes (Star Lab 1.5 ml amber tubes with yellow top (E1480-0306) – 
Label with sample name, visit number and type (cryo stickers provided).  
• Fill in form with Date, patient number and visit, sample type. 
• Receive GCF samples – fill out time in form  
• Samples are received on liquid nitrogen, remove from flask and put into -80 
freezer – time on form 
 
5. Microbiological plaque sample  
• Clinic 
• Sample plaque from the 6 deepest interproximal sites (a site is defined as 
the mesial or distal interproximal space, i.e., no differentiation is made 
between ml/mb or dl/db sites). These sites should be as distant as possible 
from each other, one per sextant, if possible.   
• Once representative teeth have been identified, they should be isolated 
using cotton wools rolls and teeth air dried 
• Subgingival plaque is collected using hand instruments 
• Confirm cryotube/buffer 
• Samples to be stored in a -80°C freezer. (Store grouping samples of the 
same subject no.) 
• Batch send to Birmingham Dental Hospital, marked FAO Prof Iain 
Chapple/Prof Thomas Dietrich, on study completion.  
 
• Lab 
• Prepare tubes (Eppendorffs containing 1ml tris EDTA (pH7.4 from Sigma 
93302-500ml) – located in Gamma fridge (cryo stickers provided).  
• Fill in form with Date, patient number and visit, sample type. 
• Receive Plaque sample – fill out time in form  
• Samples are received on ice, remove and put into -80 freezer – time on form 
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6. Saliva sample  
• Clinic 
• Ask patient if they have followed pre-sampling instructions with respect to 
eating, drinking, smoking and brushing teeth prior to sampling appointment.  
• Instruct the patient to rinse mouth with sterile water to remove food residue 
before sample collection.  Wait at least 10 minutes after rinsing before 
collecting saliva to avoid sample dilution. 
• Give the patient the sterile saliva sampling marble. 
• Label the saliva sample tube (graduated Falcon tube) with subject no. study 
time-point, date and time.  
• Remove lid from the saliva sample tube and place saliva sampling funnel 
into the saliva sample tube. 
• Place the combination of the saliva sampling funnel and the saliva sample 
tube into a cup of ice. Give to the patient to hold. 
• Instruct the patient to place a sterile marble in their mouth and continually 
roll it around for 5 minutes. 
• Instruct the patient to retain the marble in their mouth while expectorating 
the resulting saliva.  
• Time the patient for 5 minutes and ensure that a minimum of 1.0ml of saliva 
has been collected.  
• If 1.0ml of saliva has not been collected in 5 minutes then have the patient 
continue until 1.0ml has been collected.  
• Record the time it took to reach 1.0ml 
• If the patient accidentally spits the marble into the funnel, they can retrieve it 
with their fingers and replace in it their mouths. 
• Take the apparatus from the patient. Remove the funnel. Leaving the 
sample tube in the cup of ice, place the lid on. 
• Take the saliva sample to the laboratory.  
• Record total volume. Calculate flow rate (ml/min). 
 
• Lab 
• Prepare tubes (Star Lab 1.5 ml screw top tubes – Amber with blue and white 
(E1480-0304) top) – Label with sample name, visit number and type (cryo 
stickers provided). 
• Fill in form with Date, patient number and visit, sample type. 
• Receive saliva – enter time received on form and approx. volume. 
• Centrifuge (2470rpm at 4 degrees for 10mins) – this is usually on setting 3 
(using centrifuge 3) – fill in form with time – this will need to be balanced. 
• Remove tubes without disrupting the separation.  
• Remove pellet and store in the tube labelled – pellet. 
• Aliquots of 1.5 mls (2 x750ul per tube) – time on form 
• Snap freeze – time on form 
• Put into -80 freezer – time on form 
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7. PD 
• A calibrated examiner will perform full mouth probing using a manual 
constant force probe UB-CF-15  
• 4 sites on each tooth (except 3rd molars): mb, db, ml, dl 
• Record at each site recession, pocket depth and BOP 
• BOP is recorded at the end of probing each quadrant  
 
8. RA 
DAS28 
• A calibrated examiner will perform Disease Activity Score in 28 Joints 
(DAS28). 
• The examiner is going to apply a constant pressure on each of the 28 joints 
in order to assess swelling and tenderness 
• The joints are bilaterally: MCP 1-5, PIP 1-5, wrist, elbow, shoulder and 
knees 
• For each tender and each swollen joint, a point is given 
• The patient is offered a visual analogue scale (VAS) and asked to assess 
the level of pain that was experienced due to RA in the past week 
• The DAS28 is calculated using the database created by Naomi, imputing the 
total number of swollen and tender joints, the VAS score and the patients 
most recent ESR (not older than 2 weeks) 
 
Ultrasound 
• A calibrated examiner for the patients’ randomization group allocation 
(treatment or control) will perform MSK Ultrasound on all the randomized 
patients using the Philips iU22 ultrasound machine from the BDH Radiology 
Department 
• The machine is placed in a dark room, with no natural light. Lights are 
turned off and the patients screening number is inserted in the menu as well 
as the specification of baseline, 3 months FU or 6 months FU 
• Aquasonic® 100 Ultrasound Transmission Gel is applied on the patient’s 
joints. Standard longitudinal views are recorded for greyscale and power-
doppler on the following joints: Wrist (intercarpal and ulnar-carpal), MCP 1-
5, MTP 2-5 
• The images are graded on a grading sheet with scores from 0 to 3 in terms 
of synovitis  
• The images are saved both on the ultrasound machine and on the university 
servers. 
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